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This report highlights changes in general practice activity 
in Australia over the most recent decade (April 2002 to 
March 2012) of the BEACH program, a national cross-
sectional study of general practice activity. Over this 
time 9,802 GPs provided details of 980,200 GP–patient 
encounters. The report highlights changes that have 
occurred over the decade in the characteristics of GPs 
and the patients they see, the problems managed, and 
the treatments provided. Changes in prevalence of 
overweight and obesity, smoking status and alcohol use 
are also described for subsamples of more than 30,000 
adult patients each year.
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Summary 
This book presents ten years of data from the BEACH (Bettering the Evaluation and Care of 
Health) program, and reports changes that have occurred over the decade 2002–03 to     
2011–12, in the characteristics of GPs and the patients they see, the problems they manage 
and the treatments they provide. A companion report, General practice activity in Australia 
2011–12, describes the 2011–12 annual results in more detail, available at 
<hdl.handle.net/2123/7771>.1  
BEACH is a continuous cross-sectional national study that began in April 1998. Every year 
each of about 1,000 randomly selected GPs records details of 100 consecutive encounters on 
structured paper recording forms, and provides information about themselves and their 
practice. The database now holds data for 1.38 million records from 13,815 participating GPs. 
BEACH is the only continuous randomised study of general practice activity in the world, and 
the only national program that provides direct linkage of management (such as prescriptions, 
referrals, investigations) to the problem under management.  
GPs are the first port of call in the Australian healthcare system. In the 2011–12 financial year 
the universal health insurance scheme (Medicare) paid (in part or in whole) for about 
123.9 million claimed general practice service items (excluding practice nurse items),2 at an 
average of about 5.36 GP visits per head of population or 6.55 visits per person who visited 
at least once.  
This report is based on information from 9,802 participating GPs, about 980,200 
GP–patient encounters. Smaller studies are undertaken with subsamples of the BEACH 
encounters. Results for substudies on patient body mass index, smoking status and alcohol 
consumption are included in this report.  
The GP participants and their practises 
Between 2002–03 and 2011–12: 
• the feminisation of the general practice workforce was reflected in the growing 
proportion of GP participants who were female rising from 35% to 41%.  
• reflecting the ageing of the GP workforce, the proportion of participants aged 35–44 
years decreased from 27% to 19%, and the proportion aged 55 years and over increased 
from 31% to 41%. This was paralleled with an increase in the proportion who had 
worked in general practice for 20 years or more, from 50.4% to 58.4%. 
• hours spent in direct patient care decreased—the proportion of GPs working 21–40 hours 
per week increased from 42% to 53%, while the proportion working 41–60 hours 
decreased from 43% to 32%, and 60 hours or more decreased from 4% to 1%. 
• the proportion of GPs who had gained their primary medical degree in Australia, 
decreased from 72% to 67.2%. There were also significant changes in the geographic 
distribution of country of graduation among those trained overseas. 
• there was a significant increase (from 23% to 27% in 2011–12) in the proportion of 
participants who provide some consultations in a language other than English.  
• the proportion of participants in solo practice, and the proportion in smaller practices  
(of 2–4 individual GPs) significantly decreased, while the proportion in larger practices 
of 5–9 individuals increased (from 36% to 42%), and with ten or more from 12% to 21%.  
 x 
• there was a significant reduction in the proportion of GPs working in practices that 
provide their own after-hours services (from 43% to 31%), and/or in those providing 
such services in cooperation with other practices (from 17% to 13%).  
Since BEACH started surveying use of computers in 2004–05, the proportion of GPs 
indicating they use a computer to some extent in clinical steadily increased from 89% to 96%. 
The patients at encounters  
Between 2002–03 and 2011–12: 
• the proportion of BEACH encounters with patients aged 45 years and over increased 
from 51% to 57%. 
• the proportion of encounters with patients who: were new to the practice decreased from 
10% to 8%); held a Commonwealth concession card was relatively stable; held a 
repatriation health card decreased by about a third, from 4% to 2%.  
• there was a significant increase in the number of patient reasons for encounters, from 151 
to 155 per 100 encounters, a decrease in the rate of RFEs described as symptoms and 
complaints, and increases in patient presentations for medications, tests and test results.  
Problems managed at encounters 
GPs managed more problems at encounters in 2011–12 (154 per 100 encounters) than in 
2002–03 (145 per 100), suggesting 48 million more problems managed by GPs nationally in 
2011–12 than a decade earlier. This was reflected in a significant increase in the management 
rate of chronic conditions, from 49 to 56 per 100 encounters, suggesting about 20.6 million 
more GP contacts with chronic problems nationally in 2011–12 than ten years earlier. 
Between 2002–03 and 2011–12 among the most common individual problems, there were 
significant increases in the management rate of: 
• depression, from 3.5 to 4.4 per 100 encounters 
• diabetes, from 2.9 to 4.2 per 100 encounters in, suggesting about 2.3 million more 
occasions of its management in 2011–12 than a decade earlier 
• general check-up, from 1.9 to 2.8 per 100 encounters  
• lipid disorder, from 3.0 to 3.5 per 100 encounters, suggesting about 1.4 million more 
occasions of lipid disorder management in 2012 than ten years earlier. 
Management actions 
Medications 
Between 2002–03 and 2011–12, there was no significant change in total (including prescribed, 
GP–supplied, and advised for over-the-counter purchase) medication rates per 100 problems 
managed or per 100 encounters.  
Prescribing rates per 100 problems managed remained steady (58 per 100 problems in  
2002–03 and 57 per 100 in 2011–12). However the increasing number of GP encounters over 
the decade, led to an extrapolated national effect of 24.6 million more prescriptions given 
nationally by GPs in 2011–12 than a decade earlier. 
There were some significant increases in GP prescribing rate per 100 problems managed for a 
specific drug groups including: agents acting on the renin-angiotensin system (from 3.4 to 4.5 
per 100 problems managed); psychoanaleptics (from 2.1 to 2.7 per 100); lipid modifying 
agents (from 1.6 to 2.6 per 100). The last of these had a national effect of about 2.6 million 
more prescriptions for lipid modifying agents in 2011–12 than in 2002–03. 
 xi 
There were also some significant decreases in the prescribing rate per 100 problems managed 
of some medications including: drugs for obstructive airway disease (from 3.2 to 2.4 per 100 
problems), suggesting about 75,000 fewer prescriptions for drugs in this group were given in 
2011–12; anti-inflammatory and antirheumatic products (from 3.3 to 2.0); sex hormones and 
modulators of the genital system (from 2.6 to 1.6); vaccines(from 2.9 to 0.8); and diuretics 
(from 1.1 to 0.7) suggesting 200,000 fewer diuretic prescriptions nationally in 2011–12 than in 
2002–03. 
There were significant decreases in the proportions of prescribed medications with no 
repeats and with two, three, or four repeats ordered and a significant increase in the 
proportion for which five repeats were recorded, from 27% in 2002–03 to 36% in 2011–12.  
There was no change in the rate of GP-supplied medications per 100 problems managed  
(6.4 per 100 in 2002–03 and 6.3 per 100 in 2011–12. The majority were vaccines.  
The rates of advised over-the-counter purchase for individual and total medications were 
largely steady between 2002–03 and 2011–12, exceptions being a significant increase in 
unspecified simple analgesics, and a fourfold increase in vitamin D which began in 2008–09.  
Clinical treatments 
The rate at which clinical treatments were provided by the GP or by a practice nurse (PN) or 
an Aboriginal health worker (AHW) in association with the GP–patient encounter did not 
differ in 2002–03 and 2011–12 but there were major changes within the decade.  
Overall, there was no significant change in the total proportion of problems managed with 
clinical treatments. However, there was a significant increase in the rate of clinical treatments 
given in management of diabetes (from 0.8 per 100 encounters in 2002–03 to 1.1 in 2011–12). 
The clinical treatment provision rate remained steady from 2002–03 to 2004–05. Following 
the introduction of practice nurse (PN) and Aboriginal health worker (AHW) Medicare item 
numbers in 2004, there was a sudden, significant decrease in the clinical treatment rate at  
 GP–patient encounters. From 2006–07 onwards, it slowly increased to reach 24.0 clinical 
treatments per 100 problems in 2011–12, the same level as that provided ten years earlier. 
However, the 2005–06 decreased rates of counselling/advice about nutrition and weight, and 
about exercise, failed to recover. We estimate 140,000 fewer occasions of the former and 
86,000 fewer of the latter in 2011–12 than in 2002–03.  
Procedures 
The procedural rate per 100 encounters increased significantly from 14.6 per 100 encounters 
in 2002–03 to 16.9 per 100 in 2011–12. We estimate that in 2011–12 there were 6.6 million 
more procedures undertaken by GPs nationally than a decade earlier.  
There were significant increases in rates of some specific types of procedures including local 
injections/infiltration (excluding immunisations), and a significant decrease in use of 
physical medicine/rehabilitation. There was also a significant increase in the procedural rate 
in management of atrial fibrillation (associated with increased INR point of care testing). 
Practice nurse/Aboriginal health worker involvement 
As a proportion of all encounters, those involving a PN/AHW almost doubled from 4.2% in 
2005–06 to peak at 9.0% in 2009–10 then significantly decreased to 7.4% in 2011–12. The 
proportion of problems managed with a PN/AHW involvement also increased from 2.8% in 
2005–06 to peak to 6.1% in 2009–10 with no further change by 2011–12 (5.0%).  
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In 2005–06 GPs recorded at least one PN/AHW Medicare item number at 39% of encounters 
with recorded PN/AHW activity. This increased to 46% by 2009–10, and then decreased to 
40% in 2010–11. In 2011–12, which includes three months of data recorded after the change in 
practice nurse funding structure, the proportion further decreased to 27%.  
The rate at which procedures (including tests) were undertaken by PNs/AHWs more than 
doubled from 4.0 per 100 encounters in 2005–06 to 9.2 per 100 in 2009–10, but decreased in 
2011–12 to 7.2 per 100. PNs/AHWs did 23% of the recorded procedures in 2005–06 rising to 
38% in 2010–11, with no statistical change in 2011–12. 
While their provision of clinical treatments (such as advice and health education) remained 
infrequent, there was a significant increase from 0.2 clinical treatments per 100 encounters in 
2005–06 to 0.9 per 100 in 2011–12.  
Last year local injections/infiltrations had reverted to the 2005–06 level of 41 per 100 practice 
nurse involved encounters. In 2011–12 the rate decreased further to 36 per 100. This may be 
linked to the removal of the Medicare item number for immunisations in January 2012. 
Check-ups by PNs/AHWs at GP encounters doubled over the study period. International 
normalised ratio (INR) blood testing frequency more than tripled.  
There were significant increases in the rate at which PNs/AHWs were involved in 
management of check-ups, diabetes, atrial fibrillation/flutter and urinary tract infections.  
Referrals 
Over the ten years there was a significant increase in the proportion of problems that were 
referred to other health providers, at least one referral being made in 7.7% of problems 
managed in 2002–03 to 9.3% of problems managed in 2011–12.  
Referrals to medical specialists remained relatively stable at 5.3 in 2002–03 and 5.6 per 100 
problems managed in 2011–12, with a small but significant increase in referrals to 
cardiologists, and a significant decrease in referrals to gynaecologists. However, referrals to 
allied health services almost doubled, from 1.7 to 3.0 per 100 problems managed. This was 
reflected in significant increases in referral rates per 100 problems, to psychologists, 
podiatrists or chiropodists, dietitians or nutritionists, and dentists. 
Tests and investigations 
Between 2002–03 and 2011–12: 
• there was an increase in the likelihood of ordering a least one pathology test from 11% to 
14% of problems managed and an increase in the likelihood of at least one order at 
encounter from 15% of encounters to 18%, which suggests that pathology was ordered at 
about 8 million more encounters nationally in 2011–12 than a decade earlier 
• the rate of pathology orders increased from 33 to 47 per 100 encounters which suggests 
about 26 million more test/batteries ordered in 2011–12 than in 2002–03, the largest 
increase being in the order rate for chemical pathology (from 12 to 18 per 100 problems 
managed), haematology (from 4.3 to 5.5) and microbiology (3.5 to 4.0 per 100)  
• the proportion of all problems managed, for which imaging was ordered rose from 5.3% 
to 5.8%. Further, the number of imaging tests ordered increased from 5.9 tests per 
100 problems managed to 6.6 per 100. We estimate imaging was ordered at about 
3.3 million more encounters nationally in 2011–12 than ten years earlier 
• total imaging orders per 100 encounters also increased significantly from 8.6 per 100 
encounters in 2002–03 to 10.1 in 2011–12, suggesting there were 4 million more imaging 
orders in 2011–12 than in 2002–03. 
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Substudies of patient risk factors 
Body mass index: 
Adults (n = 30,000–32,000 per year): Between 2002–03 and 2011–12 prevalence of overweight 
and obesity in adults (18+ years) increased from 55% to 62%. Prevalence of obesity rose from 
21% to 27% and the increase was apparent in males and females. Prevalence of overweight 
was relatively steady at 34–36%, prevalence of normal weight decreased from 42% to 36%.  
Children (n = 3,000–4,000): Prevalence of overweight and obesity in children (aged 2–17 years) 
remained static from 2002–03 to 2011–12, with 11–12% of children being obese and about 
18% being overweight.  
Smoking (n = 31,000–34,000 per year): Among adults (18+ years) there were decreases in 
prevalence of current daily smoking (17% to 15%) and occasional smoking (4.1% to 2.5%). 
Rates of daily smoking were significantly higher among male patients than female patients 
in all years, decreasing to 18.0% of males and 12.6% of females in 2011–12. 
Alcohol consumption (n = 30,000–34,000 per year): Among adults (18+ years), between 
2002–03 and 2011–12 the prevalence of at-risk drinking remained static at about 25–26% of 
adult patients. However among male patients prevalence decreased from 33% to 29%, and 
prevalence of non-drinking increased significantly from 21% to 24% among males. 
Risk profile in adults (n = 29,000–32,000 per year): Between 2002–03 and 2011–12 there was 
a significant decrease in the proportion of adults with none of these risk factors, from 29% to 
25%, while the proportion with one risk factor increased significantly from 48% to 52%. 
There was no change in the proportion with two or three risk factors among either men or 
women. 
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1 Introduction 
This report is the 32nd book in the general practice series from the Bettering the Evaluation 
of Care and Health (BEACH) program. It includes summary results from the most recent ten 
years of the program, from 2002–03 to 2011–12 inclusive. 
BEACH is a continuous national study of general practice activity in which ever-changing 
random samples of about 1,000 general practitioners (GPs) participate in a year. Each 
participating GP records details of 100 consecutive GP–patient encounters with consenting 
patients. BEACH is run by the Family Medicine Research Centre (FMRC) at the University of 
Sydney. The program is supported financially by government instrumentalities and private 
industry (see Acknowledgments). 
BEACH began in April 1998, and at the end of its 14th year (March 2012) its database 
included records for 1.381 million GP–patient encounters from 13,815 participating GPs, 
representing about 8,800 individual GPs, almost half the sample frame from which the GP 
samples are drawn. Annual results from the BEACH study are published each year. The 
most recent annual report is General practice activity in Australia 2011–12,1 available at 
<hdl.handle.net/2123/7771>. 
From April 1998 to March 2011 the BEACH program was conducted by the FMRC, 
University of Sydney, in collaboration with the Australian Institute of Health and Welfare 
(AIHW), under the AIHW Act. The 2011–12 survey was conducted by the FMRC. 
This book brings the most recent ten years of data together to identify changes that occurred 
over the decade 2002–03 to 2011–12 in the characteristics of GPs, the patients they see, the 
problems managed and the treatments they provide. This report is based on information 
from 9,802 participating GPs, about almost 1 million GP–patient encounters.  
The structure of this report follows the usual approach of the annual BEACH reports. Ten 
years of results are provided about the GPs, the patients and the problems managed, 
followed by an overview of management, and specific chapters for each type of management 
action. Changes in prevalence of some patient risk factors are also presented. 
Each chapter contains an overview of the section (including definitions where relevant), and 
a brief description of the major findings, followed by the results tables. In the tables, 
statistically significant changes between 2002–03 and 2011–12 are marked. The national effect 
of significant change can be estimated by extrapolating the BEACH results to all GP 
Medicare claimed encounters. The method adopted for extrapolation of the effect of a change 
is described in Section 2.9. Examples of extrapolation of a measured change are also 
provided in each of chapters 5 to 12 inclusive. The reader can apply this method to any 
significant change in the BEACH data presented in terms of rate per 100 encounters, to gain 
an estimate of the size of the national effect of this change. 
In this report, changes over time in (for example) GP management actions for a specific 
problem, or changes in the problems managed for a selected group of patients, are not 
generally investigated. However, this type of specific analysis for morbidities classed in the 
National Health Priority Areas3 was published in July 2009 in General practice in Australia, 
health priorities and policies 1998 to 2008.4  
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1.1 Background 
In June 2011, the population of Australia was estimated to be 22.6 million people.5  
Like the rest of the developed world, Australia has an ageing population. Between June 1991 
and June 2011, the proportion of the population that was aged 65 years and over increased 
from 11.3% to 13.7%, and this included a doubling of the proportion aged 85 years or more, 
from 0.9% to 1.8% of total population. The proportion aged less than 15 years decreased from 
21.9% to 18.8%. The median age (the age at which half the population is older and half is 
younger) increased by 4.7 years over the two decades, from 32.4 years at 30 June 1990 to 37.1 
years at 30 June 2011. Over the next several decades, population ageing is projected to have 
significant implications for Australia, including for health.6 As life expectancy improves, 
people are living longer with disease, so that a greater part of the GP workload will involve 
management of older patients with multiple chronic diseases. 
Australia’s health expenditure in 2009–10 was $121.4 billion, an average $5,479 per 
Australian, and accounted for 9.4% of GDP. Governments funded 69.9%, with the remainder 
(30.1%) being paid by the non-government sector.7 Government expenditure on general 
practice services (including those of the practice nurses) was almost $5.6 billion dollars in the 
2011–12 financial year.8 
GPs are usually the first port of call in the Australian healthcare system. Payment for GP 
visits is largely on a fee-for-service system, there being no patient lists or registration. People 
are free to see multiple practitioners and visit multiple practices of their choice. There is a 
universal medical insurance scheme (managed by Medicare Australia), which covers all or 
most of a person’s costs for a GP visit.  
In 2009 in Australia, there were 25,707 practising primary care practitioners (vocationally 
recognised GPs and other medical practitioners), making up 24,614 full-time equivalents 
(based on a 40 hour week), or 112.1 per 100,000 people.9 While more recent labor force data 
have been published,10 the national figures reported to not include data from Queensland 
and Western Australia, so are not quoted here. 
In the April 2011 – March 2012 year, about 83% of the Australian population claimed at least 
one GP service from Medicare (personal communication, Department of Health and Ageing 
(DoHA), April 2012) and Medicare paid rebates for about 122.5 million claimed general 
practice service items (excluding practice nurse items),2 at an average of about 5.36 GP visits 
per head of population or 6.55 visits per person who visited at least once. 
A decade earlier, in the 2002–03 financial year, total Medicare claims for GP–patient 
encounters numbered 96.9 million,8 an average attendance rate of 4.9 per head of population. 
Cost of these GP services to Medicare rose from $2.8 billion in 2002–03, to $5.5 billion in 
2011–12 with a further $34.3 million spent on practice nurse services (a total of $5.6 billion), 
representing 31.5% of total Medicare costs in that year.8 
While Medicare statistics provide information about frequencies and costs of visits claimed 
from Medicare for GP services, they cannot tell us about the content of these visits. The 
BEACH program fills this gap. 
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BEACH gives us some understanding of the content of GP–patient encounters and of the 
services and treatments that general practice provides. The BEACH program aims to: 
• provide a reliable and valid data collection process for general practice that is responsive 
to the ever-changing needs of information users 
• establish an ongoing database of GP–patient encounter information 
• assess patient risk factors and health states, and their relationship with service activity. 
Users of the BEACH data might wish to consolidate information from multiple national data 
sources. Integration of data from multiple sources can provide a more comprehensive 
picture of the health and health care of the Australian community. It is therefore important 
that readers are aware of how the BEACH data differ from those drawn from other sources. 
A summary of differences between those data collected in BEACH and those in the Medicare 
Benefits Schedule, the Pharmaceutical Benefits Scheme and the National Health Survey is 
available in General practice activity in Australia 2011–12 (Section 1.3).1 The BEACH program 
has generated many papers on a wide variety of topics in journals and professional 
magazines. A full list is available at <sydney.edu.au/medicine/fmrc/>. 
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2 Methods  
In summary: 
• each year, BEACH involves a new random sample of about 1,000 GPs 
• each GP records details about 100 doctor–patient encounters of all types  
• the GP sample is a rolling (ever-changing) sample, with about 20 GPs participating in 
any one week, 50 weeks a year (with two weeks break over Christmas) 
• each GP can be selected only once per Quality Improvement & Continuing Professional 
Development (QI & CPD) Program triennium (that is, once in each three-year period) 
• the encounter information is recorded by the GPs on structured paper encounter forms 
(Appendix 1) 
• GP participants also complete a questionnaire about themselves and their practice 
(Appendix 2). 
2.1 Sampling methods 
The source population includes all vocationally registered GPs and all general practice 
registrars who claimed a minimum of 375 Medicare general practice items of service in the 
most recently available three-month Medicare data period (which equates to 1,500 such 
claims in a year). This ensures inclusion of the majority of part-time GPs, while excluding 
those who are not in private practice but claim for a few consultations a year. 
The Medicare statistics section of the DoHA updates the sample frame from the Medicare 
records quarterly from the Medicare claims data, then removes from the sample frame any 
GPs already randomly sampled in the current triennium, and draws a new sample from 
those remaining in the sample frame. This ensures the timely addition of new entries to the 
profession, and timely exclusion of those GPs who have stopped practising, or have already 
participated or been approached in the current triennium. 
2.2 Recruitment methods 
The randomly selected GPs are approached by letter, posted to the address provided by 
DoHA. 
• Over the following ten days, the telephone numbers generated from the Medicare data 
are checked using the electronic white and yellow pages. This is necessary because many 
of the telephone numbers provided from the Medicare data are incorrect. 
• The GPs are then telephoned in the order they were approached and, referring to the 
approach letter, asked whether they will participate. 
• This initial telephone contact with the practice often indicates that the selected GP has 
moved elsewhere, but is still in practice. Where new address and/or telephone number 
can be obtained, these GPs are followed up at their new address. 
• GPs who agree to participate are set an agreed recording date several weeks ahead. 
• A research pack is sent to each participant before the planned start date. 
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• Each GP receives a telephone reminder early in the agreed recording period – this also 
provides the GP with an opportunity to ask questions about the recording process. 
• GPs can use a ‘freecall’ (1800) number to ring the research team with any questions 
during their recording period. 
• Non-returns are followed up by regular telephone calls for three months. 
• Participating GPs earn clinical audit points towards their QI & CPD requirements 
through the Royal Australian College of General Practitioners (RACGP) and/or the 
Australian College of Rural and Remote Medicine (ACRRM). As part of this QI process, 
each receives an analysis of his or her results compared with those of nine other de-
identified GPs who recorded at about the same time. Comparisons with the national 
average and with targets relating to the National Health Priority Areas are also 
provided. In addition, GPs receive some educational material related to the identification 
and management of patients who smoke or consume alcohol at hazardous levels. 
Additional points can be earned if the participant chooses to do a follow-up audit of 
smoking and alcohol consumption among a sample of patients about six months later. 
2.3 Ethics approval and informed patient consent 
Ethics approval for this study in 2011–12 was obtained from the Human Ethics Committee of 
the University of Sydney.  
Although the data collected by the GPs is not sufficient to identify an individual patient, 
informed consent for GP recording of the encounter details is required from each patient. 
GPs are instructed to ensure that all patients presenting during their recording period are 
provided with a Patient Information card (Appendix 3) and that they ask the patient if they 
are happy for their data to be included in the study. If the patient refuses, details of the 
encounter are not recorded. This is in accordance with the Ethics requirements for the 
BEACH program. 
2.4 Data elements 
BEACH includes three interrelated data collections: GP characteristics, encounter data and 
patient health status. An example of the form used to collect the encounter data and the data 
on patient health status is included in Appendix 1. The GP characteristics questionnaire is 
provided in Appendix 2. The GP characteristic and encounter data collected are summarised 
below. Patient health status data are described in Section 2.6. 
GP profile form (Appendix 2) 
• GP characteristics: age and sex, years in general practice, number of direct patient care 
hours worked per week, country of graduation, postgraduate general practice training 
status, Fellow of the RACGP status, Fellow of the ACRRM status, usual bulk-billing 
behaviour, use of computers at work, work undertaken in other clinical settings. 
• Practice characteristics: postcode and GP Division of major practice, number of 
individual and number of full-time equivalent GPs working in the practice, number of 
individual and number of full-time equivalent practice nurses working in the practice, 
usual after-hours care arrangements, whether the practice is accredited, whether it is a 
teaching practice. 
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Encounter recording form (Appendix 1) 
• Encounter data: date of consultation, type of consultation (direct/indirect) (tick box 
options), up to three MBS/DVA item numbers (where applicable), and other payment 
source (where applicable) (tick boxes). 
• Patient data: date of birth, sex and postcode of residence. Tick boxes (yes/no options) 
are provided for Commonwealth concession cardholder, holder of a repatriation health 
card (from DVA), non-English-speaking background (patient self-report – a language 
other than English is the primary language at home), Aboriginal person (self-
identification), and Torres Strait Islander person (self-identification). Space is provided 
for up to three patient reasons for encounter (RFEs) (see ‘Glossary’). 
• The problems managed at encounter (at least one and up to four). Tick boxes are 
provided to denote the status of each problem as new or continuing for the patient and 
whether the problem is considered by the GP to be work-related. 
• Management of each problem, including: 
– medications prescribed, supplied by the GP and advised for over-the-counter 
purchase including brand name, form (where required), strength, regimen, status 
(new or continuing medication for this problem), number of repeats 
– other treatments provided for each problem, including counselling, advice and 
education, and procedures undertaken, and whether the recorded other treatment 
was provided by practice nurse (tick box) 
– new referrals to medical specialists, allied health services, emergency departments, 
and hospital admissions 
– investigations, including pathology tests, imaging and other investigations ordered.  
2.5 The BEACH relational database 
The BEACH relational database is described diagrammatically in Figure 2.1. Note that:  
• all variables can be directly related to GP and patient characteristics and to the encounter 
• RFEs have only an indirect relationship with problems managed, as a patient may 
describe one RFE (such as ‘repeat prescriptions’) that is related to multiple problems 
managed, or several RFEs (such as ‘runny nose’ and ‘cough’) that relate to a single 
problem (such as upper respiratory tract infection) managed (see Section 6.3)  
• all types of management are directly related to the problem being managed.  
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The encounter 
• date 
• direct (face to face) 
— Medicare/DVA item 
number(s) claimable 
— workers compensation 
— other paid 
— no charge 
• indirect (e.g. telephone) 
Patient substudies (SAND) 
• risk factors 
— body mass 
— smoking status 
— alcohol consumption  
• other topics 
Management of each problem 
Medications (up to four per problem) 
• prescribed 
• over-the-counter advised 
• provided by GP 
— drug class 
— drug group 
— generic 
— brand name 
— strength 
— regimen 
— number of repeats  
— drug status (new/continued) 
 
Other treatments (up to two per 
problem) 
• procedural treatments 
• clinical treatments (e.g. advice, 
counselling) 
• practice nurse involvement 
 
Other management 
• referrals (up to two) 
— to specialists 
— to allied health professionals 
— to emergency departments 
— hospital admissions 
• pathology tests ordered (up to five) 
• imaging ordered (up to three) 
GP characteristics 
• age and sex 
• years in general practice 
• country of graduation 
• direct patient care hours/week 
• usual bulk-billing practice 
• postgraduate GP qualifications 
• FRACGP status (yes/no) 
• FACRRM status (yes/no) 
• currently a registrar (yes/no) 
• clinical use of computers  
Practice characteristics 
• practice size (no. & FTE GPs) 
• practice nurse(s) (no. & FTE) 
• after-hours arrangements 
• postcode  
• teaching practice (yes/no) 
Problems managed 
• diagnosis/problem label 
• problem status (new/old) 
• work-related problem status 
The patient 
• age and sex 
• practice status (new/old) 
• Commonwealth concession 
card status 
• DVA Status 
• postcode of residence 
• NESB/Indigenous status 
• reasons for encounter 
Note: FRACGP – Fellow of the Royal Australian College of General 
practitioners; FACRRM – Fellow of the Australian College of Rural 
and Remote Medicine; FTE – full-time equivalent; DVA – Department 
of Veterans’ Affairs; NESB – non-English-speaking background; 
SAND – Supplementary Analysis of Nominated Data. 
Figure 2.1: The BEACH relational database 
7
  
2.6 Supplementary Analysis of Nominated Data  
A section at the bottom of each recording form investigates aspects of patient health or 
healthcare delivery in general practice not covered by the consultation-based data. These 
additional substudies are referred to as SAND, Supplementary Analysis of Nominated Data. 
• Each year the 12–month data period is divided into ten blocks, each of five weeks, with 
three substudies per block. The research team aims to gain data from 100 GPs in each 
block.  
• Each GP’s pack of 100 forms is made up of 40 forms that ask for the start and finish times 
of the encounter, and include questions about patient risk factors: patient height and 
weight (used to calculate body mass index, BMI), alcohol intake and smoking status 
(patient self-report). The methods and results of topics in the SAND substudies for 
alcohol consumption, smoking status and BMI are reported in Chapter 13. The start and 
finish times collected on these encounters are used to calculate the length of consultation. 
The length of consultation for Medicare-claimable encounters is reported in Section 5.3. 
• The remaining 60 forms in each pack are divided into two blocks of 30, so each SAND 
block includes about 3,000 records. Some topics are repeated to increase sample size. 
Different questions are asked of the patient in each block. 
• The order of SAND sections is rotated in the GP recording pack, so that 40 patient risk 
factor forms may appear first, second or third in the pad. Rotation of ordering ensures 
there is no order effect on the quality of the information collected. 
Abstracts of results and the research tools used in all SAND substudies from April 1998 to 
March 2012 have been published. Those: 
• from April 1998 to March 1999 were published in Measures of health and healthcare delivery 
in general practice in Australia11 
• from April 1999 to July 2006 were published in Patient-based substudies from BEACH: 
abstracts and research tools 1999–200612 
• conducted between August 2006 and March 2011 have been published in each of the 
general practice activity annual reports13–17 
• conducted in the 2011–12 BEACH year are provided in Chapter 14 of the companion 
publication General practice activity in Australia 2011–12.1  
Abstracts of results for all SAND substudies are also available on the FMRC’s website 
<www.fmrc.org.au/publications/SAND_abstracts.htm>. 
2.7 Statistical methods 
The analysis of all BEACH data was conducted with Statistical Analysis System (SAS) 
version 9.2.18 When originally published, data from 2001–02 to 2004–05 were analysed using 
SAS version 6.1219 (with additional programming to adjust for the cluster sample study 
design). Previously published data from 2005–06 to 2010–11 were analysed using 
SAS version 9.1.3.20 At each change in SAS version, all past data have been re-analysed. This 
has resulted in slightly tighter confidence intervals and minor variations in point estimates 
(of up to 0.1) when data published in this report are compared with data published in earlier 
annual reports.  
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BEACH is a single stage cluster sample study design, each 100 encounters forming a cluster 
around each GP participant. In cluster samples, variance needs to be adjusted to account for 
correlation between observations within clusters. Procedures in SAS version 9.218 are used to 
calculate the intracluster correlation and adjust the confidence intervals accordingly.  
Post-stratification weighting of encounter data adjusts for any variance in the characteristics 
of the participating GPs from those of the sample frame from which they were drawn, and 
for the varying activity level of each GP (measured by the number of claims each has made 
in the previous 12 months from Medicare Australia). The final sample of encounters shows 
excellent precision when the age–sex distribution of the patients is compared with the 
distribution in all Medicare-claimed services of this type.1  
The encounter is the primary unit of inference. Proportions (percentages) are used when 
describing the distribution of an event that can arise only once at a consultation (for example, 
age, sex), or to describe the distribution of events within a class of events (for example, 
problem A as a percentage of total problems). Due to rounding, proportions may not always 
add to exactly 100%. 
Rates per 100 encounters are used when an event can occur more than once at the 
consultation (for example, RFEs, problems managed or medications). Rates per 100 problems 
are also used when a management event can occur more than once per problem managed.  
The statistical significance of changes in characteristics of the GPs is tested using the  
chi-square test statistic. However, in general, the results for events occurring at GP–patient 
encounters are presented as the rate per 100 problems managed, and the rate per 100 
encounters, with 95% confidence interval. 
Statistical significance is tested by chi square statistic for GP characteristics, but significance 
of differences in/for rates is judged by non-overlapping confidence intervals of the results 
being compared. The magnitude of this difference can be described as at least p < 0.05. 
Assessment using non-overlapping CIs is a conservative measure of significance,21–23 
particularly when differences are assessed by comparing results from independent random 
samples, as is the case when changes over time are investigated using BEACH data. Due to 
the number of comparisons made in this and the companion publication we believe a 
conservative approach is warranted. 
• Changes over time in the frequency of these events are judged significant (that is, a real 
change has occurred) if the two sets of confidence intervals do not overlap. For example, 
Result A: 11.5 per 100 encounters (95% CI: 11.3–11.7) is significantly less than Result B: 
11.9 per 100 encounters (95% CI: 11.8–12.0). 
• If the two sets of confidence intervals butt together the difference is regarded as 
marginal. For example, Result A: 11.5 per 100 encounters (95% CI: 11.3–11.7) is 
marginally lower than Result B: 11.9 (95% CI: 11.7–12.1). 
• If they overlap, then no change was measured. 
• All difference discussed in this report are statistically significant unless otherwise stated. 
2.8 Changes over time 
For the ten years 2002–03 to 2011–12, patient reasons for encounter and problems managed 
are reported as rates per 100 encounters. In earlier years, rates per 100 encounters have also 
been used when measuring changes in each of the management actions (prescriptions, other 
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treatments, referrals, pathology and imaging tests ordered). However, there has been a 
significant increase in the number of problems managed per encounter. This means that at 
each encounter, there is an increased chance of a management action occurring, without any 
change in the management practise of GPs. All management actions are therefore reported in 
two ways – as rates per 100 problems managed and as rates per 100 encounters. In describing 
changes over time, the rates per 100 problems are reported as the primary measure, but the 
rates per 100 encounters are used as the basis for extrapolation to the number of events 
occurring across the country in one year compared with another (see Section 2.9). 
Data presented in this report are comparable for each result across all data years. Where 
methodological changes have occurred, the data have either: 
• been recalculated across all years using the new method (for example, body mass index 
was recalculated due to a change in the WHO body mass index groupings) 
• been regrouped for comparability. Where this occurs, it is noted in the footnotes of the 
table. An example is the combined presentation of home visits and institutional visits in 
Chapter 5 because the MBS now has only one item number for both. In previously 
published data it was possible to differentiate the two. 
• been omitted from this report (if recalculation or grouping was not possible). Where data 
are omitted, this is noted as not applicable (N/A) or not available (NAv), as appropriate. 
In measuring changes over time, the 2011–12 results are compared with those from 2002–03 
wherever possible. However, as in any long-term research program, changes occur over the 
years. For example, practice nurse activity data were not collected until 2005–06, so the 
changes are only considered between 2005–06 and 2011–12. 
Each table includes the most frequent events occurring in 2011–12, and the comparative 
results for each of the earlier year. In addition, each table includes data for events that were 
more frequent in past year(s), but were no longer in the most frequent in 2011–12.  
Results are in general presented in decreasing 2011–12 order of frequency. 
The direction and type of change between 2002–03 and 2011–12 is indicated for each result in 
the far right column of the tables: 
• / indicates a statistically significant change (increase or decrease) in 2011–12 when 
compared with the first year of data reported 
• / indicates a marginally significant change in 2011–12 when compared with the first 
year of data reported 
• indicates there was no significant change in 2011–12 when compared with the first year 
of data reported 
• and § indicates a noteworthy change during the decade. 
2.9 Extrapolated national estimates 
Extrapolations can be used to estimate the number of occurrences of a selected event at  
 GP–patient encounters in Australia at a single time point or to estimate the total national 
effect of a measured change. 
Where the results demonstrate a significant change over time, the estimated national change 
across total GP Medicare services from 2002–03 to 2011–12 can be calculated using the 
method detailed below. Note that extrapolations are always based on rate per 100 encounters 
rather than rate per 100 problems because there is no independent measure of the number of 
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problems managed in Australian general practice. In contrast, the number of national 
encounters can be drawn from Medicare claims data.  
Examples of extrapolated national change are given in each chapter in the report from 
Chapter 5 to Chapter 12 inclusive. 
When extrapolating measured change over the decade to national estimates, we: 
• divide the ‘rate per 100 encounters’ of the selected event for 2002–03 by 100, and then 
multiply by the total number of general practitioner service items claimed through 
Medicare in 2002–03 (rounded to the nearest 100,000). As shown in Table 2.1, this was 
122.5 million. This provides the estimated national number of events in 2002–03.  
• repeat the process using data from 2011–12.  
The difference between the two estimates gives the estimated national change in the 
frequency of that event between 2002–03 and 2011–12. Estimated national number of events 
are rounded to the nearest 100,000 if more than a million and to the nearest 10,000 if below a 
million. It is possible to use this method to calculate the national effect of any significant 
change in a single result over any two time points. For example, extrapolations in the 
practice nurse chapter are based on changes between 2005–06 and 2011–12. 
Change is expressed as the estimated increase or decrease over the study period, in the 
number of general practice contacts for that event (for example, an increase or decrease in the 
number of GP management contacts with problem X); or an increase or decrease in the 
number of times a particular management action (e.g. a selected generic medication) was 
prescribed in Australia in 2011–12, when compared with (usually) 2002–03. 
Extrapolations can also be made using data from a single time point to estimate the number 
of occasions that an event occurs in general practice encounters nationally in a specific year. 
When extrapolating from a single time point we: 
• divide the ‘rate per 100 encounters’ of the selected event by 100, and multiply by the 
total number of general practitioner service items claimed through Medicare that year 
(rounded to nearest 100,000) to give the estimated national number of events in that year. 
Table 2.1 provides the total (rounded) number of general practice professional service items 
claimed from Medicare in each financial year from 2002–03 to 2011–12.  
Table 2.1: Rounded number of general practice professional services claimed from Medicare 
Australia each financial year, 2002–03 to 2011–12 (million) 
 2002–03 2003–04 2004–05 2005–06 2006–07 2007–08 2008–09 2009–10 2010–11 2011–12(a) 
Rounded number of 
MBS GP items of 
service claimed 
96.9 96.3 98.2 101.1 103.4 109.5 113.0 116.6 118.1 122.5 
(a) Medicare data for the 2011–12 year included data from the April 2011 to March 2012 quarters because the 2011–12 financial year data 
were not available at the time of preparation of this report. 
Source: Medicare statistics2 
Example 1: Change in the number of problems managed by GPs nationally  
There was a significant increase in the number of problems managed at encounter, from 
144.9 per 100 encounters in 2002–03 to 153.8 in 2011–12 (see Table 7.2). The calculation used 
to extrapolate the effect of this change across Australia is:  
(144.9/100) x 96.9 million = 140.4 million problems managed nationally in 2002–03, and 
(153.8/100) x 122.5 million = 188.4 million problems managed nationally in 2011–12.  
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This suggests there were 48 million (188.4 million minus 140.4 million) more problems 
managed at GP–patient encounters in Australia in 2011–12 than in 2002–03.  
This is the result of the compound effect of the increase in the number of problems managed 
by GPs at encounters plus the increased number of visits over the decade across Australia. 
Example 2: Change in the number of GP–patient encounters at which 
depression was managed nationally (with 95% confidence intervals)  
The management of depression increased significantly from 3.5 per 100 GP–patient 
encounters (95% CI: 3.3 to 3.7) in 2002–03, to 4.4 per 100 (95% CI: 4.1–4.7) in 2011–12. In this 
example the 95% confidence intervals are incorporated in the extrapolation, to estimate the 
size of the national impact of this change and demonstrate our level of certainty of this 
estimate. 
For 2002–03 our best estimate for the total national encounters involving depression is: 3.4 
million [(3.5/100) x 96.9 million], but we are 95% confident that the true number lies between 
3.2 million [(3.3/100) x 96.9 million] and 3.6 million [(3.7/100) x 96.9 million]. 
For 2011–12 our best estimate for the total national encounters involving depression is: 5.4 
million times [(4.4/100) x 122.5 million], but we are 95% confident that the true number lies 
between 5.0 million [(4.1/100) x 122.5 million] and 5.8 million [(4.7/100) x 122.5 million]. 
Therefore we estimate that nationally in 2011–12, depression was managed at 2 million more 
GP–patient encounters than it was in 2002–03, and we are 95% confident that the true 
difference lies between 1.8 million and 2.2 million. 
This result has two causal factors: the increased attendance rate and the resulting increase in 
total attendances across the country plus its increased management rate by GPs. 
Considerations and limitations in extrapolations 
The extrapolations to the total events occurring nationally in any one year are only estimates. 
They may provide: 
• an underestimate of the true ‘GP workload’ of a condition/treatment because the 
extrapolations are made to GP Medicare items claimed, not to the total number of GP–
patient encounters per year – an additional 5% of BEACH encounters annually include 
encounters paid by sources other than Medicare, such as DVA, state governments, 
workers compensation insurance, and employers.17 
• an underestimate of activities of relatively low frequency with a skewed distribution 
across individual GPs.  
Further, the base numbers used in the extrapolations are rounded to the nearest 100,000, and 
extrapolation estimates are rounded to the nearest 100,000 if more than a million and to the 
nearest 10,000 if below a million. However, the rounding has been applied to all years, so the 
effect on measures of change will be very small. Therefore, the extrapolation still provides an 
indication of the size of the effect of measured change nationally. 
Extrapolations are based on the unit of the encounter because the number of national 
encounters is quantifiable using Medicare claims data. However, the reader should be aware 
that where an event can occur more than once per encounter, the extrapolation represents 
the number of occasions at which that event occurs in general practice encounters, rather 
than the number of encounters where that event occurs.  
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2.10 Changes to data elements and reporting 
methods 
Some changes in data elements and reporting methods have occurred since the BEACH 
study began in April 1998. 
Two changes were made to the BEACH form from 2005–06 onwards to capture practice 
nurse activity associated with the GP–patient consultations. From 2005–06 onwards: 
• GPs could record multiple (up to three) Medicare item numbers 
• in the ‘other treatments’ section, for each problem managed, the GP was asked to tick the 
practice nurse box if the treatment recorded was provided by the practice nurse rather 
than by the GP. If the box was not ticked, the research team assumed that the GP 
provided the recorded treatment. 
These changes have implications for the reporting of Medicare/DVA-claimable encounters 
(Chapter 5), other treatments (Chapter 10) and practice nurse activity (Chapter 10). 
Medicare/DVA-claimable encounters 
For the first seven years of the BEACH program (1998–99 to 2004–05), where a Medicare item 
number was claimable for the encounter, the GP was instructed to record only one item 
number. Where multiple item numbers (for example, an item for ‘standard surgery 
consultation’ and a procedural item number) were claimable for an encounter, the GP was 
instructed to record the lower of these (usually an A1 item number). For reporting purposes 
Medicare-claimable encounters were broken down according to the item number recorded 
by the GP as claimable (either through Medicare or through DVA) for the encounter. 
In this report the Medicare/DVA claimable encounters count only one item number per 
Medicare/DVA-claimable encounter for comparability with previous years (see Chapter 5). 
Practice nurse Medicare-claimable encounters are not reported in Chapter 5. 
The selection of one item number was done on a priority basis: consultation item numbers 
override incentive item numbers, which override procedural item numbers, which override 
other Medicare item numbers. 
Practice nurse activity 
The research team began to capture practice nurse activity (in 2005–06) due to the 
introduction of four new MBS item numbers in November 2004, which covered some 
selected activities done by a practice nurse on behalf of a medical practitioner.24 
The primary aim of BEACH is to describe general practice activity. Before 2005–06, ‘general 
practice activity’ was described in terms of GP–patient encounters, and this was considered 
close to equivalent to ‘general practitioner activity’. However, the introduction of the practice 
nurse item numbers meant that, if practice nurse activity associated with the GP–patient 
encounter was not included, the content of the consultation was not fully described. 
Over the years new PN item numbers were added to the MBS and some items were 
broadened to include work done by Aboriginal health workers (AHWs). In past years we 
have reported the results referring to PNs alone. However in 2011–12 a few GPs indicated (of 
their own accord) that the recorded action was done by an AHW rather than a PN. This 
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information is now included, and now refer to work undertaken at encounters by PNs and 
AHWs in conjunction with the GPs, though the vast majority will have been done by PNs. 
There is a limitation to this approach. Few GPs specifically indicated that the work was done 
by an AHW. Others may have thought that because the question referred specifically to PNs, 
and recording of work done by AHWs was not specifically requested. These results therefore 
have the potential to be an underestimate of the work undertaken at GP–patient encounters 
by PNs and AHWs. 
Chapter 10 provides a breakdown of the PN Medicare items claimed, the morbidity 
managed with the assistance of the PN, and the other treatments given by the PN as 
recorded by the GP participants from 2005–06 to 2011–12. 
When viewing these results, it must be remembered that they do not include activities done 
by the PN or AHW during the GP’s BEACH recording period that were performed 
independently the recorded encounter.  
Other treatments 
In Chapter 10 ‘Other treatments’, all recorded clinical and procedural treatments are 
included, irrespective of whether they were provided by the GP or by the PN or AHW. The 
exception is Section 10.3, where those activities reported by the GP to have been done by a 
PN or AHW are analysed separately. 
2.11 Classification of data 
The following data elements are classified according to the International Classification of 
Primary Care – Version 2 (ICPC-2), a product of the World Organization of Family Doctors 
(Wonca):25 
• patient reasons for encounter (RFEs) 
• problems managed 
• clinical treatments (for example, counselling, advice) 
• procedural treatments 
• referrals 
• investigations ordered (including pathology, imaging and other investigations). 
The ICPC-2 is used in more than 45 countries as the standard for data classification in 
primary care. It is accepted by the WHO in the WHO Family of International 
Classifications,26 and is the declared national standard in Australia for reporting of health 
data from general practice and patient self-reported health information.27 
The ICPC-2 has a biaxial structure, with 17 chapters on one axis (each with an alphabetic 
code) and seven components on the other (numeric codes) (Figure 2.2). Chapters are based 
on body systems, with additional chapters for psychological and social problems. 
Component 1 includes symptoms and complaints. Component 7 covers diagnoses, and can 
also be divided to provide data about infections, injuries, neoplasms, congenital anomalies 
and ‘other’ diagnoses. 
Components 2 to 6 cover the process of care, and are common throughout all chapters. The 
referrals, other (non-pharmacological) treatments and orders for pathology and imaging, are 
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classified in these components. Component 2 (diagnostic, screening and prevention) is also 
often applied in describing the problem managed (for example, check-up, immunisation). 
The components are standard and independent throughout all chapters.  
The ICPC-2 is an excellent epidemiological tool. The diagnostic and symptomatic rubrics 
were selected for inclusion on the basis of their relative frequency in primary care settings, or 
because of their relative importance in describing the health of the community. It has about 
1,370 rubrics, and these are sufficient for meaningful analyses. However, reliable data entry 
using ICPC-2 alone, requires a thorough knowledge of the classification. 
 
                    
 Components A B D F H K L N P R S T U W X Y Z  
 1. Symptoms, complaints                    
 2. Diagnostic, screening, prevention                   
 3. Treatment, procedures, medication                   
 4. Test results                   
 5. Administrative                   
 6. Other                   
 7. Diagnoses, disease                   
 A General and unspecified L Musculoskeletal U Urinary 
 B Blood & blood-forming organs N Neurological W Pregnancy, family planning 
 D Digestive P Psychological X Female genital  
 F Eye R Respiratory Y Male genital  
 H Ear S Skin Z Social  
 K Circulatory T Endocrine, nutritional & metabolic   
 
Figure 2.2: The structure of the International Classification of Primary Care – Version 2 (ICPC-2) 
 
In 1995, recognising a need for a coding and classification system for general practice 
electronic health records, the Family Medicine Research Centre (then the Family Medicine 
Research Unit) developed a clinical terminology classified according to the ICPC, now called 
ICPC-2 PLUS.28 This is an interface terminology, developed from all the terms used by GPs 
in studies such as the Australian Morbidity and Treatment Survey 1990–91 (113,468 
encounters),29 the country and metropolitan general practice study 1990–91 
(51,277 encounters), the Morbidity and Therapeutic Index 1992–1998 (a clinical audit tool that 
was available to GPs) (400,00 encounters), and BEACH 1998–2012 (about 1.4 million 
encounters), which together include more than 3.5 million free text descriptions of problems 
managed and a further 3.5 million for patient reasons for encounter. Readers interested in 
seeing how coding works can download the ICPC-2 PLUS Demonstrator at 
<sydney.edu.au/medicine/fmrc/icpc-2-plus/demonstrator/index.php>. 
When the free-text data are received from the GPs, trained secondary coders (who are 
undergraduate students studying health information management or medical science) code 
the data in more specific terms using ICPC-2 PLUS. This ensures high coder reliability and 
automatic classification of the concept, and provides the ability to ‘ungroup’ such 
ICPC-2 rubrics as ‘other diseases of the circulatory system’ and select a specific disease from 
the terms within it. 
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Presentation of data classified in ICPC-2 
Statistical reporting is almost always at the level of the ICPC-2 classification (for example, 
acute otitis media/myringitis – ICPC-2 code H71). However, there are some exceptions 
where data are grouped either above the ICPC-2 level or across the ICPC-2 level. These 
grouped codes are defined in Appendix 4, available at: <hdl.handle.net/2123/8676>. 
Reporting morbidity with groups of ICPC-2 codes 
When recording problems managed, GPs may not always be very specific. For example, in 
recording the management of hypertension, they may simply record the problem as 
‘hypertension’. In ICPC-2, ‘hypertension, unspecified’ is classified as ‘uncomplicated 
hypertension’ (code K86). There is another code for ‘complicated hypertension’ (K87). In 
some cases the GP may simply have failed to specify that the patient had hypertension with 
complications. The research team therefore feels that for national data reporting, it is more 
reliable to group the codes K86 and K87 and label this ‘Hypertension*’ – the asterisk 
indicating that multiple ICPC-2 codes (as in this example) or ICPC-2 PLUS codes (see below) 
are included. Appendix 4, Table A4.1 lists codes included in these groups. 
Reporting morbidity with groups of ICPC-2 PLUS codes 
In other cases a concept can be classified within multiple ICPC-2 codes but only be part of 
some of these codes. For example, osteoarthritis is classified in ICPC-2 in multiple codes 
according to site: L89 – osteoarthrosis of hip; L91 – osteoarthrosis of knee; L92–shoulder 
syndrome — the last of which includes bursitis, frozen shoulder, rotator cuff syndrome as 
well as osteoarthritis of shoulder. When reporting osteoarthritis in this publication, all the 
more specific osteoarthritis ICPC-2 PLUS terms within all the appropriate ICPC-2 codes are 
grouped. This group is labelled ‘Osteoarthritis*’ – the asterisk again indicating multiple 
codes, but in this case they are PLUS codes rather than ICPC-2 codes. Appendix 4, Table 4.1 
lists codes included in these groups. 
Reporting chronic morbidity 
Chronic conditions are medical conditions characterised by a combination of the following 
characteristics: duration that has lasted or is expected to last six months or more, a pattern of 
recurrence or deterioration, a poor prognosis, and consequences or sequelae that affect an 
individual’s quality of life. 
To identify chronic conditions, a chronic condition list30 classified according to ICPC-2 was 
applied to the BEACH data set. In general reporting, both chronic and non-chronic 
conditions (for example, diabetes and gestational diabetes) may be grouped together (for 
example, diabetes – all*). When reporting chronic morbidity, only problems regarded as 
chronic are included in the analysis. Where the group used for the chronic analysis differs 
from that used in other analyses in this report, it is marked with a double asterisk. Codes 
included in the chronic groups are provided in Appendix 4, Table A4.2. 
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Reporting pathology and imaging test orders 
All the pathology and imaging tests recorded by the GPs are coded very specifically in the 
PLUS terminology, but ICPC-2 classifies pathology and imaging tests very broadly (for 
example, a test of cardiac enzymes is classified in K34 – Blood test associated with the 
cardiovascular system; a CT scan of the lumbar spine is classified as L41 – Diagnostic 
radiology/imaging of the musculoskeletal system). In Australia, the Medicare Benefits 
Schedule (MBS) classifies pathology and imaging tests in groups that are relatively well 
recognised. We have therefore regrouped all pathology and imaging PLUS codes into MBS 
standard groups. This allows comparison of data between data sources. Such groups are 
marked with an asterisk, and inclusions provided in Appendix 4, Tables A4.8 and A4.9. 
Classification of pharmaceuticals 
Pharmaceuticals that are prescribed, provided by the GP or advised for over-the-counter 
purchase are coded and classified according to an in-house classification, the Coding Atlas 
for Pharmaceutical Substances (CAPS). 
This is a hierarchical structure that facilitates analysis of data at a variety of levels, such as 
medication class, medication group, generic composition, and brand name. 
Strength and regimen are independent fields that, when combined with the CAPS code, 
allow calculation of the prescribed daily dose for any prescribed medication. 
CAPS is mapped to the Anatomical Therapeutic Chemical (ATC)31 classification (but using 
Australian spelling), which is the Australian standard for classifying medications at the 
generic level. 
The ATC has a hierarchical structure with five levels. For example: 
• Level 1: C – Cardiovascular system 
• Level 2: C10 – Serum lipid reducing agents 
• Level 3: C10A – Cholesterol and triglyceride reducers 
• Level 4: C10AA – HMG CoA reductase inhibitors 
• Level 5: C10AA01 – Simvastatin (the generic drug). 
Reporting pharmaceutical data 
For pharmaceutical data, there is the choice of reporting in terms of the CAPS coding scheme 
or the ATC. They each have advantages in different circumstances. 
In the CAPS system, a new drug enters at the product and generic level, and is immediately 
allocated a generic code. Therefore, the CAPS classification uses a bottom-up approach. 
In the ATC, a new generic drug type may initially enter the classification at any level (1 to 5), 
not necessarily always at the generic level. Reclassification to more specific ATC levels may 
occur later. Therefore, the ATC uses a top-down approach. 
When analysing medications across time, a generic medication that is initially classified to a 
higher ATC level will not be identifiable in that data period, and may result in 
under-enumeration of that drug during earlier data collection periods. Therefore n 
measuring changes in medications over time, we have chosen to report at Level 2 of the ATC 
(which is more stable over time than Level 3), except when reporting at the generic level, 
when we use CAPS.  
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2.12 Quality assurance 
All morbidity and therapeutic data elements were secondarily coded by staff entering key 
words or word fragments, and selecting the required term or label from a pick list. This was 
then automatically coded and classified. A quality assurance program to ensure reliability of 
data entry includes ongoing development of computer-aided error checks (‘locks’) at the 
data entry stage, and a physical check of samples of data entered against those on the 
original recording form. We also conduct logical data checks through SAS on a regular basis. 
2.13 Validity and reliability 
A discussion of the reliability and validity of the BEACH program has been published 
elsewhere.32 This section touches on some aspects of reliability and validity of active data 
collection from general practice that should be considered by the reader.  
In the development of a database such as BEACH, data gathering moves through specific 
stages: GP sample selection, cluster sampling around each GP, GP data recording, secondary 
coding and data entry. At each stage the data can be invalidated by the application of 
inappropriate methods. The methods adopted to ensure maximum reliability of coding and 
data entry have been described above. The statistical techniques adopted to ensure valid 
analysis and reporting of recorded data are described in Section 2.7. Previous work has 
demonstrated the extent to which a random sample of GPs recording information about a 
cluster of patients represents all GPs and all patients attending GPs33, the degree to which GP-
reported patient RFEs and problems managed accurately reflect those recalled by the patient,34 
and reliability of secondary coding of RFEs35 and problems managed.29 The validity of ICPC as 
a tool with which to classify the data has also been investigated in earlier work.36 
However, the question of the extent to which the GP-recorded data are a reliable and valid 
reflection of the content of the encounter must also be considered. In many primary care 
consultations, a clear pathophysiological diagnosis is not reached. Bentsen37 and Barsky38 
suggest that a firm and clear diagnosis is not apparent in about half of GPs’ consultations, 
and others suggest the proportion may be even greater.39 Further, studies of general 
ambulatory medical practice have shown that a large number of patients presenting to a 
primary care practitioner are without a serious physical disorder.40,41 As a result, it is often 
necessary for a practitioner to record a problem in terms of symptoms, signs, patient 
concerns, or the service that is requested, such as immunisation. For this reason, this report 
refers to patient ‘problems’ rather than ‘diagnoses’. 
A number of studies have demonstrated wide variance in the way a GP perceives the patient’s 
RFE and the manner in which the GP describes the problem under management. Further, in a 
direct observational study of consultations via a one-way mirror, Bentsen demonstrated that 
practitioners differ in the way they labelled problems, and suggested that clinical experience 
may be an important influence on the identification of problems within the consultation.37 Two 
other factors that might affect GPs’ descriptions of patient RFEs have been identified: 
although individuals may select the same stimuli, some label each stimulus separately, 
whereas others cluster them under one label; and individuals differ in the number of stimuli 
they select (selective perception).42 
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The extent to which therapeutic decisions may influence the diagnostic label selected has also 
been discussed. Howie43 and Anderson40 argue that, while it is assumed that the diagnostic 
process used in general practice is one of symptom  diagnosis  management, the 
therapeutic method may well be selected on the basis of the symptom, and the diagnostic label 
chosen last. They suggest that the selection of the diagnostic label is therefore influenced by the 
management decision already made. 
Alderson contends that to many practitioners ‘diagnostic accuracy is only important to the 
extent that it will assist them in helping the patient’. He further suggests that if major symptoms 
are readily treatable, some practitioners may feel no need to define the problem in diagnostic 
terms.44 Crombie identified ‘enormous variability in the rates at which doctors perceive and 
record illnesses’. He was unable to account statistically for this variation by the effect of 
geography, age, sex or class differences in the practice populations.45 Differences in the way 
male and female GPs label problems also appear to be independent of such influences.46 
These problems are inherent in the nature of general practice. Knottnerus argues that the GP 
is confronted with a fundamentally different pattern of problems from the medical specialist, 
and often has to draw up general diagnostic hypotheses related to probability, severity and 
consequences.47 Anderson suggests that morbidity statistics from family practice should 
therefore be seen as ‘a reflection of the physician’s diagnostic opinions about the problems that 
patients bring to them rather than an unarguable statement of the problems managed’.40  
While these findings regarding limitations in the reliability and validity of 
practitioner-recorded morbidity should be kept in mind, they apply equally to data drawn 
from health records, whether paper or electronic, as they do to active data collection 
methods.48,49 There is as yet no more reliable method of gaining detailed data about 
morbidity and its management in general practice. Further, irrespective of the differences 
between individual GPs in their labelling of the problems, morbidity data collected by GPs in 
active data collection methods have been shown to provide a reliable overview of the 
morbidity managed in general practice.50 
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3 The samples 
For annual response rates and measures of representativeness of individual annual GP 
samples, please see the annual report for each year in question (available at: 
<sydney.edu.au/medicine/fmrc/publications/books/GP-series/index.php>). 
More detailed analyses of the samples in 2011–12 can be found in Chapter 3 in General 
practice activity in Australia 2011–12.1 
Table 3.1 shows the number of encounter records contained in each year of the BEACH 
program since April 2002, and the size of the database for those ten years for each variable 
(weighted), upon which all comparisons over time described in this report are based. 
Table 3.1: Annual summary of data sets, 2002–03 to 2011–12 (final weighted data) 
Variable 2002–03 2003–04 2004–05 2005–06 2006–07 2007–08 2008–09 2009–10 2010–11 2011–12 
Total ten 
years 
General 
practitioners 
1,008 1,000 953 1,017 930 953 1,011 988 958 984 9,802 
Encounters 100,987 98,877 94,386 101,993 91,805 95,898 96,688 101,349 95,839 99,030 976,852 
Reasons for 
encounter 
152,341 148,521 141,215 153,309 138,434 146,696 151,282 157,071 149,005 153,218 1,491,092 
Problems 
managed 
146,336 144,674 137,330 149,088 136,333 145,078 149,462 155,373 146,141 152,286 1,462,101 
Medications 104,813 103,210 95,816 106,493 93,193 98,439 102,737 108,001 100,817 106,007 1,019,526 
Other 
treatments 
53,676 50,775 51,632 44,504 41,011 49,130 49,048 53,243 50,235 53,395 496,649 
Referrals & 
admissions 
11,261 11,507 10,890 12,242 11,230 12,017 13,251 13,481 13,526 14,382 123,787 
Pathology 33,234 34,831 34,652 39,358 38,963 41,375 44,066 45,594 43,313 46,544 401,930 
Imaging 8,678 8,121 7,840 9,003 8,229 9,143 9,469 9,877 9,370 9,978 89,708 
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4 The participating GPs 
4.1 Characteristics of the participating GPs 
In BEACH, each GP participant completes a profile questionnaire about themselves and the 
major practice at which they are employed (see Appendix 2). Over the ten years, the 
questions have occasionally been altered to improve the quality and clarity of the data 
collected, or to investigate topics not previously surveyed as they became relevant. 
Therefore, for some characteristics we have data over the full ten-year period, and for some, 
we have data over shorter periods. 
More detailed analyses of the participating GPs in 2011–12 can be found in Chapter 4 in 
General practice activity in Australia 2011–12.1 
Over the period 2002–03 to 2011–12 some trends emerged in the characteristics of GP 
BEACH participants (Table 4.1). The most noticeable changes over the ten years are listed 
below and some are presented in Figure 4.1. 
• The feminisation of the general practice workforce is reflected in the growing proportion 
of GP participants who are female. The proportion of female participants increased from 
35.2% in 2002–03 to 40.8% in 2011–12. This change reflects change in the sex distribution 
of all recognised GPs claiming more than 375 general practice Medicare items of service 
in the previous quarter (33.2% in 2002–0351 and 39.1% in 2011–12), as provided each year 
by DoHA, from Medicare claims data. In Table 4.1, there was a ‘spike’ in the proportion 
of female GPs among the participating sample in 2009–10. As reported last year this was 
the result of female GPs being over-represented in the sample provided by DoHA when 
compared with the national sample frame (as may occasionally happen in the random 
sampling process).16  
• From 2002–03 to 2011–12 there was a significant change in the age distribution of 
participants, with a decrease in the proportion aged 35–44 years (from 26.6% to 19.4%), 
and an increase in the proportion aged 55 years and over (from 30.9% to 41.1%). Again, 
these changes reflect the changes in the practising GP population (as defined for 
BEACH) from Medicare claims data, in which the proportion aged 35–44 years 
decreased from 25.1%51 to 19.8%, and the proportion aged 55 years or more increased 
from 32.0%51 to 42.2%. 
• The ageing of the GP workforce was reflected in the increasing proportion of GPs who 
had worked in general practice for 20 years or longer, from 50.4% in 2002–03 to 58.4% in 
2011–12. 
• There was a significant increase in the proportion of GPs working 21–40 hours per week 
on direct patient care (from 41.6% in 2002–03 to 53.0% in 2011–12), and a significant 
decrease in the proportion working 41–60 hours (42.8% in 2002–03 to 32.1% in 2011–12),  
the dramatic drop occurring in 2009–10 (from 40.2% to 30.8%). The proportion working 
more than 60 hours per week in direct patient care also steadily decreased (from 4.1% to 
1.4%). When the last two results are combined, there was a decrease for 46.9% of 
participants working more than 40 hours per week in direct patients care in 2002–03 to 
33.5% working these hours in 2011–12. This has implications for workforce planning. 
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• There was a significant decrease over the decade in the proportion of Australian GPs 
who had gained their primary medical degree in Australia, from 72.0% in 2002–03 to 
67.2% in 2011–12. There were also significant changes in the geographic distribution of 
country of graduation for those trained overseas. 
• There was a significant increase (from 23.1% in 2003–04 to 27.4% in 2011–12) in the 
proportion of participants who provide some consultations in a language other than 
English. This change may be associated with the increase in the proportion of GPs who 
gained their primary medical degree in a country other than Australia. Anecdotally, a 
number of city practices now advertise the variety of languages spoken by their 
clinicians. The uptake of services by patients who have immigrated, and the opportunity 
to consult with a GP in their native language, may have contributed to this change. 
• The proportion of GP participants holding Fellowship of the RACGP significantly 
increased, from 35.5% in 2002–03 to 56.8% in 2011–12. Since 1995, Fellowship of the 
RACGP has been mandatory for new clinicians entering general practice, so this change 
reflects the inclusion of new GPs into practice who hold FRACGP. 
4.2 Characteristics of participants’ major practice 
Over the period 2002–03 to 2011–12 some trends emerged in the characteristics of the GP 
participants’ major practices (Table 4.2). The most noticeable changes over the ten years are 
listed below.  
• The proportion of participants in solo practice, and the proportion in smaller practices of 
2–4 GPs significantly decreased. There was an associated significant increase in the 
proportion working in practices with 5–9 individual GPs (from 36.1% to 42.3%), and the 
proportion in practices with ten or more individual GPs (from 11.8% in 2002–03 to 
20.5%). Data were not available for 2007–08 and 2008–09, as the question was altered to 
capture full-time equivalent GPs at the practice instead of number of individuals. 
However from 2009–10, both data elements were captured. 
• There was a significant reduction in the proportion of GPs working in practices that 
provide their own after-hours services (from 42.9% to 30.6%), and in the proportion at 
practices providing these services in cooperation with other practices (from 16.7% to 
12.5%). However, the proportion of GPs working in practices using a deputising service 
for after-hours care provision increased significantly, from 47.6% in 2002–03 to 53.0% in 
2011–12. Multiple responses were allowed to this question. 
• The proportion of GPs with a computer available at their major practice increased 
significantly, from 91.7% in 2002–03 to 96.8% in 2011–12. Actual use of the computer has 
only been collected since 2004–05. From that time, the proportion of GPs indicating that 
they use a computer to some extent in their clinical activity (89.0%) steadily increased to 
94.6% in 2008–09. This level has been maintained since then, with the exception of a 
spike (97.7%) in 2009–10. As previously reported, random sampling resulted in an over-
representation of female GPs in that BEACH year,16 and female GPs have been found to 
be significantly more likely to use computers for clinical activity than their male 
counterparts.52 The over-representation of female GPs in that year may have influenced 
the higher computer use rate observed. 
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2011–12 40.8 26.0 41.1 10.7 20.5 56.8 30.6 12.5 53.0
Female <45 years 55+ years Solo GP 10+ GPs FRACGP
Own 
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Deputising 
A.H.(a)
 
(a) Multiple responses across these options were allowed. 
Note:  FRACGP – Fellows of the Royal Australian College of General Practitioners; own A.H. – the practice provides its own after-hours 
service for their patients; Co-op A.H. – the practice provides after-hours services in a cooperative arrangement with  
other practices. 
Figure 4.1: Selected characteristics of participating GPs and their practices, 2002–03 and 2011–12 
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5 The encounters 
This chapter includes details about the encounters in general practice from each of the most 
recent ten years of the BEACH study from 2002–03 to 2011–12. The direction and type of 
change from 2002–03 to 2011–12 is indicated for each result in the far right column of the 
tables: / indicates a statistically significant change (increase or decrease) in 2011–12 
compared with 2002–03; / indicates a marginally significant change in 2011–12 
compared with 2002–03; — indicates there was no significant change in 2011–12 compared 
with 2002–03; and § indicates a noteworthy change during the decade. 
Significant changes in rates per 100 encounters can be extrapolated to estimate the national 
increase or decrease in the measured event between 2002–03 and 2011–12. Some examples of 
extrapolated change are provided. The method used to extrapolate to national change 
estimates is described in Section 2.9. More detailed analyses of the GP–patient encounters in 
2011–12 can be found in Chapter 5 in General practice activity in Australia 2011–12.1 
5.1 Content of the encounters 
Table 5.1 provides an overview of the changes over time from data in BEACH between  
2002–03 and 2011–12. The number of patient reasons for encounter recorded by the GP 
increased significantly over the decade, from 150.9 RFEs per 100 encounters in 2002–03 to 
154.7 per 100 encounters in 2011–12. Changes in types of RFEs are reported in Chapter 6. 
The rate of problems managed occurred over the decade increased from 144.9 per 100 
encounters in 2002–03 to 153.8 per 100 encounters in 2011–12. This represents an additional 
48 million problems managed in general practice in 2011–12 than a decade earlier. There was 
also a significant increase in the rate of chronic problems managed, from 49.1 per 100 
encounters in 2002–03 to 55.6 per 100 in 2011–12. This represents an estimated additional 20.5 
million chronic problems managed in general practice nationally in 2011–12 than in 2002–03. 
Further details about the types of changes in problems managed are presented in Chapter 7. 
The changes in management actions described below are measured in terms of rates per 100 
encounters. As there was a significant increase in the number of problems managed at 
encounters, it may be more informative to consider changes in management actions in terms 
of rates per 100 problems managed as described in Chapters 8 to 12, inclusive. 
There was no change in the rate of medications recorded per 100 encounters over the decade. 
Specific changes in the types of medications recorded are detailed in Chapter 9. 
There was a significant increase in the number of procedural treatments performed in 
general practice between 2002–03 and 2011–12, from 14.6 per 100 encounters to 16.9 per 
100 encounters. This increase represents an additional 6.6 million procedures performed in 
2011–12 compared with a decade earlier. More detail can be found in Chapter 10. 
Between 2002–03 and 2004–05 there was no change in the rate of clinical treatments (such as 
advice and counselling), but the rate then dropped dramatically from 39.2 per 100 encounters 
in 2004–05 to 29.2 per 100 encounters in 2005–06. Since then it has gradually increased, and in 
2011–12 was 37.0 per 100 encounters, no different from the 2002–03 rate. This pattern was 
also reflected in the fluctuation of the total of other treatments of which clinical treatments 
are the major component. These changes are described in further detail in Chapter 10. 
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Referrals increased over the decade 2002–03 to 2011–12 from 11.2 per 100 encounters to 14.5 
per 100. This represented 6.9 million more referrals nationally in 2011–12 than a decade 
earlier. The increase was reflected in increased referrals to medical specialists, allied health 
services and emergency departments, and is described further in Chapter 11. 
Orders for pathology and imaging tests also increased significantly between 2002–03 and 
2011–12. These changes are reported in greater detail in Chapter 12. 
5.2 Medicare/DVA–claimable encounters 
Table 5.2 provides a summary of Medicare/DVA-claimable encounters recorded in BEACH, 
expressed as a proportion of all Medicare/DVA-claimable encounters. Between 2002–03 and 
2004–05 only one item number was recorded on the BEACH encounter form. In 2005–06 this 
increased to three items, to capture practice nurse item numbers and other additional 
information about the Medicare items used in general practice.  
To allow comparability of data over time only one item number per Medicare/DVA-
claimable item per encounter was counted in Table 5.2. The selection of one item number per 
encounter was based on priority whereby: consultation item numbers override Practice 
Incentives Program payment item numbers, which override procedural item numbers, which 
override other Medicare item numbers. Table 5.2 includes only items claimed by GPs 
(excluding items claimed by practice nurses etc.) and shows that: 
• short surgery consultations increased significantly from 1.2% of Medicare/DVA-
claimable encounters in 2002–03 to 1.9% in 2011–12. Previous research suggests that part 
of this increase is related to increasing practice nurse involvement in GP–patient 
encounters.53 
• the proportion of long surgery consultations did not change overall. However, after 
peaking at 10.5% in 2004–05, the proportion of long consultations remained steady until 
2007–08 then dropped significantly in 2008–09 and in 2011–12 represented 8.5% of 
Medicare/DVA-claimable encounters. 
• encounters claimable under chronic disease management items, GP mental healthcare 
items and health assessments all significantly increased. 
In May 2010 changes were made to the Medicare Benefits Schedule (MBS) that combined the 
existing Medicare items for home visits, consultations at hospitals and consultations at other 
institutions.54 To allow the comparison of changes over time we have applied this change to 
all previous years in the decade, and now report a single line for ‘Home and institution 
visits’. There was a significant decrease in the proportion of home and institution visits 
(together) from 1.7% to 0.7% between 2002–03 and 2011–12. This equates to 790,000 fewer 
home and institutional visits carried out by GPs in 2011–12 than in 2002–03. Unfortunately, 
this change no longer allows a discrete measure of GP home visit frequency through MBS.  
5.3 Consultation length 
In the subsample study of consultations start and finish times were recorded. there was no 
significant change in the mean length of consultation between 2002–03 and 2011–12 for A1 
Medicare/DVA-claimable encounters, nor for all Medicare/DVA-claimable encounters 
(Table 5.3).
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6 The patients 
This chapter includes data about the patients who participated in the BEACH study, 
including their characteristics and their reasons for encounter (RFEs), from each of the most 
recent ten years of the BEACH study from 2002–03 to 2011–12: / indicates a statistically 
significant change (increase or decrease) in 2011–12 compared with 2002–03; / indicates a 
marginally significant change in 2011–12 compared with 2002–03; — indicates there was no 
significant change in 2011–12 compared with 2002–03; and § indicates a noteworthy change 
during the decade. 
Significant changes in rates per 100 encounters can be extrapolated to estimate the national 
increase or decrease in the measured event between 2002–03 and 2011–12. In 2011–12 there 
were 25.6 million more encounters claimed through Medicare than there were in 2002–03 
(122.5 million versus 96.9 million). It should be noted that because of this increase, a lower 
rate of events per 100 encounters can result in an increase in the estimated number of events 
recorded. Some examples of extrapolated change are provided. The method used to 
extrapolate to national change estimates is described in Section 2.9. 
6.1 Age and sex of patients at encounter 
Figure 6.1 and Table 6.1 show the age and sex distribution of patients at BEACH encounters 
from 2002–03 to 2011–12. Over this period there was no significant change in the proportion 
of encounters with male and female patients. The proportion of encounters with patients 
aged less than 45 years decreased from 49.3% to 42.6%, while over the same period the 
proportion with patients aged 45 years and over increased from 50.7% to 57.4%. Specifically, 
the largest growth occurred in encounters with patients aged 75 years and over and the 
largest decrease was in encounters with patients aged 25–44 years of age. When extrapolated, 
even with the increased number of encounters nationally, the number of encounters with 
patients aged less than 45 years only increased by about 4.4 million over the decade, while 
the number of encounters with patients aged 65 years and over increased by about 
21.2 million nationally. The relationship between patient age, general practice attendance 
rates and the age distribution of the Australian population was investigated in Chapter 4 of 
General practice in Australia, health priorities and policies 1998 to 2008.4 
6.2 Other patient characteristics 
Over the decade there was a significant decrease in the proportion of encounters that were 
with patients who were new to the practice (from 9.9% in 2002–03 to 7.9% in 2011–12). The 
proportion of encounters with patients holding a Commonwealth concession card was 
relatively stable across the decade. Between 2002–03 and 2011–12, the proportion of 
encounters with patients holding a repatriation health card decreased by about a third (3.7% 
to 2.4%). There was no significant change in the proportion of encounters that were with 
patients from a non-English-speaking background or with Indigenous patients (Table 6.1). 
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0
10
20
30
40
50
60
70
2002–03 42.2 57.8 1.9 5.0 6.6 10.1 25.7 26.5 11.6 12.7
2011–12 43.5 56.5 1.8 4.4 5.3 8.5 22.6 27.7 13.4 16.3
Male Female <1 year
1–4 
years
5–14 
years
25–24 
years
25–44 
years
45–64 
years
65–74 
years
75+ 
years
 
Note: Missing data removed.  
Figure 6.1: Age and sex distribution of patients at encounters, 2002–03 and 2011–12 (95% 
confidence interval) 
6.3 Patient reasons for encounter 
Reasons for encounter (RFEs) are those concerns and expectations that patients bring to the 
GP. RFEs reflect the patient’s demand for care, and can provide an indication of service use 
patterns that may benefit from intervention at a population level. 
Participating GPs were asked to record at least one and up to three patient RFEs in words as 
close as possible to those used by the patient, before the diagnostic or management process 
had begun. RFEs can be expressed in terms of one or more symptoms (for example, ‘itchy 
eyes’, ‘chest pain’), in diagnostic terms (for example, ‘about my diabetes’, ‘for my 
hypertension’), a request for a service (‘I need more scripts’, ‘I want a referral’), an expressed 
fear of disease, or a need for a check-up. 
Patient RFEs can have a one-to-one, one-to-many, many-to-one and many-to-many 
relationship to problems managed. That is, the patient may describe a single RFE that relates 
to a single problem managed at the encounter, one RFE that relates to multiple problems, 
multiple symptoms that relate to a single problem managed at the encounter, or multiple 
RFEs that relate to multiple problems managed at the encounter. GPs may also manage a 
problem that was unrelated to the patient’s RFE (e.g. a patient presents about their diabetes 
but while they are there the GP also provides an immunisation and performs a Pap smear). 
Per cent of encounters 
Patient characteristics 
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Number of reasons for encounter 
Table 6.2 shows that between 2002–03 and 2011–12 there was a significant decrease in the 
proportion of encounters involving a single RFE, from 60.7% to 57.9% in 2011–12. To balance 
this there was an increase in the proportion of encounters with two RFEs, from 27.8% in 
2002–03 to 29.6% of all encounters in 2011–12. There was no significant change across the 
decade in the proportion of encounters with three RFEs. Extrapolation of the effect of this 
change suggests there were about 9.3 million more encounters nationally where two RFEs 
were reported in 2011–12 than in 2002–03. 
This increase in multiple RFEs encounters meant there was a significant increase in the 
overall rate of RFEs, from 150.9 per 100 encounters in 2002–03 to 154.7 per 100 encounters in 
2011–12 (Tables 6.3 and 6.4). This increase when extrapolated equates to about 43 million 
extra RFEs nationally in 2011–12 than in 2002–03. 
Reasons for encounter by ICPC-2 component 
The distribution of patient RFEs by ICPC-2 component is presented in Table 6.3. 
Symptoms and diagnoses 
• RFEs expressed in terms of a symptom or complaint (for example, ‘tired’, ‘feeling 
anxious’) were the most frequent in all years. However, their presentation rate 
significantly decreased, from 71.5 per 100 encounters in 2002–03 to 66.6 per 100 
encounters in 2011–12. 
• With one exception, the rate of RFEs relating to specific diagnoses (including infections, 
injuries, neoplasms, congenital anomalies, and other diagnoses) did not significantly 
change across the decade. The exception was a marginal decrease in the rate of 
congenital anomaly RFEs from 0.3 to 0.2 per 100 encounters. 
Processes of care 
• Patient requests for diagnostic and preventative procedures (such as immunisation) 
significantly increased from 23.7 per 100 encounters in 2002–03 to 27.0 in 2009–10, then 
decreased to 24.6 per 100 encounters in 2011–12, a rate similar to the 2002–03 rate. 
• Patient requests for medications, treatments and therapeutics (such as repeat 
prescriptions) increased by about 15%, from 13.0 to 15.0 per 100 encounters. This equates 
to an estimated 5.8 million more such requests in 2011–12 than in 2002–03. 
• Presentations for test results increased by about 60%, from 5.4 to 8.5 per 100 encounters. 
When extrapolated, we estimate 5.2 million more encounters nationally with a RFE of 
this type in 2011–12 than in 2002–03 when extrapolated. 
• The rate of requests for an administrative procedure (such as a sickness certificate) 
increased about 80%, from 1.6 to 2.9 per 100 encounters. Most of this change happened in 
2007–08. This change equates to an estimated increase of approximately 2.0 million 
requests for an administrative procedure nationally between 2002–03 and 2011–12 when 
extrapolated. 
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Reasons for encounter by ICPC-2 chapter 
Table 6.4 shows that between 2002–03 and 2011–12 there were significant increases in: 
• the rate of general and unspecified RFEs, which increased by about 20%. When 
extrapolated, this equates to about 18.2 million more general and unspecified RFEs in 
2011–12 than in 2002–03  
• RFEs related to psychological problems, which increased by about 20%. This equates to 
approximately 3.8 million more RFEs related to psychological problems nationally in 
2011–12 than in 2002–03. The increased role of GPs in the management of mental health 
was the focus of Chapter 14 in the book General practice activity in Australia, health 
priorities and policies 1998 to 20084 
• the rate of RFEs relating to the blood system, which increased by about 70%. This is 
likely to be linked to increased INR testing (as discussed in Chapter 10) 
• RFEs related to the male genital system, which increased marginally by about 20%.  
In contrast there were significant decreases in RFEs related to the female genital system and 
in RFEs related to neurological, ear and eye problems. 
Most frequent patient reasons for encounter 
Table 6.5 shows that between 2002–03 and 2011–12: 
• requests for a check-up (all types) significantly increased from 13.6 per 100 encounters in 
2002–03 to 15.2 in 2008–09, then decreased to 13.7 per 100 encounters in 2011–12, which is 
not significantly different from the 2002–03 rate 
• the rate of presentations for immunisation/vaccination did not significantly change, 
except there was a significant spike in 2009–10 coinciding with the swine flu pandemic. 
Over the decade there were significant increases in: 
• the rate at which patients cited a need for prescription(s) as a RFE increased by about 
20%, equating to 5.1 million more encounters with this RFE in 2011–12 than in 2002–03 
• the rate of RFEs for test results increased by about 60% and the rate of RFEs relating to 
the need for a blood test increased by a third 
• patient requests for administrative procedures (such as doctors’ certificates) increased 
80% while requests for a referral increased by about 70% 
• requests for health education, counselling and advice increased by about a third 
• patients presenting for their diabetes increased by about 60%, equating to when 
extrapolated an estimated increase of 820,000 encounters with diabetes as an RFE 
• patients presenting about their depression increased by 15%, while anxiety as an RFE 
increased by about a third. 
From 2002–03 to 2011–12: 
• the rate at which patients presented with asthma as a RFE nearly halved, equating to a 
national estimated decrease of about 330,000 encounters with asthma as an RFE 
• there were significant decreases in the RFE rates for headache (about 30%), neck 
complaint (about 25%) and ear problems (about 25%) 
• there were marginally significant decreases in presentations for back complaints, throat 
complaints, leg/thigh complaints, chest pain and vomiting.
38
  Ta
bl
e 
6.
1:
 C
ha
ra
ct
er
is
tic
s 
of
 p
at
ie
nt
s 
at
 e
nc
ou
nt
er
s,
 2
00
2–
03
 to
 2
01
1–
12
 
 
R
at
e 
pe
r 1
00
 e
nc
ou
nt
er
s 
(9
5%
 C
I) 
 
 
20
02
–0
3 
 
20
03
–0
4 
 
20
04
–0
5 
 
20
05
–0
6 
 
20
06
–0
7 
 
20
07
–0
8 
 
20
08
–0
9 
 
20
09
–1
0 
 
20
10
–1
1 
 
20
11
–1
2 

(a
)  
 
 
Pa
tie
nt
 c
ha
ra
ct
er
is
tic
s 
(n
 =
 1
00
,9
87
) 
 
(n
 =
 9
8,
87
7)
 
 
(n
 =
 9
4,
38
6)
 
 (
n 
= 
10
1,
99
3)
  
(n
 =
 9
1,
80
5)
 
 
(n
 =
 9
5,
89
8)
 
 (
n 
= 
96
,6
88
) 
 (n
 =
 1
01
,3
49
) 
 (
n 
= 
95
,8
39
) 
 (
n 
= 
99
,0
30
) 
S
ex
 (m
is
si
ng
 n
)(b
)  
(9
11
) 
 
(9
32
) 
 
(8
09
) 
 
(7
88
) 
 
(7
65
) 
 
(8
76
) 
 
(8
67
) 
 
(9
31
) 
 
(8
88
) 
 
(8
42
) 
 
M
al
e 
42
.2
 
(4
1.
4–
42
.9
) 
 
42
.6
 
(4
1.
8–
43
.3
) 
 
43
.5
 
(4
2.
7–
44
.3
) 
 
44
.0
 
(4
3.
2–
44
.7
) 
 
43
.7
 
(4
2.
9–
44
.5
) 
 
42
.9
 
(4
2.
1–
43
.7
) 
 
42
.4
 
(4
1.
5–
43
.3
) 
 
43
.1
 
(4
2.
3–
43
.9
) 
 
42
.9
 
(4
2.
0–
43
.7
) 
 
43
.5
 
(4
2.
7–
44
.3
) 
—
 
Fe
m
al
e 
57
.8
 
(5
7.
0–
58
.6
) 
 
57
.4
 
(5
6.
7–
58
.2
) 
 
56
.5
 
(5
5.
7–
57
.3
) 
 
56
.0
 
(5
5.
3–
56
.8
) 
 
56
.3
 
(5
5.
5–
57
.1
) 
 
57
.1
 
(5
6.
3–
57
.9
) 
 
57
.6
 
(5
6.
7–
58
.5
) 
 
56
.9
 
(5
6.
1–
57
.7
) 
 
57
.1
 
(5
6.
3–
58
.0
) 
 
56
.5
 
(5
5.
7–
57
.3
) 
—
 
A
ge
 g
ro
up
 (m
is
si
ng
 n
)(b
)  
(8
95
) 
 
(9
05
) 
 
(9
25
) 
 
(7
69
) 
 
(7
79
) 
 
(7
84
) 
 
(7
04
) 
 
(7
81
) 
 
(7
71
) 
 
(7
93
) 
 
 
< 
1 
ye
ar
 
1.
9 
(1
.8
–2
.1
) 
 
1.
8 
(1
.7
–1
.9
) 
 
1.
9 
(1
.8
–2
.1
) 
 
2.
1 
(1
.9
–2
.2
) 
 
1.
8 
(1
.7
–2
.0
) 
 
2.
0 
(1
.8
–2
.1
) 
 
2.
0 
(1
.8
–2
.1
) 
 
2.
1 
(1
.9
–2
.3
) 
 
1.
8 
(1
.7
–2
.0
) 
 
1.
8 
(1
.7
–1
.9
) 
—
 
 
1–
4 
ye
ar
s 
5.
0 
(4
.7
–5
.3
) 
 
4.
6 
(4
.3
–4
.8
) 
 
4.
3 
(4
.0
–4
.7
) 
 
4.
3 
(4
.0
–4
.5
) 
 
4.
1 
(3
.9
–4
.4
) 
 
4.
3 
(4
.1
–4
.6
) 
 
4.
2 
(4
.0
–4
.4
) 
 
4.
7 
(4
.5
–5
.0
) 
 
4.
6 
(4
.3
–4
.9
) 
 
4.
4 
(4
.2
–4
.7
) 

 
 
5–
14
 y
ea
rs
 
6.
6 
(6
.3
–6
.9
) 
 
5.
9 
(5
.6
–6
.3
) 
 
5.
8 
(5
.5
–6
.1
) 
 
6.
0 
(5
.7
–6
.3
) 
 
5.
6 
(5
.3
–5
.9
) 
 
5.
5 
(5
.2
–5
.8
) 
 
5.
3 
(5
.1
–5
.6
) 
 
5.
7 
(5
.4
–6
.0
) 
 
5.
5 
(5
.2
–5
.8
) 
 
5.
3 
(5
.1
–5
.6
) 

 
 
15
–2
4 
ye
ar
s 
10
.1
 
(9
.7
–1
0.
4)
 
 
9.
6 
(9
.2
–1
0.
1)
 
 
9.
0 
(8
.6
–9
.4
) 
 
9.
4 
(9
.0
–9
.8
) 
 
9.
1 
(8
.6
–9
.5
) 
 
9.
5 
(9
.0
–9
.9
) 
 
8.
4 
(8
.0
–8
.9
) 
 
8.
6 
(8
.2
–9
.0
) 
 
8.
7 
(8
.3
–9
.1
) 
 
8.
5 
(8
.1
–8
.9
) 

 
 
25
–4
4 
ye
ar
s 
25
.7
 
(2
4.
9–
26
.4
) 
 
24
.1
 
(2
3.
4–
24
.8
) 
 
24
.4
 
(2
3.
7–
25
.1
) 
 
23
.9
 
(2
3.
2–
24
.7
) 
 
23
.3
 
(2
2.
6–
24
.0
) 
 
23
.4
 
(2
2.
7–
24
.1
) 
 
21
.4
 
(2
0.
7–
22
.1
) 
 
22
.9
 
(2
2.
1–
23
.6
) 
 
22
.8
 
(2
2.
0–
23
.5
) 
 
22
.6
 
(2
1.
7–
23
.4
) 

 
 
45
–6
4 
ye
ar
s 
26
.5
 
(2
5.
9–
27
.0
) 
 
27
.2
 
(2
6.
7–
27
.7
) 
 
28
.0
 
(2
7.
4–
28
.6
) 
 
27
.6
 
(2
7.
0–
28
.2
) 
 
28
.2
 
(2
7.
6–
28
.7
) 
 
28
.1
 
(2
7.
5–
28
.6
) 
 
29
.1
 
(2
8.
5–
29
.6
) 
 
28
.2
 
(2
7.
7–
28
.8
) 
 
27
.7
 
(2
7.
1–
28
.2
) 
 
27
.7
 
(2
7.
1–
28
.3
) 

 
 
65
–7
4 
ye
ar
s 
11
.6
 
(1
1.
1–
12
.0
) 
 
12
.4
 
(1
1.
9–
12
.9
) 
 
12
.6
 
(1
2.
1–
13
.2
) 
 
12
.2
 
(1
1.
7–
12
.6
) 
 
12
.7
 
(1
2.
2–
13
.2
) 
 
12
.6
 
(1
2.
1–
13
.1
) 
 
13
.4
 
(1
2.
9–
13
.9
) 
 
12
.7
 
(1
2.
2–
13
.2
) 
 
13
.3
 
(1
2.
7–
13
.8
) 
 
13
.4
 
(1
2.
8–
13
.9
) 

 
 
75
+ 
ye
ar
s 
12
.7
 
(1
1.
9–
13
.4
) 
 
14
.4
 
(1
3.
6–
15
.2
) 
 
13
.9
 
(1
3.
1–
14
.7
) 
 
14
.6
 
(1
3.
7–
15
.4
) 
 
15
.2
 
(1
4.
4–
16
.0
) 
 
14
.7
 
(1
3.
9–
15
.5
) 
 
16
.2
 
(1
5.
4–
17
.0
) 
 
15
.1
 
(1
4.
3–
16
.0
) 
 
15
.7
 
(1
4.
8–
16
.6
) 
 
16
.3
 
(1
5.
3–
17
.3
) 

 
(c
on
tin
ue
d)
 
39
  Ta
bl
e 
6.
1 
(c
on
tin
ue
d)
: C
ha
ra
ct
er
is
tic
s 
of
 p
at
ie
nt
s 
at
 e
nc
ou
nt
er
s,
 2
00
2–
03
 to
 2
01
1–
12
 
 
R
at
e 
pe
r 1
00
 e
nc
ou
nt
er
s 
(9
5%
 C
I) 
 
 
20
02
–0
3 
 
20
03
–0
4 
 
20
04
–0
5 
 
20
05
–0
6 
 
20
06
–0
7 
 
20
07
–0
8 
 
20
08
–0
9 
 
20
09
–1
0 
 
20
10
–1
1 
 
20
11
–1
2 

(a
)  
 
 
Pa
tie
nt
 c
ha
ra
ct
er
is
tic
s 
(n
 =
 1
00
,9
87
) 
 
(n
 =
 9
8,
87
7)
 
 
(n
 =
 9
4,
38
6)
 
 (
n 
= 
10
1,
99
3)
  
(n
 =
 9
1,
80
5)
 
 
(n
 =
 9
5,
89
8)
 
 (
n 
= 
96
,6
88
) 
 (n
 =
 1
01
,3
49
) 
 (
n 
= 
95
,8
39
) 
 (
n 
= 
99
,0
30
) 
O
th
er
 c
ha
ra
ct
er
is
tic
s(
b)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N
ew
 p
at
ie
nt
 to
 p
ra
ct
ic
e 
9.
9 
(9
.1
–1
0.
8)
 
 
9.
3 
(8
.6
–1
0.
0)
 
 
9.
1 
(8
.4
–9
.9
) 
 
9.
1 
(8
.3
–9
.9
) 
 
8.
7 
(7
.9
–9
.4
) 
 
8.
6 
(7
.8
–9
.4
) 
 
5.
9 
(5
.5
–6
.3
) 
 
7.
7 
(7
.1
–8
.3
) 
 
7.
3 
(6
.6
–7
.9
) 
 
7.
9 
(7
.0
–8
.8
) 

 
 
C
om
m
on
w
ea
lth
 c
on
ce
ss
io
n 
 
ca
rd
 
45
.0
 
(4
3.
4–
46
.5
) 
 
46
.6
 
(4
5.
1–
48
.2
) 
 
47
.5
 
(4
6.
0–
49
.0
) 
 
45
.4
 
(4
3.
8–
47
.0
) 
 
45
.4
 
(4
3.
8–
46
.9
) 
 
45
.5
 
(4
4.
0–
47
.1
) 
 
45
.7
 
(4
4.
3–
47
.0
) 
 
45
.9
 
(4
4.
3–
47
.4
) 
 
44
.9
 
(4
3.
3–
46
.4
) 
 
44
.7
 
(4
3.
1–
46
.2
) 
—
 
 
R
ep
at
ria
tio
n 
he
al
th
 c
ar
d 
3.
7 
(3
.4
–4
.0
) 
 
3.
9 
(3
.6
–4
.2
) 
 
3.
6 
(3
.3
–3
.8
) 
 
3.
4 
(3
.1
–3
.6
) 
 
3.
4 
(3
.2
–3
.7
) 
 
3.
1 
(2
.8
–3
.3
) 
 
3.
1 
(2
.9
–3
.4
) 
 
2.
9 
(2
.7
–3
.2
) 
 
2.
5 
(2
.3
–2
.7
) 
 
2.
4 
(2
.2
–2
.7
) 

 
 
N
on
-E
ng
lis
h-
sp
ea
ki
ng
 
 
ba
ck
gr
ou
nd
 
12
.0
 
(1
0.
1–
13
.8
) 
 
10
.8
 
(8
.7
–1
2.
8)
 
 
12
.1
 
(1
0.
1–
14
.1
) 
 
10
.8
 
(9
.0
–1
2.
5)
 
 
8.
0 
(6
.5
–9
.5
) 
 
11
.0
 
(9
.2
–1
2.
8)
 
 
10
.4
 
(8
.7
–1
2.
1)
 
 
9.
0 
(7
.3
–1
0.
6)
 
 
10
.7
 
(8
.9
–1
2.
5)
 
 
11
.3
 
(9
.4
–1
3.
2)
 
—
 
 
A
bo
rig
in
al
 p
er
so
n 
an
d/
or
 
 
To
rr
es
 S
tra
it 
Is
la
nd
er
 
1.
2 
(0
.9
–1
.4
) 
 
1.
8 
(1
.3
–2
.3
) 
 
1.
5 
(1
.1
–2
.0
) 
 
1.
0 
(0
.7
–1
.2
) 
 
1.
0 
(0
.7
–1
.3
) 
 
1.
0 
(0
.8
–1
.3
) 
 
0.
9 
(0
.6
–1
.1
) 
 
1.
3 
(1
.0
–1
.6
) 
 
1.
2 
(0
.9
–1
.5
) 
 
1.
6 
(1
.2
–1
.9
) 
—
 
(a
) 
T
he
 d
ire
ct
io
n 
an
d 
ty
pe
 o
f c
ha
ng
e 
fr
om
 2
00
2–
03
 to
 2
01
1–
12
 is
 in
di
ca
te
d 
fo
r e
ac
h 
re
su
lt:
 
/
 in
di
ca
te
s 
a 
st
at
is
tic
al
ly
 s
ig
ni
fic
an
t c
ha
ng
e 
(in
cr
ea
se
 o
r 
de
cr
ea
se
) i
n 
20
11
–1
2 
co
m
pa
re
d 
w
ith
 2
00
2–
03
; —
 in
di
ca
te
s 
th
er
e 
w
as
 n
o 
si
gn
ifi
ca
nt
 c
ha
ng
e 
in
 2
01
1–
12
 c
om
pa
re
d 
w
ith
 2
00
2–
03
. 
(b
) 
M
is
si
ng
 d
at
a 
re
m
ov
ed
. 
N
ot
e:
 C
I –
 c
on
fid
en
ce
 in
te
rv
al
. 
Ta
bl
e 
6.
2:
 N
um
be
r o
f p
at
ie
nt
 re
as
on
s 
fo
r e
nc
ou
nt
er
, 2
00
2–
03
 to
 2
01
1–
12
 
 
R
at
e 
pe
r 1
00
 e
nc
ou
nt
er
s 
(9
5%
 C
I) 
 
N
um
be
r o
f r
ea
so
ns
  
fo
r e
nc
ou
nt
er
 
20
02
–0
3 
 
20
03
–0
4 
 
20
04
–0
5 
 
20
05
–0
6 
 
20
06
–0
7 
 
20
07
–0
8 
 
20
08
–0
9 
 
20
09
–1
0 
 
20
10
–1
1 
 
20
11
–1
2 

(a
)  

 
(n
 =
 1
00
,9
87
) 
 
(n
 =
 9
8,
87
7)
 
 
(n
 =
 9
4,
38
6)
 
 (
n 
= 
10
1,
99
3)
  
(n
 =
 9
1,
80
5)
 
 
(n
 =
 9
5,
89
8)
 
 (
n 
= 
96
,6
88
) 
 (n
 =
 1
01
,3
49
) 
 (n
 =
 1
49
,0
05
) 
 (
n 
= 
99
,0
30
) 
O
ne
 R
FE
 
60
.7
 
(5
9.
5–
61
.9
) 
 
61
.0
 
(5
9.
9–
62
.2
) 
 
61
.4
 
(6
0.
2–
62
.6
) 
 
60
.9
 
(5
9.
7–
62
.2
) 
 
60
.6
 
(5
9.
4–
61
.9
) 
 
58
.9
 
(5
7.
7–
60
.2
) 
 
56
.6
 
(5
5.
5–
57
.8
) 
 
57
.7
 
(5
6.
5–
58
.9
) 
 
57
.6
 
(5
6.
3–
58
.8
) 
 
57
.9
 
(5
6.
6–
59
.1
) 

 
Tw
o 
R
FE
s 
27
.8
 
(2
7.
1–
28
.4
) 
 
27
.7
 
(2
7.
0–
28
.4
) 
 
27
.6
 
(2
6.
9–
28
.3
) 
 
27
.8
 
(2
7.
1–
28
.5
) 
 
27
.9
 
(2
7.
2–
28
.7
) 
 
29
.1
 
(2
8.
5–
29
.8
) 
 
30
.3
 
(2
9.
6–
30
.9
) 
 
29
.7
 
(2
9.
0–
30
.4
) 
 
29
.4
 
(2
8.
7–
30
.1
) 
 
29
.6
 
(2
8.
9–
30
.3
) 

 
Th
re
e 
R
FE
s 
11
.6
 
(1
0.
8–
12
.3
) 
 
11
.3
 
(1
0.
5–
12
.0
) 
 
11
.0
 
(1
0.
3–
11
.7
) 
 
11
.2
 
(1
0.
5–
11
.9
) 
 
11
.4
 
(1
0.
7–
12
.2
) 
 
11
.9
 
(1
1.
2–
12
.6
) 
 
13
.1
 
(1
2.
4–
13
.8
) 
 
12
.6
 
(1
1.
9–
13
.4
) 
 
13
.0
 
(1
2.
3–
13
.8
) 
 
12
.6
 
(1
1.
8–
13
.3
) 
—
 
(a
) 
T
he
 d
ire
ct
io
n 
an
d 
ty
pe
 o
f c
ha
ng
e 
fr
om
 2
00
2–
03
 to
 2
01
1–
12
 is
 in
di
ca
te
d 
fo
r e
ac
h 
re
su
lt:
 
/
 in
di
ca
te
s 
a 
st
at
is
tic
al
ly
 s
ig
ni
fic
an
t c
ha
ng
e,
 a
nd
 —
 in
di
ca
te
s 
no
 s
ig
ni
fic
an
t d
iff
er
en
ce
 b
et
w
ee
n 
20
02
–0
3 
an
d 
20
11
–1
2.
 
N
ot
e:
 C
I –
 c
on
fid
en
ce
 in
te
rv
al
; R
FE
 –
 r
ea
so
n 
fo
r 
en
co
un
te
r.
 
40
  Ta
bl
e 
6.
3:
 P
at
ie
nt
 re
as
on
s 
fo
r e
nc
ou
nt
er
 b
y 
IC
PC
-2
 c
om
po
ne
nt
, 2
00
2–
03
 to
 2
01
1–
12
 
 
R
at
e 
pe
r 1
00
 e
nc
ou
nt
er
s 
(9
5%
 C
I) 
 
 
20
02
–0
3 
 
20
03
–0
4 
 
20
04
–0
5 
 
20
05
–0
6 
 
20
06
–0
7 
 
20
07
–0
8 
 
20
08
–0
9 
 
20
09
–1
0 
 
20
10
–1
1 
 
20
11
–1
2 

(a
)  
 
 
IC
PC
 c
om
po
ne
nt
 
(n
 =
 1
00
,9
87
) 
 (
n 
= 
98
,8
77
) 
 (
n 
= 
94
,3
86
) 
 (
n 
= 
10
1,
99
3)
  
(n
 =
 9
1,
80
5)
 
 
(n
 =
 9
5,
89
8)
 
 
(n
 =
 9
6,
68
8)
 
 (
n 
= 
10
1,
34
9)
  
(n
 =
 9
5,
83
9)
 
 
(n
 =
 9
9,
03
0)
 
S
ym
pt
om
s 
an
d 
co
m
pl
ai
nt
s 
71
.5
 
(6
9.
5–
73
.6
) 
 
69
.1
 
(6
7.
3–
71
.0
) 
 
68
.7
 
(6
6.
8–
70
.6
) 
 
67
.0
 
(6
5.
2–
68
.8
) 
 
65
.2
 
(6
3.
4–
67
.0
) 
 
65
.1
 
(6
3.
2–
67
.0
) 
 
66
.3
 
(6
4.
6–
68
.0
) 
 
65
.0
 
(6
3.
1–
67
.0
) 
 
66
.8
 
(6
4.
7–
68
.9
) 
 
66
.6
 
(6
4.
7–
68
.5
) 

 
D
ia
gn
os
is
, d
is
ea
se
s 
28
.6
 
(2
7.
1–
30
.0
) 
 
27
.7
 
(2
6.
4–
28
.9
) 
 
27
.2
 
(2
6.
0–
28
.4
) 
 
29
.5
 
(2
8.
0–
30
.9
) 
 
30
.6
 
(2
8.
9–
32
.2
) 
 
30
.4
 
(2
8.
9–
32
.0
) 
 
30
.3
 
(2
8.
8–
31
.8
) 
 
30
.7
 
(2
9.
1–
32
.3
) 
 
30
.9
 
(2
9.
4–
32
.4
) 
 
29
.3
 
(2
7.
8–
30
.8
) 
—
 
 
In
fe
ct
io
ns
 
7.
5 
(7
.0
–8
.0
) 
 
7.
4 
(7
.0
–7
.9
) 
 
7.
0 
(6
.6
–7
.4
) 
 
8.
3 
(7
.7
–8
.9
) 
 
8.
1 
(7
.5
–8
.6
) 
 
7.
9 
(7
.4
–8
.5
) 
 
7.
9 
(7
.5
–8
.4
) 
 
8.
0 
(7
.4
–8
.5
) 
 
7.
7 
(7
.2
–8
.2
) 
 
7.
3 
(6
.8
–7
.8
) 
—
 
 
In
ju
rie
s 
4.
4 
(4
.2
–4
.6
) 
 
4.
3 
(4
.1
–4
.6
) 
 
4.
4 
(4
.2
–4
.6
) 
 
4.
4 
(4
.2
–4
.7
) 
 
4.
3 
(4
.1
–4
.5
) 
 
4.
5 
(4
.3
–4
.7
) 
 
4.
3 
(4
.1
–4
.5
) 
 
4.
6 
(4
.4
–4
.9
) 
 
4.
4 
(4
.2
–4
.7
) 
 
4.
4 
(4
.2
–4
.7
) 
—
 
 
N
eo
pl
as
m
s 
1.
0 
(0
.9
–1
.1
) 
 
1.
0 
(0
.9
–1
.1
) 
 
0.
9 
(0
.8
–1
.1
) 
 
1.
0 
(0
.9
–1
.1
) 
 
1.
2 
(1
.0
–1
.3
) 
 
1.
2 
(1
.0
–1
.3
) 
 
1.
0 
(0
.9
–1
.1
) 
 
1.
1 
(1
.0
–1
.2
) 
 
1.
1 
(1
.0
–1
.2
) 
 
1.
0 
(0
.9
–1
.1
) 
—
 
 
C
on
ge
ni
ta
l a
no
m
al
ie
s 
0.
3 
(0
.3
–0
.4
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.3
) 

 
 
O
th
er
 d
ia
gn
os
es
, d
is
ea
se
s 
15
.3
 
(1
4.
3–
16
.4
) 
 
14
.7
 
(1
3.
7–
15
.6
) 
 
14
.6
 
(1
3.
7–
15
.5
) 
 
15
.4
 
(1
4.
4–
16
.4
) 
 
16
.7
 
(1
5.
5–
17
.9
) 
 
16
.5
 
(1
5.
4–
17
.7
) 
 
16
.8
 
(1
5.
7–
17
.9
) 
 
16
.8
 
(1
5.
6–
17
.9
) 
 
17
.4
 
(1
6.
3–
18
.5
) 
 
16
.4
 
(1
5.
2–
17
.5
) 
—
 
D
ia
gn
os
tic
 a
nd
 p
re
ve
nt
iv
e 
pr
oc
ed
ur
es
 
23
.7
 
(2
2.
8–
24
.7
) 
 
24
.0
 
(2
3.
1–
25
.0
) 
 
23
.4
 
(2
2.
6–
24
.3
) 
 
24
.3
 
(2
3.
4–
25
.3
) 
 
24
.8
 
(2
3.
9–
25
.7
) 
 
25
.6
 
(2
4.
7–
26
.5
) 
 
26
.9
 
(2
6.
0–
27
.8
) 
 
27
.0
 
(2
6.
0–
27
.9
) 
 
25
.1
 
(2
4.
1–
26
.2
) 
 
24
.6
 
(2
3.
7–
25
.6
) 
§ 
M
ed
ic
at
io
ns
, t
re
at
m
en
ts
 a
nd
 
th
er
ap
eu
tic
s 
13
.0
 
(1
2.
4–
13
.6
) 
 
14
.4
 
(1
3.
7–
15
.1
) 
 
14
.5
 
(1
3.
8–
15
.3
) 
 
14
.4
 
(1
3.
7–
15
.1
) 
 
14
.2
 
(1
3.
5–
14
.8
) 
 
15
.1
 
(1
4.
3–
15
.8
) 
 
15
.3
 
(1
4.
6–
15
.9
) 
 
14
.1
 
(1
3.
4–
14
.8
) 
 
14
.5
 
(1
3.
8–
15
.2
) 
 
15
.0
 
(1
4.
2–
15
.8
) 

 
R
es
ul
ts
 
5.
4 
(5
.0
–5
.7
) 
 
6.
0 
(5
.7
–6
.4
) 
 
6.
8 
(6
.4
–7
.2
) 
 
6.
5 
(6
.1
–6
.9
) 
 
6.
9 
(6
.5
–7
.3
) 
 
7.
6 
(7
.2
–8
.1
) 
 
7.
8 
(7
.4
–8
.2
) 
 
8.
1 
(7
.7
–8
.6
) 
 
8.
0 
(7
.5
–8
.5
) 
 
8.
5 
(8
.1
–9
.0
) 

 
R
ef
er
ra
ls
 a
nd
 o
th
er
 R
FE
s 
7.
0 
(6
.6
–7
.5
) 
 
7.
2 
(6
.8
–7
.6
) 
 
7.
3 
(6
.9
–7
.8
) 
 
6.
9 
(6
.5
–7
.4
) 
 
7.
3 
(6
.9
–7
.8
) 
 
6.
8 
(6
.4
–7
.2
) 
 
7.
5 
(7
.0
–7
.9
) 
 
7.
6 
(7
.2
–8
.1
) 
 
7.
5 
(7
.1
–7
.9
) 
 
7.
7 
(7
.3
–8
.2
) 
—
 
A
dm
in
is
tra
tiv
e 
1.
6 
(1
.5
–1
.8
) 
 
1.
8 
(1
.6
–1
.9
) 
 
1.
7 
(1
.5
–1
.8
) 
 
1.
7 
(1
.5
–1
.8
) 
 
1.
8 
(1
.7
–2
.0
) 
 
2.
3 
(2
.2
–2
.5
) 
 
2.
4 
(2
.2
–2
.6
) 
 
2.
4 
(2
.2
–2
.6
) 
 
2.
6 
(2
.4
–2
.8
) 
 
2.
9 
(2
.7
–3
.2
) 

 
To
ta
l R
FE
s 
15
0.
9 
(1
49
.0
–1
52
.7
)  
15
0.
2 
(1
48
.4
–1
52
.0
)  
14
9.
6 
(1
47
.8
–1
51
.5
)  
15
0.
3 
(1
48
.4
–1
52
.2
)  
15
0.
8 
(1
48
.9
–1
52
.7
)  
15
3.
0 
(1
51
.1
–1
54
.8
)  
15
6.
5 
(1
54
.7
–1
58
.2
)  
15
5.
0 
(1
53
.1
–1
56
.8
) 
 
15
5.
5 
(1
53
.5
–1
57
.5
)  
15
4.
7 
(1
52
.8
–1
56
.7
) 

 
(a
) 
T
he
 d
ire
ct
io
n 
an
d 
ty
pe
 o
f c
ha
ng
e 
fr
om
 2
00
2–
03
 to
 2
01
1–
12
 is
 in
di
ca
te
d 
fo
r e
ac
h 
re
su
lt:
 
/
 in
di
ca
te
s 
a 
st
at
is
tic
al
ly
 s
ig
ni
fic
an
t c
ha
ng
e 
(in
cr
ea
se
 o
r 
de
cr
ea
se
) i
n 
20
11
–1
2 
co
m
pa
re
d 
w
ith
 2
00
2–
03
; 
/
 in
di
ca
te
s 
a 
m
ar
gi
na
lly
 s
ig
ni
fic
an
t c
ha
ng
e 
in
 2
01
1–
12
 c
om
pa
re
d 
w
ith
 2
00
2–
03
; —
 in
di
ca
te
s 
th
er
e 
w
as
 n
o 
si
gn
ifi
ca
nt
 c
ha
ng
e 
in
 2
01
1–
12
 c
om
pa
re
d 
w
ith
 2
00
2–
03
; a
nd
 §
 in
di
ca
te
s 
a 
no
te
w
or
th
y 
ch
an
ge
 d
ur
in
g 
th
e 
de
ca
de
. 
N
ot
e:
 C
I –
 c
on
fid
en
ce
 in
te
rv
al
; R
FE
 –
 r
ea
so
n 
fo
r 
en
co
un
te
r.
 
41
  Ta
bl
e 
6.
4:
 P
at
ie
nt
 re
as
on
s 
fo
r e
nc
ou
nt
er
 b
y 
IC
PC
-2
 c
ha
pt
er
, 2
00
2–
03
 to
 2
01
1–
12
 
 
R
at
e 
pe
r 1
00
 e
nc
ou
nt
er
s 
(9
5%
 C
I) 
 
 
20
02
–0
3 
 
20
03
–0
4 
 
20
04
–0
5 
 
20
05
–0
6 
 
20
06
–0
7 
 
20
07
–0
8 
 
20
08
–0
9 
 
20
09
–1
0 
 
20
10
–1
1 
 
20
11
–1
2 

(a
)  

 
IC
PC
-2
 c
ha
pt
er
 
(n
 =
 1
00
,9
87
) 
 (
n 
= 
98
,8
77
) 
 (
n 
= 
94
,3
86
) 
 (
n 
= 
10
1,
99
3)
  
(n
 =
 9
1,
80
5)
 
 
(n
 =
 9
5,
89
8)
 
 (
n 
= 
96
,6
88
) 
 (n
 =
 1
01
,3
49
) 
 (
n 
= 
95
,8
39
) 
 (
n 
= 
99
,0
30
) 
G
en
er
al
 a
nd
 u
ns
pe
ci
fie
d 
34
.6
 
(3
3.
5–
35
.6
) 
 
36
.1
 
(3
5.
1–
37
.2
) 
 
36
.5
 
(3
5.
5–
37
.6
) 
 
36
.3
 
(3
5.
2–
37
.4
) 
 
37
.7
 
(3
6.
7–
38
.8
) 
 
40
.1
 
(3
8.
9–
41
.2
) 
 
40
.6
 
(3
9.
6–
41
.7
) 
 
42
.7
 
(4
1.
5–
43
.9
) 
 
41
.0
 
(3
9.
8–
42
.3
) 
 
42
.2
 
(4
1.
0–
43
.5
) 

 
R
es
pi
ra
to
ry
 
23
.0
 
(2
2.
0–
24
.0
) 
 
21
.4
 
(2
0.
6–
22
.2
) 
 
20
.6
 
(1
9.
7–
21
.4
) 
 
21
.9
 
(2
1.
1–
22
.7
) 
 
20
.7
 
(1
9.
9–
21
.6
) 
 
20
.6
 
(1
9.
8–
21
.5
) 
 
22
.0
 
(2
1.
2–
22
.9
) 
 
22
.8
 
(2
1.
9–
23
.8
) 
 
21
.7
 
(2
0.
9–
22
.6
) 
 
21
.3
 
(2
0.
3–
22
.2
) 
—
 
M
us
cu
lo
sk
el
et
al
 
16
.8
 
(1
6.
2–
17
.3
) 
 
16
.4
 
(1
5.
8–
16
.9
) 
 
16
.7
 
(1
6.
0–
17
.3
) 
 
16
.4
 
(1
5.
8–
16
.9
) 
 
16
.1
 
(1
5.
6–
16
.6
) 
 
15
.4
 
(1
4.
9–
15
.9
) 
 
16
.1
 
(1
5.
5–
16
.6
) 
 
15
.4
 
(1
4.
7–
16
.2
) 
 
15
.3
 
(1
4.
9–
15
.8
) 
 
15
.8
 
(1
5.
3–
16
.3
) 
—
 
S
ki
n 
14
.7
 
(1
4.
3–
15
.2
) 
 
15
.1
 
(1
4.
5–
15
.8
) 
 
15
.6
 
(1
5.
0–
16
.2
) 
 
15
.0
 
(1
4.
5–
15
.6
) 
 
15
.7
 
(1
5.
1–
16
.3
) 
 
15
.4
 
(1
4.
8–
16
.1
) 
 
15
.1
 
(1
4.
6–
15
.6
) 
 
14
.8
 
(1
4.
3–
15
.3
) 
 
15
.3
 
(1
4.
8–
15
.8
) 
 
15
.1
 
(1
4.
5–
15
.6
) 
—
 
D
ig
es
tiv
e 
10
.4
 
(1
0.
0–
10
.8
) 
 
10
.7
 
(1
0.
3–
11
.1
) 
 
9.
9 
(9
.5
–1
0.
3)
 
 
9.
9 
(9
.5
–1
0.
3)
 
 
10
.1
 
(9
.7
–1
0.
5)
 
 
10
.3
 
(1
0.
0–
10
.7
) 
 
9.
8 
(9
.4
–1
0.
1)
 
 
9.
8 
(9
.5
–1
0.
1)
 
 
10
.2
 
(9
.8
–1
0.
6)
 
 
10
.2
 
(9
.9
–1
0.
6)
 
—
 
C
ar
di
ov
as
cu
la
r 
10
.6
 
(1
0.
0–
11
.1
) 
 
10
.6
 
(1
0.
1–
11
.2
) 
 
10
.5
 
(1
0.
0–
11
.0
) 
 
10
.8
 
(1
0.
2–
11
.3
) 
 
11
.2
 
(1
0.
7–
11
.8
) 
 
11
.2
 
(1
0.
6–
11
.8
) 
 
11
.5
 
(1
0.
9–
12
.0
) 
 
10
.0
 
(9
.5
–1
0.
5)
 
 
10
.5
 
(1
0.
0–
11
.1
) 
 
10
.2
 
(9
.6
–1
0.
7)
 
—
 
P
sy
ch
ol
og
ic
al
 
7.
3 
(6
.9
–7
.7
) 
 
7.
3 
(6
.9
–7
.7
) 
 
7.
6 
(7
.2
–8
.0
) 
 
7.
8 
(7
.3
–8
.3
) 
 
7.
5 
(7
.1
–7
.8
) 
 
7.
8 
(7
.5
–8
.2
) 
 
8.
7 
(8
.2
–9
.1
) 
 
8.
5 
(8
.0
–8
.9
) 
 
9.
0 
(8
.6
–9
.4
) 
 
8.
9 
(8
.4
–9
.4
) 

 
E
nd
oc
rin
e 
an
d 
m
et
ab
ol
ic
 
6.
0 
(5
.7
–6
.3
) 
 
6.
1 
(5
.8
–6
.5
) 
 
6.
1 
(5
.8
–6
.5
) 
 
6.
2 
(5
.8
–6
.5
) 
 
6.
4 
(6
.1
–6
.8
) 
 
6.
5 
(6
.1
–6
.8
) 
 
6.
9 
(6
.5
–7
.3
) 
 
6.
1 
(5
.8
–6
.4
) 
 
6.
5 
(6
.2
–6
.9
) 
 
6.
3 
(5
.9
–6
.6
) 
—
 
Fe
m
al
e 
ge
ni
ta
l s
ys
te
m
 
6.
1 
(5
.7
–6
.5
) 
 
5.
1 
(4
.8
–5
.5
) 
 
5.
0 
(4
.6
–5
.4
) 
 
5.
1 
(4
.8
–5
.5
) 
 
5.
1 
(4
.7
–5
.4
) 
 
5.
2 
(4
.8
–5
.6
) 
 
5.
3 
(4
.9
–5
.6
) 
 
4.
7 
(4
.4
–5
.1
) 
 
5.
0 
(4
.6
–5
.3
) 
 
4.
8 
(4
.4
–5
.1
) 

 
N
eu
ro
lo
gi
ca
l 
5.
7 
(5
.5
–6
.0
) 
 
5.
3 
(5
.1
–5
.6
) 
 
5.
1 
(4
.9
–5
.4
) 
 
4.
9 
(4
.7
–5
.2
) 
 
4.
9 
(4
.7
–5
.2
) 
 
4.
8 
(4
.6
–5
.0
) 
 
4.
8 
(4
.6
–5
.0
) 
 
4.
4 
(4
.1
–4
.6
) 
 
4.
6 
(4
.4
–4
.9
) 
 
4.
5 
(4
.3
–4
.8
) 

 
E
ar
 
3.
9 
(3
.8
–4
.1
) 
 
3.
7 
(3
.5
–3
.9
) 
 
3.
9 
(3
.7
–4
.1
) 
 
3.
9 
(3
.7
–4
.1
) 
 
3.
5 
(3
.4
–3
.7
) 
 
3.
6 
(3
.4
–3
.8
) 
 
3.
7 
(3
.5
–3
.9
) 
 
3.
6 
(3
.4
–3
.8
) 
 
3.
7 
(3
.5
–3
.9
) 
 
3.
4 
(3
.3
–3
.6
) 

 
P
re
gn
an
cy
 a
nd
 fa
m
ily
 p
la
nn
in
g 
3.
6 
(3
.3
–3
.9
) 
 
3.
7 
(3
.4
–3
.9
) 
 
3.
4 
(3
.2
–3
.6
) 
 
3.
4 
(3
.1
–3
.6
) 
 
3.
3 
(3
.0
–3
.6
) 
 
3.
2 
(3
.0
–3
.5
) 
 
3.
1 
(2
.8
–3
.3
) 
 
3.
4 
(3
.2
–3
.7
) 
 
3.
4 
(3
.1
–3
.7
) 
 
3.
3 
(3
.1
–3
.6
) 
—
 
U
ro
lo
gy
 
2.
4 
(2
.3
–2
.6
) 
 
2.
5 
(2
.4
–2
.7
) 
 
2.
5 
(2
.4
–2
.7
) 
 
2.
6 
(2
.5
–2
.8
) 
 
2.
6 
(2
.4
–2
.7
) 
 
2.
5 
(2
.4
–2
.7
) 
 
2.
7 
(2
.5
–2
.8
) 
 
2.
6 
(2
.5
–2
.8
) 
 
2.
7 
(2
.6
–2
.9
) 
 
2.
6 
(2
.4
–2
.7
) 
—
 
(c
on
tin
ue
d)
 
42
  Ta
bl
e 
6.
4 
(c
on
tin
ue
d)
: P
at
ie
nt
 re
as
on
s 
fo
r e
nc
ou
nt
er
 b
y 
IC
PC
-2
 c
ha
pt
er
, 2
00
2–
03
 to
 2
01
1–
12
 
 
R
at
e 
pe
r 1
00
 e
nc
ou
nt
er
s 
(9
5%
 C
I) 
 
 
20
02
–0
3 
 
20
03
–0
4 
 
20
04
–0
5 
 
20
05
–0
6 
 
20
06
–0
7 
 
20
07
–0
8 
 
20
08
–0
9 
 
20
09
–1
0 
 
20
10
–1
1 
 
20
11
–1
2 

(a
)  

 
IC
PC
-2
 c
ha
pt
er
 
(n
 =
 1
00
,9
87
) 
 (
n 
= 
98
,8
77
) 
 (
n 
= 
94
,3
86
) 
 (
n 
= 
10
1,
99
3)
  
(n
 =
 9
1,
80
5)
 
 
(n
 =
 9
5,
89
8)
 
 
(n
 =
 9
6,
68
8)
 
 (
n 
= 
10
1,
34
9)
  
(n
 =
 9
5,
83
9)
 
 
(n
 =
 9
9,
03
0)
 
E
ye
 
2.
7 
(2
.5
–2
.9
) 
 
2.
7 
(2
.6
–2
.8
) 
 
2.
7 
(2
.6
–2
.9
) 
 
2.
8 
(2
.6
–2
.9
) 
 
2.
5 
(2
.4
–2
.7
) 
 
2.
5 
(2
.4
–2
.6
) 
 
2.
6 
(2
.4
–2
.7
) 
 
2.
3 
(2
.2
–2
.5
) 
 
2.
4 
(2
.3
–2
.6
) 
 
2.
3 
(2
.1
–2
.4
) 

 
B
lo
od
 
1.
0 
(0
.9
–1
.1
) 
 
1.
3 
(1
.1
–1
.4
) 
 
1.
2 
(1
.1
–1
.4
) 
 
1.
2 
(1
.0
–1
.3
) 
 
1.
2 
(1
.1
–1
.4
) 
 
1.
4 
(1
.2
–1
.5
) 
 
1.
4 
(1
.3
–1
.6
) 
 
1.
4 
(1
.2
–1
.5
) 
 
1.
6 
(1
.4
–1
.8
) 
 
1.
7 
(1
.5
–1
.8
) 

 
M
al
e 
ge
ni
ta
l s
ys
te
m
 
1.
0 
(0
.9
–1
.1
) 
 
1.
1 
(1
.0
–1
.1
) 
 
1.
2 
(1
.1
–1
.3
) 
 
1.
3 
(1
.2
–1
.4
) 
 
1.
2 
(1
.1
–1
.3
) 
 
1.
2 
(1
.1
–1
.3
) 
 
1.
3 
(1
.2
–1
.4
) 
 
1.
2 
(1
.1
–1
.4
) 
 
1.
3 
(1
.2
–1
.3
) 
 
1.
2 
(1
.1
–1
.3
) 

 
S
oc
ia
l p
ro
bl
em
s 
1.
0 
(0
.9
–1
.1
) 
 
0.
9 
(0
.8
–1
.0
) 
 
1.
0 
(0
.9
–1
.1
) 
 
0.
9 
(0
.8
–1
.0
) 
 
0.
9 
(0
.8
–1
.0
) 
 
1.
1 
(1
.0
–1
.2
) 
 
0.
9 
(0
.9
–1
.0
) 
 
1.
2 
(1
.1
–1
.3
) 
 
1.
0 
(0
.9
–1
.1
) 
 
0.
9 
(0
.8
–1
.0
) 
—
 
To
ta
l R
FE
s 
15
0.
9 
(1
49
.0
–1
52
.7
)  
15
0.
2 
(1
48
.4
–1
52
.0
)  
14
9.
6 
(1
47
.8
–1
51
.5
)  
15
0.
3 
(1
48
.4
–1
52
.2
)  
15
0.
8 
(1
48
.9
–1
52
.7
)  
15
3.
0 
(1
51
.1
–1
54
.8
)  
15
6.
5 
(1
54
.7
–1
58
.2
)  
15
5.
0 
(1
53
.1
–1
56
.8
) 
 
15
5.
5 
(1
53
.5
–1
57
.5
)  
15
4.
7 
(1
52
.8
–1
56
.7
) 

 
(a
) 
T
he
 d
ire
ct
io
n 
an
d 
ty
pe
 o
f c
ha
ng
e 
fr
om
 2
00
2–
03
 to
 2
01
1–
12
 is
 in
di
ca
te
d 
fo
r e
ac
h 
re
su
lt:
 
/
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t c
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 c
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7 Problems managed 
A ‘problem managed’ is a formal statement of the provider’s understanding of a health 
problem presented by the patient, family or community, and can be described in terms of a 
disease, symptom or complaint, social problem, or ill-defined condition managed at the 
encounter. As GPs were instructed to record each problem at the most specific level possible 
from the information available, the problem managed may at times be limited to the level of 
a presenting symptom. 
At each patient encounter, up to four problems could be recorded by the GP. A minimum of 
one problem was compulsory. The status of each problem to the patient – new (first 
presentation to a medical practitioner) or old (follow-up of previously managed problem) – 
was also indicated. The concept of a principal diagnosis, which is often used in hospital 
statistics, is not adopted in studies of general practice where multiple problem management 
is the norm rather than the exception. Further, the range of problems managed at the 
encounter often crosses multiple body systems and may include undiagnosed symptoms, 
psychosocial problems, chronic disease or preventive health, which makes the designation of 
a principal diagnosis difficult. Thus the order in which the problems were recorded by the 
GP is not significant. 
This chapter includes data about the problems managed in general practice from each of the 
most recent ten years of the BEACH study from 2002–03 to 2011–12. The direction and type 
of change from 2002–03 to 2011–12 is indicated for each result in the far right column of the 
tables: / indicates a statistically significant change (increase or decrease) in 2011–12 
compared with 2002–03; / indicates a marginally significant change in 2011–12 
compared with 2002–03; — indicates there was no significant change in 2011–12 compared 
with 2002–03; and § indicates a noteworthy change during the decade. 
Significant changes in the rate per 100 encounters can be extrapolated to estimate the 
national increase or decrease in the measured event between 2002–03 and 2011–12. Examples 
of extrapolated change are given. The method used to extrapolate to national change 
estimates is described in Section 2.9. The number of GP–patient encounters claimed through 
the MBS nationally increased by 25.6 million (26.4%) between 2002–03 (96.9 million 
encounters) and 2011–12 (122.5 million encounters). As a result, a decreased rate of a 
particular ‘measured event’ per 100 encounters may occasionally yield a national increased 
absolute number of those events. 
More detailed analyses of ‘problems managed’ by participating GPs in the 2011–12 BEACH 
year can be found in the companion report General practice activity in Australia 2011–12.1 
There are two ways to describe the relative frequency of problems managed: as a percentage 
of all problems managed in the study, or as a rate of problems managed per 100 encounters. 
Where groups of problems are reported (for example, cardiovascular problems), it must be 
remembered that more than one of that type of problem (such as hypertension and heart 
failure) may have been managed at a single encounter. In considering these results, the 
reader must be mindful that a rate per 100 encounters for a single ungrouped problem, for 
example ‘asthma, 2.2 per 100 encounters,’ can be regarded as equivalent to ‘asthma is 
managed at 2.2% of encounters’, and can be extrapolated (with the methods described in 
Section 2.9) to accurately estimate the number of national encounters involving management 
of the selected problem. This is not the case for grouped concepts (ICPC-2 chapters and those 
marked with asterisks in the tables) for which extrapolations represent the number of 
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problem contacts involving the management of any of the problems within the group at 
general practice encounters nationally. In these cases an extrapolated result may be an 
overestimate of the number of encounters involving management of these problems. This is 
because multiple problems (within the selected group) can be recorded within a single 
encounter. In order to estimate the number of encounters nationally that involve 
management of the grouped concept the extrapolation would have to be based on the 
proportion of encounters involving at least one of the concepts within the group.  
7.1 Number of problems managed 
GPs are asked to record information about the management of up to four problems at each 
encounter. Table 7.1 shows the number of problems managed at encounters over the decade. 
There were increases in the proportion of encounters at which two, three and four problems 
were managed, and a decrease in encounters where only one problem was managed. When 
extrapolated to all GP–patient encounters in Australia, this suggests there were about 
8.6 million more occasions where two problems were managed, 3.8 million more occasions 
where three problems were managed, and 2.1 million more occasions where four problems 
were managed by GPs in Australia in 2011–12 than in 2002–03. 
This resulted in a significant increase in the average number of problems managed at 
encounter, from 144.9 per 100 encounters in 2002–03 to 153.8 in 2011–12 (Table 7.2). This 
suggests there were an additional 48.0 million problems managed at GP–patient encounters 
in Australia in 2011–12 than in 2002–03. This was reflected in a significant increase in the 
management rate of chronic conditions (Table 7.6). 
7.2 Problems managed by ICPC-2 component 
Problems managed in general practice may also be examined using the components of the 
ICPC-2 classification to provide a better understanding of the types of problems managed 
during general practice encounters. Table 7.2 provides the distribution of problems managed 
by ICPC-2 component.  
There were significant increases in the management rate of problems described and classified 
as ‘diagnosis, diseases’, ‘results’ and ‘administrative procedures’ between 2002–03 and  
2011–12 (Table 7.2). Extrapolated to the national general practice encounters, these increases 
represent about: 
• 32.8 million additional contacts with problems classified as ‘diagnosis, diseases’ in  
2011–12 than in 2002–03 
• 1.1 million more test result contacts in 2011–12 than in 2002–03 
• 1.1 million more contacts with problems classified as ‘administrative’ in 2011–12 than  
in 2002–03. 
The management rate of problems described and classified as ‘diagnostic and preventive 
procedures’ showed changes across the decade.  
There were significant changes in the rates of the subtypes of ‘diagnosis, diseases’: the 
management of problems classified as ‘other diagnoses, diseases’ increased from 2002–03 to 
2011–12, and problems classified as ‘infections’ decreased from 2002–03 to 2011–12. 
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There was no change in the management rate of problems described and classified as 
‘symptoms and complaints’ and ‘medications, treatments and therapeutics’. There was a 
marginal decrease in the rate of problems classified as ‘referrals and other reason for 
encounter’ (Table 7.2). 
7.3 Problems managed by ICPC-2 chapter and 
individual problems managed 
Problems managed at general practice encounters classified by ICPC-2 chapter are described 
in Table 7.3 for all years from 2002–03 to 2011–12. Problems related to the respiratory system 
remained the most common type of problem managed since 2002–03, and although there 
was no significant change in their management rate comparing 2002–03 with 2011–12, there 
were changes during the decade: increasing from 2007–08 to 2008–09, then decreasing from 
2009–10 to 2010–11. It is likely that the increase in the management rate in 2009–10 was 
related to the concern regarding H1N1 influenza. A similar pattern of change is shown in the 
management rate of immunisation/vaccination problems (described in Table 7.4).  
There were significant increases in the management rate of problems classified as ‘general 
and unspecified’, ‘endocrine and metabolic’, ‘psychological’, ‘digestive’, and ‘male genital 
system’ (Table 7.3). When extrapolated to general practice encounters across Australia, these 
changes represent: 
• 7.4 million more contacts with problems classified as ‘general and unspecified’ in  
2011–12 than in 2002–03 
• 6.2 million more contacts with endocrine and metabolic problems 
• 5.9 million more contacts with psychological problems  
• 3.8 million more contacts with digestive problems  
• 850,000 more contacts with problems classified to the male genital system.  
There were significant decreases in the management rate of problems classified as ‘female 
genital system’ and ‘neurological’ (Table 7.3). When extrapolated to general practice 
encounters across Australia, these changes represent: 
• 340,000 more contacts with problems classified to the female genital system in 2011–12 
than in 2002–03 (which is about 1.3 million fewer than the 1.7 million expected if the rate 
had been constant)  
• 340,000 more contacts with neurological problems in 2011–12 than in 2002–03 (which is 
about 740,000 fewer than the 1.1 million expected if the rate had been constant). 
The individual problems managed most frequently are described in Table 7.4, which 
demonstrates that in all years 2002–03 to 2011–12 the most frequently managed were 
hypertension, check-up, immunisation/vaccination, and upper respiratory tract infection.  
There were noteworthy changes across the decade in some of the most frequently managed 
problems, described in Table 7.4.  
• The management rate of immunisation/vaccinations did not change between 2002–03 
(4.6 per 100 encounters) and 2011–12 (4.7). However there was a significant spike in 
2009–10 (7.3 per 100) that coincided with the concern about H1N1 influenza.  
• Although the management rate of depression significantly increased between 2002–03 
and 2008–09, it remained steady in subsequent years.  
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There were statistically significant increases in the management rates of general check-ups, 
depression, diabetes, osteoarthritis, lipid disorders, oesophageal disease, anxiety, test results, 
pregnancy, atrial fibrillation, vitamin/nutritional deficiency, administrative procedures and 
abnormal test results. When extrapolated to the general practice encounters across Australia, 
these changes represent: 
• 1.6 million more general check-ups in 2011–12 than in 2002–03. The availability of MBS 
items for health assessments including the annual assessment of patients aged 75 years 
and over, the health assessment for 45–49 year olds at-risk of developing chronic disease 
and the assessment of 40–49 year olds at-risk of Type 2 diabetes;55 are likely to have 
contributed to the increased rate of general check-ups.  
• 2.0 million more occasion of depression management 
• 2.3 million more occasion of diabetes management 
• 1.2 million more osteoarthritis contacts 
• 1.4 million more management contacts with lipid disorders 
• 1.5 million more occasion of oesophageal disease management  
• 870,000 more anxiety contacts 
• 1.1 million more contacts for test results and 790,000 more contacts for abnormal test 
results. These increases are not surprising considering the 43% increase in the rate of 
pathology ordering (per 100 encounters) over the decade (see Chapter 12). 
• 820,000 more contacts for the management of pregnancy  
• 1.1 million more management occasions for atrial fibrillation  
• 1.2 million more contacts with vitamin/nutritional deficiency problems  
• 1.1 million more contacts for administrative procedures. 
In contrast, there were significant decreases over the decade in the management rate of 
asthma, acute otitis media and menopausal problems managed. When extrapolated to 
general practice encounters across Australia, these changes represent:  
• 170,000 fewer asthma contacts in 2011–12 than a decade earlier. This is about 860,000 
fewer than expected if the management rate had remained constant, given the increased 
absolute number of attendances  
• 30,000 fewer otitis media contacts. This is about 370,000 fewer than expected if the rate 
had remained constant given the increased absolute number of attendances  
• 600,000 fewer contacts with menopausal problems in 2011–12 than in 2002–03. This is 
about 980,000 fewer than expected if the rate had remained constant. 
7.4 Most common new problems 
There was no change in the management rate of all new problems over the decade. Table 7.5 
shows the most frequently managed new problems between 2002–03 and 2011–12.  
The most common new problems managed in general practice in all years were upper 
respiratory tract infection, immunisation/vaccination, check-up and acute bronchitis/ 
bronchiolitis. Only four significant changes in the management rate of the most common 
new problems were identified when comparing 2011–12 with 2002–03.  
50
  
The management rate of new check-ups increased significantly (from 2.2 to 2.9 per 100 
encounters) and is likely due to the ageing population and new MBS items for check-ups (as 
discussed above). When extrapolated, this increase represents 1.4 million additional 
occasions where a check-up was managed as a new problem in Australia in 2011–12 
compared with 2002–03.  
The rate of new immunisation/vaccination did not change between 2002–03 and  
2011–12, however there was a spike in the rate in 2009–10 that coincides with the concern 
regarding H1N1 influenza (as discussed above). 
7.5 Most frequently managed chronic problems 
Table 7.6 shows the most frequently managed chronic problems between 2002–03 and  
2011–12. The management rate of chronic conditions significantly increased from 49.0 per 
100 encounters in 2002–03 to 55.6 per 100 in 2011–12, suggesting approximately 20.6 million 
more contacts with chronic problems in Australia in 2011–12 than in 2002–03. The most 
common chronic problems managed were non-gestational hypertension, depressive 
disorder, non-gestational diabetes, chronic arthritis and lipid disorders.  
The increases in the management rate of the chronic conditions depression, diabetes, 
oesophageal disease and atrial fibrillation may be related to increases in the proportion of 
GP–patient encounters accounted for by older patients over the study period (see Chapter 6). 
The Australian Government has invested considerable resources in the prevention and 
management of chronic disease (such as the National Chronic Disease Strategy,56 and MBS 
items for chronic disease management).55 A major reason for this focus is the ageing 
population57 and the associated expected fiscal pressures (especially healthcare costs).6  
From 2002–03 to 2011–12, there were significant increases in the management rates of 
depressive disorder, non-gestational diabetes, lipid disorders, oesophageal disease, atrial 
fibrillation and hypothyroidism. There were also significant decreases in the management 
rates of asthma and heart failure (Table 7.6). Many of the changes noted in Table 7.6 are also 
apparent in Table 7.4.
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) 
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.9
) 
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(1
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19
.5
 
(1
8.
8–
20
.1
) 
 
20
.8
 
(2
0.
2–
21
.5
) 
 
22
.2
 
(2
1.
4–
22
.9
) 
 
20
.4
 
(1
9.
7–
21
.1
) 
 
20
.0
 
(1
9.
3–
20
.7
) 
§ 
G
en
er
al
 a
nd
 u
ns
pe
ci
fie
d 
15
.7
 
(1
5.
2–
16
.3
) 
 
14
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n 
an
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f c
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cr
ea
se
 o
r 
de
cr
ea
se
) i
n 
20
11
–1
2 
co
m
pa
re
d 
w
ith
 2
00
2–
03
; 
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 c
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 c
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.2
) 
 
1.
1 
(1
.0
–1
.2
) 
 
1.
0 
(0
.9
–1
.2
) 
 
1.
1 
(1
.0
–1
.2
) 
 
1.
0 
(0
.9
–1
.1
) 
 
1.
0 
(0
.9
–1
.1
) 
 
0.
9 
(0
.8
–1
.0
) 
 
0.
9 
(0
.8
–1
.0
) 
 
1.
0 
(0
.9
–1
.2
) 
 
0.
9 
(0
.8
–1
.0
) 

 
O
bs
er
va
tio
n/
he
al
th
 
ed
uc
at
io
n/
ad
vi
ce
/d
ie
t –
 
al
l* 
0.
8 
(0
.7
–0
.9
) 
 
0.
8 
(0
.7
–0
.9
) 
 
0.
8 
(0
.7
–0
.9
) 
 
0.
7 
(0
.6
–0
.8
) 
 
0.
7 
(0
.7
–0
.8
) 
 
0.
7 
(0
.7
–0
.8
) 
 
0.
8 
(0
.7
–0
.9
) 
 
1.
1 
(0
.9
–1
.3
) 
 
1.
0 
(0
.8
–1
.3
) 
 
0.
8 
(0
.7
–0
.9
) 
—
 
Fr
ac
tu
re
* 
1.
0 
(0
.9
–1
.1
) 
 
1.
0 
(0
.9
–1
.1
) 
 
1.
0 
(0
.9
–1
.1
) 
 
1.
0 
(0
.9
–1
.1
) 
 
1.
0 
(1
.0
–1
.1
) 
 
1.
0 
(0
.9
–1
.1
) 
 
0.
9 
(0
.9
–1
.0
) 
 
0.
9 
(0
.8
–0
.9
) 
 
0.
9 
(0
.9
–1
.0
) 
 
0.
9 
(0
.8
–1
.0
) 
—
 
O
st
eo
po
ro
si
s 
0.
8 
(0
.7
–0
.9
) 
 
0.
8 
(0
.7
–0
.9
) 
 
0.
9 
(0
.8
–1
.0
) 
 
0.
9 
(0
.8
–1
.0
) 
 
0.
9 
(0
.8
–1
.0
) 
 
1.
0 
(0
.9
–1
.1
) 
 
0.
9 
(0
.8
–1
.0
) 
 
0.
9 
(0
.8
–1
.0
) 
 
0.
7 
(0
.6
–0
.8
) 
 
0.
8 
(0
.7
–0
.9
) 
—
 
M
en
op
au
sa
l c
om
pl
ai
nt
 
1.
5 
(1
.3
–1
.6
) 
 
1.
0 
(0
.9
–1
.1
) 
 
0.
9 
(0
.8
–1
.0
) 
 
0.
9 
(0
.8
–0
.9
) 
 
0.
9 
(0
.8
–1
.0
) 
 
0.
8 
(0
.7
–0
.9
) 
 
0.
8 
(0
.7
–0
.9
) 
 
0.
7 
(0
.7
–0
.8
) 
 
0.
7 
(0
.6
–0
.8
) 
 
0.
7 
(0
.6
–0
.8
) 

 
To
ta
l p
ro
bl
em
s 
14
4.
9 
(1
43
.0
–1
46
.8
) 
 
14
6.
3 
(1
44
.4
–1
48
.2
) 
 
14
5.
5 
(1
43
.6
–1
47
.4
) 
 
14
6.
2 
(1
44
.2
–1
48
.2
) 
 
14
8.
5 
(1
46
.4
–1
50
.6
) 
 
15
1.
3 
(1
49
.2
–1
53
.4
) 
 
15
4.
6 
(1
52
.6
–1
56
.5
) 
 
15
3.
3 
(1
51
.1
–1
55
.5
) 
 
15
2.
5 
(1
50
.2
–1
54
.7
) 
 
15
3.
8 
(1
51
.4
–1
56
.1
) 

 
(a
) 
T
he
 d
ire
ct
io
n 
an
d 
ty
pe
 o
f c
ha
ng
e 
fr
om
 2
00
2–
03
 to
 2
01
1–
12
 is
 in
di
ca
te
d 
fo
r e
ac
h 
re
su
lt:
 
/
 in
di
ca
te
s 
a 
st
at
is
tic
al
ly
 s
ig
ni
fic
an
t c
ha
ng
e 
(in
cr
ea
se
 o
r 
de
cr
ea
se
) i
n 
20
11
–1
2 
co
m
pa
re
d 
w
ith
 2
00
2–
03
; 
/
 in
di
ca
te
s 
a 
m
ar
gi
na
lly
 s
ig
ni
fic
an
t c
ha
ng
e 
in
 2
01
1–
12
 c
om
pa
re
d 
w
ith
 2
00
2–
03
; —
 in
di
ca
te
s 
th
er
e 
w
as
 n
o 
si
gn
ifi
ca
nt
 c
ha
ng
e 
in
 2
01
1–
12
 c
om
pa
re
d 
w
ith
 2
00
2–
03
; a
nd
 §
 in
di
ca
te
s 
a 
no
te
w
or
th
y 
ch
an
ge
 d
ur
in
g 
th
e 
de
ca
de
. 
* 
In
cl
ud
es
 m
ul
tip
le
 IC
P
C
-2
 o
r 
IC
P
C
-2
 P
LU
S
 c
od
es
 (
se
e 
4.
1)
. 
N
ot
e:
 C
I –
 c
on
fid
en
ce
 in
te
rv
al
; N
O
S
 –
 n
ot
 o
th
er
w
is
e 
sp
ec
ifi
ed
. T
hi
s 
ta
bl
e 
in
cl
ud
es
 in
di
vi
du
al
 p
ro
bl
em
s 
th
at
 w
er
e 
m
an
ag
ed
 a
t ≥
 1
.0
 p
er
 1
00
 e
nc
ou
nt
er
s 
in
 a
ny
 y
ea
r.
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  Ta
bl
e 
7.
5:
 M
os
t f
re
qu
en
tly
 m
an
ag
ed
 n
ew
 p
ro
bl
em
s,
 2
00
2–
03
 to
 2
01
1–
12
 
 
R
at
e 
pe
r 1
00
 e
nc
ou
nt
er
s 
(9
5%
 C
I) 
 
 
20
02
–0
3 
 
20
03
–0
4 
 
20
04
–0
5 
 
20
05
–0
6 
 
20
06
–0
7 
 
20
07
–0
8 
 
20
08
–0
9 
 
20
09
–1
0 
 
20
10
–1
1 
 
20
11
–1
2 

(a
)  
 
 
N
ew
 p
ro
bl
em
 m
an
ag
ed
 
(n
 =
 1
00
,9
87
) 
 
(n
 =
 9
8,
87
7)
 
 
(n
 =
 9
4,
38
6)
 
 (
n 
= 
10
1,
99
3)
  
(n
 =
 9
1,
80
5)
 
 (
n 
= 
95
,8
98
) 
 (
n 
= 
96
,6
88
) 
 (n
 =
 1
01
,3
49
) 
 (
n 
= 
95
,8
39
) 
 (
n 
= 
99
,0
30
) 
U
pp
er
 re
sp
ira
to
ry
 tr
ac
t 
in
fe
ct
io
n 
5.
1 
(4
.7
–5
.5
) 
 
4.
2 
(3
.8
–4
.5
) 
 
4.
3 
(4
.0
–4
.6
) 
 
4.
8 
(4
.4
–5
.2
) 
 
4.
4 
(4
.1
–4
.8
) 
 
4.
8 
(4
.4
–5
.2
) 
 
4.
7 
(4
.4
–5
.0
) 
 
4.
6 
(4
.3
–5
.0
) 
 
4.
1 
(3
.8
–4
.5
) 
 
4.
6 
(4
.3
–5
.0
) 
—
 
Im
m
un
is
at
io
n/
 
va
cc
in
at
io
n 
– 
al
l* 
2.
9 
(2
.6
–3
.2
) 
 
2.
9 
(2
.6
–3
.3
) 
 
2.
7 
(2
.4
–3
.1
) 
 
2.
7 
(2
.5
–3
.0
) 
 
2.
8 
(2
.5
–3
.1
) 
 
2.
8 
(2
.5
–3
.0
) 
 
2.
8 
(2
.5
–3
.1
) 
 
4.
3 
(3
.9
–4
.7
) 
 
3.
0 
(2
.7
–3
.3
) 
 
2.
6 
(2
.3
–2
.9
) 
§ 
C
he
ck
-u
p 
– 
al
l* 
2.
2 
(2
.0
–2
.4
) 
 
2.
1 
(1
.9
–2
.3
) 
 
2.
2 
(2
.0
–2
.4
) 
 
2.
2 
(2
.1
–2
.4
) 
 
2.
5 
(2
.3
–2
.7
) 
 
2.
5 
(2
.3
–2
.7
) 
 
2.
5 
(2
.3
–2
.7
) 
 
2.
8 
(2
.6
–3
.0
) 
 
2.
7 
(2
.4
–2
.9
) 
 
2.
9 
(2
.6
–3
.1
) 

 
A
cu
te
 b
ro
nc
hi
tis
/ 
br
on
ch
io
lit
is
 
1.
9 
(1
.7
–2
.1
) 
 
1.
8 
(1
.6
–1
.9
) 
 
1.
7 
(1
.5
–1
.9
) 
 
1.
9 
(1
.7
–2
.1
) 
 
1.
6 
(1
.5
–1
.7
) 
 
1.
7 
(1
.6
–1
.9
) 
 
1.
9 
(1
.8
–2
.1
) 
 
1.
7 
(1
.6
–1
.9
) 
 
1.
8 
(1
.7
–2
.0
) 
 
1.
8 
(1
.6
–2
.0
) 
—
 
G
as
tro
en
te
rit
is
* 
1.
3 
(1
.2
–1
.5
) 
 
1.
3 
(1
.2
–1
.5
) 
 
1.
2 
(1
.1
–1
.3
) 
 
1.
3 
(1
.2
–1
.4
) 
 
1.
3 
(1
.2
–1
.4
) 
 
1.
3 
(1
.2
–1
.5
) 
 
1.
1 
(1
.0
–1
.2
) 
 
1.
1 
(1
.0
–1
.2
) 
 
1.
1 
(1
.0
–1
.2
) 
 
1.
2 
(1
.0
–1
.3
) 
—
 
U
rin
ar
y 
tra
ct
 in
fe
ct
io
n*
 
1.
1 
(1
.0
–1
.2
) 
 
1.
1 
(1
.0
–1
.1
) 
 
1.
1 
(1
.0
–1
.1
) 
 
1.
2 
(1
.1
–1
.3
) 
 
1.
1 
(1
.0
–1
.2
) 
 
1.
0 
(0
.9
–1
.1
) 
 
1.
0 
(1
.0
–1
.1
) 
 
1.
1 
(1
.0
–1
.2
) 
 
1.
1 
(1
.0
–1
.2
) 
 
1.
1 
(1
.0
–1
.2
) 
—
 
S
pr
ai
n/
st
ra
in
* 
1.
0 
(0
.9
–1
.1
) 
 
1.
0 
(0
.9
–1
.0
) 
 
1.
0 
(0
.9
–1
.1
) 
 
1.
1 
(1
.0
–1
.2
) 
 
0.
9 
(0
.8
–1
.0
) 
 
0.
9 
(0
.8
–1
.0
) 
 
0.
9 
(0
.8
–0
.9
) 
 
0.
9 
(0
.8
–1
.0
) 
 
0.
9 
(0
.8
–1
.0
) 
 
0.
9 
(0
.8
–1
.0
) 
—
 
V
ira
l d
is
ea
se
, o
th
er
/N
O
S
 
1.
1 
(0
.9
–1
.2
) 
 
1.
0 
(0
.9
–1
.1
) 
 
0.
9 
(0
.8
–1
.0
) 
 
0.
9 
(0
.8
–1
.0
) 
 
0.
8 
(0
.7
–0
.9
) 
 
0.
9 
(0
.8
–1
.1
) 
 
0.
9 
(0
.7
–1
.0
) 
 
0.
9 
(0
.7
–1
.0
) 
 
0.
9 
(0
.7
–1
.0
) 
 
0.
9 
(0
.7
–1
.1
) 
—
 
To
ta
l n
ew
 p
ro
bl
em
s 
56
.9
 
(5
5.
5–
58
.4
) 
 
55
.9
 
(5
4.
5–
57
.3
) 
 
55
.2
 
(5
3.
8–
56
.5
) 
 
56
.9
 
(5
5.
5–
58
.2
) 
 
56
.5
 
(5
5.
1–
57
.9
) 
 
57
.7
 
(5
6.
3–
59
.1
) 
 
57
.4
 
(5
6.
0–
58
.7
) 
 
59
.1
 
(5
7.
6–
60
.5
) 
 
57
.8
 
(5
6.
4–
59
.3
) 
 
58
.6
 
(5
7.
1–
60
.0
) 
—
 
(a
) 
T
he
 d
ire
ct
io
n 
an
d 
ty
pe
 o
f c
ha
ng
e 
fr
om
 2
00
2–
03
 to
 2
01
1–
12
 is
 in
di
ca
te
d 
fo
r e
ac
h 
re
su
lt:
 
/
 in
di
ca
te
s 
a 
st
at
is
tic
al
ly
 s
ig
ni
fic
an
t c
ha
ng
e 
(in
cr
ea
se
 o
r 
de
cr
ea
se
) i
n 
20
11
–1
2 
co
m
pa
re
d 
w
ith
 2
00
2–
03
; —
 in
di
ca
te
s 
th
er
e 
w
as
 n
o 
si
gn
ifi
ca
nt
 c
ha
ng
e 
in
 2
01
1–
12
 c
om
pa
re
d 
w
ith
 2
00
2–
03
; a
nd
 §
 in
di
ca
te
s 
a 
no
te
w
or
th
y 
ch
an
ge
 d
ur
in
g 
th
e 
de
ca
de
. 
* 
In
cl
ud
es
 m
ul
tip
le
 IC
P
C
-2
 o
r 
IC
P
C
-2
 P
LU
S
 c
od
es
 (
se
e 
A
pp
en
di
x 
4,
 T
ab
le
 A
4.
1,
 <
hd
l.h
an
dl
e.
ne
t/2
12
3/
86
76
)>
. 
N
ot
e:
 C
I –
 c
on
fid
en
ce
 in
te
rv
al
; N
O
S
 –
 n
ot
 o
th
er
w
is
e 
sp
ec
ifi
ed
. T
hi
s 
ta
bl
e 
in
cl
ud
es
 in
di
vi
du
al
 n
ew
 p
ro
bl
em
s 
th
at
 w
er
e 
m
an
ag
ed
 a
t >
= 
1.
0 
pe
r 1
00
 e
nc
ou
nt
er
s 
in
 a
ny
 y
ea
r.
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  Ta
bl
e 
7.
6:
 M
os
t f
re
qu
en
tly
 m
an
ag
ed
 c
hr
on
ic
 p
ro
bl
em
s,
 2
00
2–
03
 to
 2
01
1–
12
 
 
R
at
e 
pe
r 1
00
 e
nc
ou
nt
er
s 
(9
5%
 C
I) 
 
C
hr
on
ic
 p
ro
bl
em
 
m
an
ag
ed
 
20
02
–0
3 
 
20
03
–0
4 
 
20
04
–0
5 
 
20
05
–0
6 
 
20
06
–0
7 
 
20
07
–0
8 
 
20
08
–0
9 
 
20
09
–1
0 
 
20
10
–1
1 
 
20
11
–1
2 

(a
)  
 
 
(n
 =
 1
00
,9
87
) 
 
(n
 =
 9
8,
87
7)
 
 
(n
 =
 9
4,
38
6)
 
 (
n 
= 
10
1,
99
3)
  
(n
 =
 9
1,
80
5)
 
 (
n 
= 
95
,8
98
) 
 (
n 
= 
96
,6
88
) 
 (n
 =
 1
01
,3
49
) 
 (
n 
= 
95
,8
39
) 
 (
n 
= 
99
,0
30
) 
H
yp
er
te
ns
io
n 
(n
on
-g
es
ta
tio
na
l)*
* 
8.
8 
(8
.3
–9
.3
) 
 
9.
2 
(8
.7
–9
.7
) 
 
8.
9 
(8
.4
–9
.4
) 
 
9.
4 
(8
.9
–1
0.
0)
 
 
9.
5 
(9
.0
–1
0.
0)
 
 
9.
9 
(9
.3
–1
0.
4)
 
 
10
.1
 
(9
.6
–1
0.
6)
 
 
9.
1 
(8
.6
–9
.5
) 
 
8.
7 
(8
.2
–9
.1
) 
 
9.
0 
(8
.5
–9
.6
) 
—
 
D
ep
re
ss
iv
e 
di
so
rd
er
**
 
3.
5 
(3
.3
–3
.7
) 
 
3.
6 
(3
.4
–3
.8
) 
 
3.
7 
(3
.5
–3
.9
) 
 
3.
6 
(3
.4
–3
.8
) 
 
3.
7 
(3
.5
–3
.9
) 
 
4.
0 
(3
.7
–4
.2
) 
 
4.
2 
(4
.0
–4
.4
) 
 
4.
2 
(4
.0
–4
.5
) 
 
4.
2 
(3
.9
–4
.4
) 
 
4.
4 
(4
.1
–4
.6
) 

 
D
ia
be
te
s 
 
(n
on
-g
es
ta
tio
na
l)*
* 
2.
9 
(2
.7
–3
.1
) 
 
3.
3 
(3
.0
–3
.5
) 
 
3.
2 
(3
.0
–3
.4
) 
 
3.
5 
(3
.3
–3
.7
) 
 
3.
6 
(3
.4
–3
.9
) 
 
3.
8 
(3
.6
–4
.1
) 
 
4.
1 
(3
.8
–4
.3
) 
 
3.
7 
(3
.5
–3
.9
) 
 
4.
0 
(3
.7
–4
.2
) 
 
4.
1 
(3
.9
–4
.4
) 

 
C
hr
on
ic
 a
rth
rit
is
**
 
3.
7 
(3
.5
–3
.9
) 
 
4.
0 
(3
.8
–4
.2
) 
 
3.
9 
(3
.7
–4
.1
) 
 
3.
8 
(3
.5
–4
.0
) 
 
3.
7 
(3
.5
–3
.9
) 
 
3.
6 
(3
.4
–3
.8
) 
 
3.
8 
(3
.6
–4
.0
) 
 
3.
9 
(3
.6
–4
.3
) 
 
3.
7 
(3
.5
–3
.9
) 
 
3.
9 
(3
.7
–4
.2
) 
—
 
Li
pi
d 
di
so
rd
er
 
3.
0 
(2
.8
–3
.2
) 
 
3.
1 
(2
.9
–3
.4
) 
 
3.
3 
(3
.1
–3
.6
) 
 
3.
4 
(3
.1
–3
.7
) 
 
3.
5 
(3
.2
–3
.7
) 
 
3.
7 
(3
.4
–4
.0
) 
 
3.
9 
(3
.7
–4
.2
) 
 
3.
5 
(3
.2
–3
.7
) 
 
3.
1 
(2
.8
–3
.3
) 
 
3.
5 
(3
.3
–3
.7
) 

 
O
es
op
ha
ge
al
 d
is
ea
se
 
1.
9 
(1
.8
–2
.1
) 
 
2.
2 
(2
.0
–2
.4
) 
 
2.
1 
(2
.0
–2
.3
) 
 
2.
4 
(2
.2
–2
.5
) 
 
2.
3 
(2
.1
–2
.5
) 
 
2.
3 
(2
.2
–2
.5
) 
 
2.
5 
(2
.3
–2
.7
) 
 
2.
5 
(2
.3
–2
.7
) 
 
2.
3 
(2
.1
–2
.5
) 
 
2.
7 
(2
.5
–2
.8
) 

 
A
st
hm
a 
2.
7 
(2
.6
–2
.9
) 
 
2.
6 
(2
.4
–2
.7
) 
 
2.
3 
(2
.2
–2
.5
) 
 
2.
3 
(2
.1
–2
.4
) 
 
2.
3 
(2
.1
–2
.4
) 
 
2.
2 
(2
.0
–2
.3
) 
 
2.
2 
(2
.1
–2
.3
) 
 
2.
1 
(1
.9
–2
.3
) 
 
2.
2 
(2
.0
–2
.3
) 
 
2.
0 
(1
.9
–2
.1
) 

 
A
tri
al
 fi
br
ill
at
io
n/
flu
tte
r 
0.
6 
(0
.6
–0
.7
) 
 
0.
8 
(0
.7
–0
.9
) 
 
0.
8 
(0
.7
–0
.9
) 
 
0.
9 
(0
.8
–1
.0
) 
 
1.
0 
(0
.9
–1
.1
) 
 
1.
0 
(0
.9
–1
.1
) 
 
1.
3 
(1
.2
–1
.4
) 
 
1.
2 
(1
.1
–1
.3
) 
 
1.
3 
(1
.2
–1
.4
) 
 
1.
4 
(1
.2
–1
.5
) 

 
Is
ch
ae
m
ic
 h
ea
rt 
di
se
as
e*
* 
1.
2 
(1
.1
–1
.3
) 
 
1.
4 
(1
.2
–1
.5
) 
 
1.
2 
(1
.1
–1
.3
) 
 
1.
3 
(1
.2
–1
.4
) 
 
1.
3 
(1
.2
–1
.4
) 
 
1.
1 
(1
.0
–1
.2
) 
 
1.
3 
(1
.2
–1
.4
) 
 
1.
2 
(1
.0
–1
.3
) 
 
1.
1 
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8 Overview of management 
This chapter provides an overview of management of problems in general practice from each 
of the most recent ten years of the BEACH study from 2002–03 to 2011–12. More detailed 
analyses of the overview of management in 2011–12 can be found in Chapter 8 in General 
practice activity in Australia 2011–12.1 
As discussed in Chapter 2 – Methods, we can consider changes in GP management actions 
over time in terms of the number of the selected action per 100 GP–patient encounters, or in 
terms of the number of problems managed. If the number of problems managed on average 
at encounters has not altered it would not matter which way we analysed the data to 
measure change. 
However, as reported in Chapter 7, there was a significant increase in the number of 
problems managed at GP–patient encounters over the decade of this study. If we simply 
compared management actions (e.g. number of prescriptions) as a rate per 100 encounters, 
we would be ignoring the fact that more problems were managed in 2011–12 than in  
2002–03. If more problems are managed, more management actions should result, without 
any change having occurred in GP use of the selected management action. 
In this, and the following management chapters, we report changes over time in two ways: 
• rate (of the selected action) per 100 problems managed 
• rate (of the selected action) per 100 encounters. 
The rate per 100 problems managed gives the clearer idea of how GP management actions 
have (or have not) changed. The rate per 100 encounters is used as the basis of extrapolation 
to national estimated change.  
The direction and type of change from 2002–03 to 2011–12 is indicated for each result in the 
far right column of the tables: / indicates a statistically significant change (increase or 
decrease) in 2011–12 compared with 2002–03; / indicates a marginally significant change 
in 2011–12 compared with 2002–03; — indicates there was no significant change in 2011–12 
compared with 2002–03; and § indicates a noteworthy change during the decade. 
Examples of extrapolations are provided in each of the specific management chapters 
(Chapters 9 to 12, inclusive). The method used to extrapolate to national change estimates is 
described in Section 2.9. 
Between 2002–03 and 2011–12, some trends emerged in management actions per 100 
problems managed (Table 8.1a), and per 100 encounters (Table 8.1b). The most noticeable 
changes in rates per 100 problems managed are listed below. 
• There was a marginal increase in the rate at which procedural treatments were 
undertaken, from 10.1 per 100 problems managed in 2002–03 to 11.0 per 100 problems  
in 2011–12. 
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• The introduction of MBS item numbers for practice nurse activity in 2005–06 led to a 
significant decrease in the rate of clinical treatments given by GPs, from a peak of 27.0  
in 2004–05 to a low point of 19.9 per 100 problems managed in 2006–07. However, since 
then, the rate of GP-provided clinical treatments gradually increased again such that 
there was no significant difference between the start and end of the decade. The original 
impact of practice nurses on this area of GP workload was no longer observed, 
suggesting that by 2011–12 GPs were again performing clinical treatments at a similar 
rate to that prior to the introduction of practice nurse item numbers.  
• The rate of referrals to other health providers significantly increased, from 7.7 to 9.4 per 
100 problems between 2002–03 and 2011–12, influenced by referrals to allied health 
services, which almost doubled over the period (1.7 to 3.0 per 100 problems managed). It 
was further influenced by a significant increase in referrals to emergency departments 
(0.1 to 0.2), and in ‘other referrals’ (0.2 to 0.4 per 100 problems managed). Conversely, the 
rate of referrals to hospital halved between 2002–03 and 2011–12. 
• The rate at which pathology tests/batteries of tests were ordered significantly increased 
by 35%, from 22.7 tests/batteries of tests per 100 problems managed in 2002–03 to 30.6 in 
2011–12.  
• The rate at which imaging was ordered increased significantly, from 5.9 imaging orders 
per 100 problems managed in 2002–03 to 6.6 per 100 in 2011–12. 
Similar changes between 2001–03 and 2011–12 are apparent for each of these areas, in the 
percentage of problems for which at least one management type was provided (Table 8.2a), 
and of encounters where at least one management type was recorded (Table 8.2b). This 
reflects any change in the likelihood of each action eventuating in the management of a 
single problem managed at the encounter.  
The proportion of problems for which: 
• at least one medication was provided in the management of the problem, decreased 
marginally (from 56.8% of problems in 2002–03 to 54.8% in 2011–12), mainly influenced 
by a marginal decrease in the proportion of problems for which medication was 
prescribed, from 47.2% to 45.4% over this time.  
• at least one GP–supplied medication was recorded did not increase significantly over the 
decade, but spiked in 2009–10 at the time of the H1N1 virus concerns. This correlates 
with the observed spike in vaccinations for the same period (Chapter 9). 
• at least one procedure was undertaken, marginally increased from 9.4% in 2002–03 to 
10.3% in 2011–12. 
• at least one referral was given, increased significantly (from 7.7% of problems in 2002–03 
to 9.3% in 2011–12), particularly to allied health services (1.7% to 3.0%), and emergency 
departments (0.1% to 0.2%). 
• at least one investigation was ordered, increased significantly from 16.2% in 2002–03 to 
18.6% in 2011–12. In 2002–03, the likelihood of at least one pathology test being ordered 
was 11.4%, which increased significantly to 13.6%. For imaging tests, the likelihood of at 
least one being ordered increased marginally, from 5.3% to 5.8% of problems by 2011–12. 
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6.
9–
40
.3
) 
 
42
.4
 
(4
0.
7–
44
.2
) 
 
43
.1
 
(4
1.
3–
45
.0
) 
 
45
.6
 
(4
3.
8–
47
.4
) 
 
45
.0
 
(4
3.
1–
46
.9
) 
 
45
.2
 
(4
3.
4–
47
.0
) 
 
47
.0
 
(4
4.
9–
49
.1
) 

 
Im
ag
in
g 
8.
6 
(8
.2
–9
.0
) 
 
8.
2 
(7
.8
–8
.6
) 
 
8.
3 
(8
.0
–8
.6
) 
 
8.
8 
(8
.4
–9
.2
) 
 
9.
0 
(8
.6
–9
.3
) 
 
9.
5 
(9
.2
–9
.9
) 
 
9.
8 
(9
.4
–1
0.
2)
 
 
9.
8 
(9
.3
–1
0.
1)
 
 
9.
8 
(9
.4
–1
0.
2)
 
 
10
.1
 
(9
.6
–1
0.
5)
 

 
O
th
er
 in
ve
st
ig
at
io
ns
 
1.
0 
(0
.9
–1
.1
) 
 
1.
0 
(0
.9
–1
.1
) 
 
1.
1 
(1
.0
–1
.2
) 
 
1.
0 
(0
.9
–1
.1
) 
 
1.
1 
(0
.9
–1
.2
) 
 
1.
0 
(0
.8
–1
.1
) 
 
1.
0 
(0
.9
–1
.1
) 
 
0.
7 
(0
.7
–0
.8
) 
 
0.
7 
(0
.7
–0
.8
) 
 
0.
9 
(0
.8
–1
.0
) 
—
 
(a
) 
T
he
 d
ire
ct
io
n 
an
d 
ty
pe
 o
f c
ha
ng
e 
fr
om
 2
00
2–
03
 to
 2
01
1–
12
 is
 in
di
ca
te
d 
fo
r e
ac
h 
re
su
lt:
 
/
 in
di
ca
te
s 
a 
st
at
is
tic
al
ly
 s
ig
ni
fic
an
t c
ha
ng
e 
(in
cr
ea
se
 o
r 
de
cr
ea
se
) i
n 
20
11
–1
2 
co
m
pa
re
d 
w
ith
 2
00
2–
03
; —
 in
di
ca
te
s 
th
er
e 
w
as
 n
o 
si
gn
ifi
ca
nt
 c
ha
ng
e 
in
 2
01
1–
12
 c
om
pa
re
d 
w
ith
 2
00
2–
03
; a
nd
 §
 in
di
ca
te
s 
a 
no
te
w
or
th
y 
ch
an
ge
 d
ur
in
g 
th
e 
de
ca
de
. 
* 
In
cl
ud
es
 m
ul
tip
le
 IC
P
C
-2
 o
r 
IC
P
C
-2
 P
LU
S
 c
od
es
 (
se
e 
A
pp
en
di
x 
4 
<h
dl
.h
an
dl
e.
ne
t/2
12
3/
86
76
>)
. 
N
ot
e:
 C
I –
 c
on
fid
en
ce
 in
te
rv
al
; O
T
C
 –
 o
ve
r-
th
e-
co
un
te
r.
 
67
  Ta
bl
e 
8.
2a
: P
ro
bl
em
s 
fo
r w
hi
ch
 a
t l
ea
st
 o
ne
 m
an
ag
em
en
t w
as
 re
co
rd
ed
 (p
er
 c
en
t o
f p
ro
bl
em
s)
, 2
00
2–
03
 to
 2
01
1–
12
 
 
Pe
r c
en
t o
f p
ro
bl
em
s 
(9
5%
 C
I) 

(a
)  
 
 
 
20
02
–0
3 
 
20
03
–0
4 
 
20
04
–0
5 
 
20
05
–0
6 
 
20
06
–0
7 
 
20
07
–0
8 
 
20
08
–0
9 
 
20
09
–1
0 
 
20
10
–1
1 
 
20
11
–1
2 
At
 le
as
t o
ne
 …
 
(n
 =
 1
46
,3
36
) 
 (
n 
= 
14
4,
67
4)
  
(n
 =
 1
37
,3
30
) 
 (
n 
= 
14
9,
08
8)
  
(n
 =
 1
36
,3
33
) 
 (
n 
= 
14
5,
07
8)
  
(n
 =
 1
49
,4
62
) 
 (
n 
= 
15
5,
37
3)
  
(n
 =
 1
46
,1
41
) 
 (
n 
= 
15
2,
28
6)
 
M
an
ag
em
en
t t
yp
e 
86
.4
 
(8
5.
7–
87
.1
) 
 
86
.8
 
(8
6.
2–
87
.4
) 
 
87
.1
 
(8
6.
4–
87
.7
) 
 
86
.2
 
(8
5.
6–
86
.9
) 
 
85
.3
 
(8
4.
6–
85
.9
) 
 
86
.3
 
(8
5.
6–
86
.9
) 
 
86
.3
 
(8
5.
6–
86
.9
) 
 
85
.8
 
(8
5.
1–
86
.4
) 
 
85
.9
 
(8
5.
3–
86
.5
) 
 
86
.8
 
(8
6.
1–
87
.4
) 
—
 
 
M
ed
ic
at
io
n 
or
 o
th
er
 
 
tre
at
m
en
t 
75
.1
 
(7
4.
3–
75
.9
) 
 
75
.0
 
(7
4.
2–
75
.8
) 
 
74
.9
 
(7
4.
1–
75
.7
) 
 
73
.5
 
(7
2.
7–
74
.4
) 
 
71
.8
 
(7
0.
9–
72
.6
) 
 
73
.2
 
(7
2.
4–
74
.1
) 
 
72
.9
 
(7
2.
1–
73
.7
) 
 
72
.8
 
(7
1.
9–
73
.7
) 
 
72
.4
 
(7
1.
5–
73
.3
) 
 
73
.4
 
(7
2.
6–
74
.3
) 

 
 
 
M
ed
ic
at
io
n 
 
56
.8
 
(5
5.
8–
57
.8
) 
 
56
.6
 
(5
5.
7–
57
.6
) 
 
55
.2
 
(5
4.
2–
56
.2
) 
 
56
.5
 
(5
5.
4–
57
.5
) 
 
54
.5
 
(5
3.
5–
55
.5
) 
 
54
.1
 
(5
3.
1–
55
.1
) 
 
54
.3
 
(5
3.
4–
55
.3
) 
 
54
.2
 
(5
3.
2–
55
.1
) 
 
54
.0
 
(5
3.
1–
55
.0
) 
 
54
.8
 
(5
3.
8–
55
.8
) 

 
 
 
 
P
re
sc
rip
tio
n 
47
.2
 
(4
6.
0–
48
.4
) 
 
47
.8
 
(4
6.
7–
48
.9
) 
 
46
.7
 
(4
5.
7–
47
.8
) 
 
47
.7
 
(4
6.
6–
48
.8
) 
 
45
.6
 
(4
4.
6–
46
.6
) 
 
44
.4
 
(4
3.
5–
45
.4
) 
 
44
.9
 
(4
3.
9–
45
.8
) 
 
43
.2
 
(4
2.
1–
44
.3
) 
 
44
.7
 
(4
3.
7–
45
.6
) 
 
45
.4
 
(4
4.
3–
46
.5
) 
—
 
 
 
 
G
P
-s
up
pl
ie
d 
5.
2 
(4
.5
–6
.0
) 
 
4.
8 
(4
.2
–5
.3
) 
 
6.
2 
(5
.7
–6
.7
) 
 
4.
5 
(4
.2
–4
.9
) 
 
4.
7 
(4
.3
–5
.1
) 
 
5.
3 
(5
.0
–5
.7
) 
 
5.
7 
(5
.3
–6
.1
) 
 
7.
2 
(6
.7
–7
.7
) 
 
5.
4 
(5
.0
–5
.8
) 
 
5.
0 
(4
.7
–5
.4
) 
§ 
 
 
 
A
dv
is
ed
 O
TC
 
6.
4 
(5
.9
–6
.9
) 
 
6.
0 
(5
.6
–6
.5
) 
 
4.
4 
(4
.0
–4
.7
) 
 
6.
0 
(5
.6
–6
.5
) 
 
5.
8 
(5
.4
–6
.2
) 
 
6.
1 
(5
.6
–6
.5
) 
 
5.
3 
(4
.9
–5
.6
) 
 
5.
6 
(5
.1
–6
.0
) 
 
5.
8 
(5
.4
–6
.2
) 
 
6.
2 
(5
.7
–6
.7
) 
—
 
 
 
O
th
er
 tr
ea
tm
en
t 
30
.9
 
(2
9.
7–
32
.2
) 
 
30
.5
 
(2
9.
3–
31
.8
) 
 
32
.4
 
(3
1.
1–
33
.6
) 
 
26
.9
 
(2
5.
8–
28
.1
) 
 
27
.0
 
(2
5.
8–
28
.2
) 
 
30
.2
 
(2
9.
1–
31
.4
) 
 
29
.3
 
(2
8.
2–
30
.4
) 
 
30
.3
 
(2
9.
0–
31
.7
) 
 
30
.4
 
(2
9.
1–
31
.7
) 
 
30
.7
 
(2
9.
4–
31
.9
) 
—
 
 
 
 
C
lin
ic
al
 tr
ea
tm
en
t 
22
.7
 
(2
1.
5–
23
.8
) 
 
22
.2
 
(2
1.
0–
23
.3
) 
 
23
.7
 
(2
2.
5–
24
.8
) 
 
18
.3
 
(1
7.
2–
19
.3
) 
 
18
.0
 
(1
7.
0–
19
.1
) 
 
20
.6
 
(1
9.
6–
21
.7
) 
 
20
.0
 
(1
8.
9–
21
.0
) 
 
20
.6
 
(1
9.
3–
21
.8
) 
 
20
.9
 
(1
9.
6–
22
.1
) 
 
21
.4
 
(2
0.
2–
22
.6
) 
§ 
 
 
 
P
ro
ce
du
ra
l  
 
 
 
tre
at
m
en
t 
9.
4 
(9
.0
–9
.8
) 
 
9.
4 
(8
.9
–9
.8
) 
 
9.
8 
(9
.3
–1
0.
3)
 
 
9.
3 
(8
.7
–9
.7
) 
 
9.
6 
(9
.2
–1
0.
1)
 
 
10
.3
 
(9
.8
–1
0.
8)
 
 
10
.1
 
(9
.7
–1
0.
5)
 
 
10
.7
 
(1
0.
1–
11
.3
) 
 
10
.4
 
(9
.9
–1
0.
9)
 
 
10
.3
 
(9
.8
–1
0.
7)
 

 
 
R
ef
er
ra
ls
 &
 a
dm
is
si
on
s 
7.
7 
(7
.4
–8
.0
) 
 
8.
0 
(7
.6
–8
.3
) 
 
7.
9 
(7
.7
–8
.2
) 
 
8.
2 
(7
.9
–8
.5
) 
 
8.
3 
(8
.0
–8
.6
) 
 
8.
3 
(8
.0
–8
.6
) 
 
8.
9 
(8
.5
–9
.2
) 
 
8.
7 
(8
.4
–9
.0
) 
 
9.
2 
(8
.9
–9
.5
) 
 
9.
3 
(9
.0
–9
.7
) 

 
 
 
M
ed
ic
al
 s
pe
ci
al
is
t*
 
5.
3 
(5
.1
–5
.6
) 
 
5.
4 
(5
.2
–5
.7
) 
 
5.
4 
(5
.2
–5
.6
) 
 
5.
6 
(5
.4
–5
.9
) 
 
5.
5 
(5
.3
–5
.8
) 
 
5.
3 
(5
.1
–5
.5
) 
 
5.
9 
(5
.7
–6
.1
) 
 
5.
6 
(5
.4
–5
.8
) 
 
5.
7 
(5
.5
–5
.9
) 
 
5.
6 
(5
.4
–5
.9
) 
—
 
A
lli
ed
 h
ea
lth
 
se
rv
ic
es
* 
1.
7 
(1
.6
–1
.9
) 
 
1.
8 
(1
.7
–2
.0
) 
 
1.
9 
(1
.7
–2
.0
) 
 
2.
0 
(1
.8
–2
.1
) 
 
2.
1 
(1
.9
–2
.2
) 
 
2.
3 
(2
.2
–2
.4
) 
 
2.
5 
(2
.4
–2
.7
) 
 
2.
6 
(2
.4
–2
.7
) 
 
2.
7 
(2
.6
–2
.9
) 
 
3.
0 
(2
.8
–3
.2
) 

 
 
 
H
os
pi
ta
l* 
0.
4 
(0
.3
–0
.5
) 
 
0.
4 
(0
.3
–0
.5
) 
 
0.
3 
(0
.3
–0
.4
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.3
) 

 
(c
on
tin
ue
d)
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  Ta
bl
e 
8.
2a
 (c
on
tin
ue
d)
: P
ro
bl
em
s 
fo
r w
hi
ch
 a
t l
ea
st
 o
ne
 m
an
ag
em
en
t w
as
 re
co
rd
ed
 (p
er
 c
en
t o
f p
ro
bl
em
s)
, 2
00
2–
03
 to
 2
01
1–
12
 
 
Pe
r c
en
t o
f p
ro
bl
em
s 
(9
5%
 C
I) 

(a
)  
 
 
 
20
02
–0
3 
 
20
03
–0
4 
 
20
04
–0
5 
 
20
05
–0
6 
 
20
06
–0
7 
 
20
07
–0
8 
 
20
08
–0
9 
 
20
09
–1
0 
 
20
10
–1
1 
 
20
11
–1
2 
At
 le
as
t o
ne
 …
 
(n
 =
 1
46
,3
36
) 
 (
n 
= 
14
4,
67
4)
  
(n
 =
 1
37
,3
30
) 
 (
n 
= 
14
9,
08
8)
  
(n
 =
 1
36
,3
33
) 
 (
n 
= 
14
5,
07
8)
  
(n
 =
 1
49
,4
62
) 
 (
n 
= 
15
5,
37
3)
  
(n
 =
 1
46
,1
41
) 
 (
n 
= 
15
2,
28
6)
 
 
 
E
m
er
ge
nc
y 
 
 
 
de
pa
rtm
en
t*
 
0.
1 
(0
.1
–0
.1
) 
 
0.
1 
(0
.1
–0
.1
) 
 
0.
1 
(0
.1
–0
.1
) 
 
0.
1 
(0
.1
–0
.2
) 
 
0.
1 
(0
.1
–0
.1
) 
 
0.
2 
(0
.1
–0
.2
) 
 
0.
1 
(0
.1
–0
.2
) 
 
0.
1 
(0
.1
–0
.2
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.2
) 

 
 
 
O
th
er
 re
fe
rr
al
s*
 
0.
2 
(0
.2
–0
.2
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
3 
(0
.3
–0
.4
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
4 
(0
.3
–0
.4
) 
 
0.
3 
(0
.3
–0
.4
) 
 
0.
2 
(0
.2
–0
.2
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
4 
(0
.3
–0
.5
) 
 
0.
4 
(0
.4
–0
.5
) 

 
 
In
ve
st
ig
at
io
n 
16
.2
 
(1
5.
7–
16
.6
) 
 
16
.5
 
(1
6.
0–
17
.0
) 
 
16
.9
 
(1
6.
4–
17
.3
) 
 
17
.6
 
(1
7.
1–
18
.1
) 
 
18
.2
 
(1
7.
7–
18
.7
) 
 
18
.1
 
(1
7.
6–
18
.6
) 
 
18
.5
 
(1
8.
0–
19
.0
) 
 
18
.1
 
(1
7.
6–
18
.6
) 
 
18
.2
 
(1
7.
7–
18
.7
) 
 
18
.6
 
(1
8.
1–
19
.2
) 

 
 
 
P
at
ho
lo
gy
 o
rd
er
 
11
.4
 
(1
1.
0–
11
.8
) 
 
11
.9
 
(1
1.
5–
12
.4
) 
 
12
.2
 
(1
1.
8–
12
.6
) 
 
12
.7
 
(1
2.
2–
13
.2
) 
 
13
.4
 
(1
3.
0–
13
.9
) 
 
13
.1
 
(1
2.
7–
13
.6
) 
 
13
.6
 
(1
3.
2–
14
.0
) 
 
13
.2
 
(1
2.
8–
13
.7
) 
 
13
.3
 
(1
2.
9–
13
.7
) 
 
13
.6
 
(1
3.
1–
14
.1
) 

 
 
 
Im
ag
in
g 
or
de
r 
5.
3 
(5
.1
–5
.6
) 
 
5.
1 
(4
.8
–5
.3
) 
 
5.
2 
(5
.0
–5
.4
) 
 
5.
5 
(5
.3
–5
.7
) 
 
5.
5 
(5
.3
–5
.7
) 
 
5.
7 
(5
.4
–5
.9
) 
 
5.
7 
(5
.4
–5
.9
) 
 
5.
7 
(5
.5
–6
.0
) 
 
5.
7 
(5
.5
–5
.9
) 
 
5.
8 
(5
.6
–6
.1
) 

 
 
 
O
th
er
 in
ve
st
ig
at
io
n 
0.
7 
(0
.6
–0
.7
) 
 
0.
7 
(0
.6
–0
.7
) 
 
0.
7 
(0
.7
–0
.8
) 
 
0.
7 
(0
.6
–0
.7
) 
 
0.
7 
(0
.6
–0
.8
) 
 
0.
6 
(0
.5
–0
.7
) 
 
0.
6 
(0
.6
–0
.7
) 
 
0.
5 
(0
.4
–0
.5
) 
 
0.
5 
(0
.4
–0
.5
) 
 
0.
6 
(0
.5
–0
.6
) 

 
(a
) 
T
he
 d
ire
ct
io
n 
an
d 
ty
pe
 o
f c
ha
ng
e 
fr
om
 2
00
2–
03
 to
 2
01
1–
12
 is
 in
di
ca
te
d 
fo
r e
ac
h 
re
su
lt:
 
/
 in
di
ca
te
s 
a 
st
at
is
tic
al
ly
 s
ig
ni
fic
an
t c
ha
ng
e 
(in
cr
ea
se
 o
r 
de
cr
ea
se
) i
n 
20
11
–1
2 
co
m
pa
re
d 
w
ith
 2
00
2–
03
; 
/
 in
di
ca
te
s 
a 
m
ar
gi
na
lly
 s
ig
ni
fic
an
t c
ha
ng
e 
in
 2
01
1–
12
 c
om
pa
re
d 
w
ith
 2
00
2–
03
; —
 in
di
ca
te
s 
th
er
e 
w
as
 n
o 
si
gn
ifi
ca
nt
 c
ha
ng
e 
in
 2
01
1–
12
 c
om
pa
re
d 
w
ith
 2
00
2–
03
; a
nd
 §
 in
di
ca
te
s 
a 
no
te
w
or
th
y 
ch
an
ge
 d
ur
in
g 
th
e 
de
ca
de
. 
Ŧ
 
R
at
es
 a
re
 r
ep
or
te
d 
to
 o
ne
 d
ec
im
al
 p
la
ce
. T
hi
s 
in
di
ca
te
s 
th
at
 th
e 
ra
te
 is
 le
ss
 th
an
 0
.0
5 
pe
r 
10
0 
en
co
un
te
rs
. 
N
ot
e:
 C
I –
 c
on
fid
en
ce
 in
te
rv
al
; O
T
C
 –
 o
ve
r-
th
e-
co
un
te
r.
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  Ta
bl
e 
8.
2b
: E
nc
ou
nt
er
s 
at
 w
hi
ch
 a
t l
ea
st
 o
ne
 m
an
ag
em
en
t w
as
 re
co
rd
ed
 (p
er
 c
en
t o
f e
nc
ou
nt
er
s)
, 2
00
2–
03
 to
 2
01
1–
12
 
 
Pe
r c
en
t o
f e
nc
ou
nt
er
s 
(9
5%
 C
I) 

(a
)  
 
 
 
20
02
–0
3 
 
20
03
–0
4 
 
20
04
–0
5 
 
20
05
–0
6 
 
20
06
–0
7 
 
20
07
–0
8 
 
20
08
–0
9 
 
20
09
–1
0 
 
20
10
–1
1 
 
20
11
–1
2 
At
 le
as
t o
ne
…
 
(n
 =
 1
00
,9
87
) 
 
(n
 =
 9
8,
87
7)
 
 
(n
 =
 9
4,
38
6)
 
 (
n 
= 
10
1,
99
3)
  
(n
 =
 9
1,
80
5)
 
 
(n
 =
 9
5,
89
8)
 
 
(n
 =
 9
6,
68
8)
 
 (
n 
= 
10
1,
34
9)
  
(n
 =
 9
5,
83
9)
 
 
(n
 =
 9
9,
03
0)
 
M
an
ag
em
en
t t
yp
e 
91
.3
 
(9
0.
6–
92
.0
) 
 
91
.5
 
(9
0.
9–
92
.0
) 
 
91
.9
 
(9
1.
3–
92
.5
) 
 
91
.2
 
(9
0.
6–
91
.8
) 
 
90
.4
 
(8
9.
8–
91
.0
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9 Medications 
This chapter summarises the medications prescribed, advised or supplied by general 
practitioners in each of ten years of the BEACH study from 2002–03 to 2011–12. The direction 
and type of change over the study period is indicated for each result in the far right column 
of the tables: / indicates a statistically significant change (increase or decrease) in 2011–
12 compared with 2002–03; / indicates a marginally significant change in 2011–12 
compared with 2002–03; — indicates there was no significant change in 2011–12 compared 
with 2002–03; and § indicates a noteworthy change during the decade. 
Significant change in rate per 100 encounters can be extrapolated to estimate the national 
increase or decrease in the number of prescribed, supplied, or advised medications between 
the first and last years of the study period. Some examples of extrapolated changes are given 
in this chapter. The method used to extrapolate to national change estimates is described 
fully in Section 2.9. In 2011–12 there were 25.6 million more encounters claimed through 
Medicare than there were in 2002–03 (122.5 million versus 96.9 million). It should be noted 
that because of this increase, it is possible that a rate of medication per 100 encounters that 
shows a decrease over time can result in an increase in the extrapolated national estimates of 
that medication.  
GPs could record up to four medications for each of four problems – a maximum of 
16 medications per encounter. Each medication could be recorded as prescribed (the default), 
supplied by the GP, or recommended for over-the-counter (OTC) purchase. 
Medication data for the ten years 2002–03 to 2011–12, are reported in two ways in this 
chapter: as rates per 100 problems managed and as rates per 100 encounters. In describing 
data over time, the rates per 100 problems are reported as the primary measure, because 
there was a significant increase in the number of problems managed per encounter over the 
decade. The tables with rates per 100 encounters are included to show the basis for the 
extrapolations discussed above. Therefore, the rates shown in the examples below are per 
100 problems managed and are taken from results shown in Tables 9.1a, 9.2a, 9.3a, 9.4a and 
9.5a. On the other hand, the extrapolations are based on rate per 100 encounters so that they 
are equivalent to the national encounter data from Medicare and are based on results shown 
in Tables 9.1b, 9.2b, 9.3b, 9.4b and 9.5b. 
Tables 9.1a and 9.1b show that between 2002–03 and 2011–12, there was no significant 
change in total medication rates per 100 problems managed or per 100 encounters. The peak 
in rates of GP–supplied medications in 2009–10 (Tables 9.1a and 9.1b) reflects a high rate of 
influenza virus vaccine which coincided with the H1N1 influenza pandemic of 2009. 
9.1 Prescribed medications 
The rate at which medications were prescribed overall did not change significantly from 
2002–03 (58.2 per 100 problems) to 2011–12 (56.5 per 100) (Table 9.1a). There was also no 
significant change per 100 encounters (Table 9.1b). However, the extrapolated national effect 
of the increased number of encounters (described above) resulted in 24.6 million more 
prescriptions being given nationally by GPs in 2011–12 than in 2002–03. Tables 9.2a and 9.2b 
show prescribing rates of common drug groups over the ten-year period at ATC drug group 
Level 2, because this level is the most stable of the ATC groups.  
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There were significant changes in GP prescribing rate per 100 problems managed for a wide 
range of drug groups (Table 9.2a). In particular, there were measured increases in the 
prescription rate per 100 problems for:  
• agents acting on the renin-angiotensin system from 3.4 per 100 problems managed in 
2002–03 to 4.5 in 2011–12. The extrapolated national effect of this change (calculated from 
the encounter rate from Table 9.2b) was about 3.7 million more prescriptions for drugs in 
this group given in 2011–12 than in 2002–03 
• psychoanaleptics from 2.1 per 100 problems in 2002–03 to 2.7 per 100 in 2011–12, with an 
extrapolated national effect of about 2.2 million more prescriptions for psychoanaleptics 
nationally in 2011–12 than in 2002–03 
• lipid modifying agents from 1.6 per 100 problems in 2002–03 to 2.6 in 2011–12. The 
extrapolated national effect of this change was that about 2.6 million more prescriptions 
for drugs in this group were given in 2011–12 than in 2002–03 
• drugs for acid related disorders from 1.8 per 100 problems in 2002–03 to 2.2 in 2011–12, 
an estimated increase of 1.7 million prescriptions nationally in 2011–12 than in 2002–03 
• drugs used in diabetes from 1.3 per 100 problems in 2002–03 to 1.9 in 2011–12, 
suggesting 1.7 million more prescriptions nationally in 2011–12 than in 2002–03. 
There were also significant decreases in the prescribing rate per 100 problems managed for 
some drug groups. As earlier suggested, the increase in number of encounters claimed 
through Medicare over the decade could cause the decreases in medication numbers in the 
extrapolated national estimates to be less than they would have been had Medicare 
encounter numbers remained steady. As shown in Table 9.2a, there were measured 
decreases in the prescription rate per 100 problems for:  
• drugs for obstructive airway disease from 3.2 per 100 problems managed in 2002–03 to 
2.4 in 2011–12. The extrapolated national effect of this change (calculated on the 
encounter rate from Table 9.2b) was that about 75,000 fewer prescriptions for drugs in 
this group were given in 2011–12 than in 2002–03 
• anti-inflammatory and antirheumatic products from 3.3 per 100 problems in 2002–03 to 
2.0 in 2011–12, with an extrapolated national effect of about 980,000 fewer prescriptions 
for these products nationally in 2011–12 than in 2002–03 
• sex hormones and modulators of the genital system from 2.6 per 100 problems in 2002–
03 to 1.6 in 2011–12, with an extrapolated national effect of about 520,000 fewer 
prescriptions for them nationally in 2011–12 than in 2002–03 
• vaccines from 2.9 per 100 problems in 2002–03 to 0.8 in 2011–12, an estimated decrease of 
2.5 million vaccine prescriptions nationally in 2011–12 than in 2002–03 
• diuretics from 1.1 per 100 problems in 2002–03 to 0.7 in 2011–12, suggesting 200,000 
fewer diuretic prescriptions nationally in 2011–12 than in 2002–03. 
Some of the changes referred to here can be linked to changes in the patterns of morbidity 
managed, for example, the rise in psychoanaleptics and the significant increase in 
management rates of depression. Other changes coincide with policy initiatives such as the 
rise in drugs used in diabetes (and management rates of diabetes) which began in 2005–06 
after the introduction of the government Action Plan on Diabetes. Likewise, the steady rise 
in rates of lipid modifying agents accelerated in 2006–07, which was when criteria for PBS-
subsidised access to these medications were broadened. 
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Decreases in prescribing rates of drug groups can sometimes be linked to medications within 
the group becoming available over-the-counter (e.g. salbutamol; the ‘morning after pill’ 
contraceptive); becoming more likely to be supplied directly to the patient by the GP (e.g. 
vaccines); or being included in combination medication products (e.g. diuretics). 
When no change occurs in prescribing rate per 100 problems managed, there may still be a 
national increase due to the increased attendance rates. An example of this is prescriptions 
for analgesics, the rate of which remained steady over the study period. However, we 
estimate that due to the increase in attendances, about 3.5 million more were prescribed in 
2011–12 than in 2002–03.  
Tables 9.3a and 9.3b show prescribed medication rates at the individual generic level. The 
same effect of increased number of Medicare encounters over time applies to these 
individual drugs. There were significant changes in GP prescribing rate per 100 problems for 
a number of drugs, including increased prescription rate per 100 problems managed for:  
• the opioid oxycodone, which demonstrated a fivefold increase from 0.2 per 100 problems 
managed in 2002–03 to 1.0 in 2011–12, with an extrapolated national effect of about 1.5 
million more prescriptions for oxycodone nationally in 2011–12 than ten years earlier 
(calculated from the encounter rate from Table 9.3b) 
• the proton pump inhibitor esomeprazole, also showed a fivefold increase from 0.2 per 
100 problems in 2002–03 to 1.0 in 2011–12 with an extrapolated national effect of 1.5 
million more prescriptions for esomeprazole given in 2011–12 than in 2002–03 
• the lipid modifying agent rosuvastatin, which was first listed on the PBS in December 
2006, and rose from 0.2 per 100 problems in 2007–08 to 0.7 in 2011–12 – an estimated 
increase of 1.1 million prescriptions during that period 
• the non-steroid anti-inflammatory meloxicam from 0.2 per 100 problems in 2002–03 to 
0.5 in 2011–12, suggesting 690,000 more prescriptions for meloxicam nationally in 2011–
12 than in 2002–03. 
A number of medications were prescribed less often than in 2002–03, with decreases 
observed in the prescription rate per 100 problems for:  
• the lipid modifying agent simvastatin, from 0.6 per 100 problems in 2002–03 to 0.4 in 
2011–12, an extrapolated national decrease of 140,000 thousand prescriptions for 
simvastatin given in 2011–12 than in 2002–03 
• the non-steroid anti-inflammatory celecoxib from 0.7 per 100 problems in 2002–03 to 0.3 
in 2011–12, suggesting 450,000 fewer prescriptions nationally for celecoxib in 2011–12 
than in 2002–03 
• the cefaclor monohydrate, from 0.7 per 100 problems in 2002–03 to 0.3 in 2011–12, an 
estimated decrease of 360,000 prescriptions for cefaclor over the ten-year period. 
Number of repeats ordered 
The pattern of the number of repeat prescriptions recorded by GPs changed between 2002–03 
and 2011–12 (Table 9.4). There was a significant decrease in the proportion of prescribed 
medications with ‘no’ or ‘two’ or ‘three or four’ repeats ordered. On the other hand, there 
was a significant increase in the proportion of prescriptions for which ‘five’ repeats were 
recorded. The proportion of prescriptions given with five repeats increased from 27.4% in 
2002–03 to 35.5% in 2011–12.  
74
  
9.2 Medications supplied by GPs 
Rates of GP-supplied medications per 100 problems managed were similar in 2002–03 (6.4) 
and in 2011–12 (6.3) (Table 9.1a). Per 100 encounters, the rates were also similar in 2002–03 
(9.3) and in 2011–12 (9.7) (Table 9.1b).  
Table 9.5a shows rates per 100 problems managed of individual medications most frequently 
supplied by GPs between 2002–03 and 2011–12. The majority of these medications were 
vaccines, and rates for many of them increased significantly over the period. The supply of 
influenza virus vaccine rose from 0.5 per 100 problems managed in 2002–03 to 1.3 per 100 in 
2011–12. The rate per 100 encounters increased from 0.7 to 1.9 (Table 9.5b), and the 
extrapolated national effect of this change is that influenza virus vaccine was supplied 
1.6 million more times in 2011–12 than in 2002–03. The move away from prescribing towards 
GP supply of the vaccine was evident in this significant increase in its supply, which 
coincided with the significant decrease in its prescribing rate (Table 9.3a). This change 
follows federal government policy starting in 2001, which made the vaccine available free of 
charge to all Australians aged 65 years and over, to Aboriginal and Torres Strait Islander 
people aged 50 years and older, and to younger Aboriginal and Torres Strait Islander 
persons with health risks. Vaccines can be ordered by the GP directly from the supplier. In 
Tables 9.5a and 9.5b, one can also see the 2009–10 peak in the rate of influenza virus vaccine 
coinciding with the H1N1 influenza pandemic of 2009.  
9.3 Medications advised for over-the-counter 
purchase 
Table 9.6a shows rates per 100 problems managed for the most commonly advised 
over-the-counter medications at the generic level. Rates for individual and total medications 
advised for over-the-counter purchase largely remained steady between 2002–03 and  
2011–12, except for significant increases in unspecified simple analgesics and in vitamin D. 
There was a fourfold increase in the rate vitamin D was advised per 100 encounters, with the 
increase starting to become apparent in 2008–09 (Table 9.6b).  
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fo
r e
ac
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lt:
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/
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at
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tic
al
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ni
fic
an
t c
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ng
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(in
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ea
se
 o
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de
cr
ea
se
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–1
2 
co
m
pa
re
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w
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 2
00
2–
03
; 
/
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ca
te
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a 
m
ar
gi
na
lly
 s
ig
ni
fic
an
t c
ha
ng
e 
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 2
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1–
12
 c
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pa
re
d 
w
ith
 2
00
2–
03
; —
 in
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ca
te
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th
er
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w
as
 n
o 
si
gn
ifi
ca
nt
 c
ha
ng
e 
in
 2
01
1–
12
 c
om
pa
re
d 
w
ith
 2
00
2–
03
. 
Ŧ
 
R
at
es
 a
re
 r
ep
or
te
d 
to
 o
ne
 d
ec
im
al
 p
la
ce
. T
hi
s 
in
di
ca
te
s 
th
at
 th
e 
ra
te
 is
 le
ss
 th
an
 0
.0
5 
pe
r 
10
0 
en
co
un
te
rs
.  
N
ot
e:
 C
I –
 c
on
fid
en
ce
 in
te
rv
al
; N
/A
 –
 n
ot
 a
pp
lic
ab
le
 (t
ha
t i
s,
 d
ru
g 
w
as
 n
ot
 a
va
ila
bl
e 
at
 th
at
 ti
m
e)
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
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l p
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0.
3–
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87
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—
 
(a
) 
T
he
 d
ire
ct
io
n 
an
d 
ty
pe
 o
f c
ha
ng
e 
fr
om
 2
00
2–
03
 to
 2
01
1–
12
 is
 in
di
ca
te
d 
fo
r e
ac
h 
re
su
lt:
 
/
 in
di
ca
te
s 
a 
st
at
is
tic
al
ly
 s
ig
ni
fic
an
t c
ha
ng
e 
(in
cr
ea
se
 o
r 
de
cr
ea
se
) i
n 
20
11
–1
2 
co
m
pa
re
d 
w
ith
 2
00
2–
03
; 
/
 in
di
ca
te
s 
a 
m
ar
gi
na
lly
 s
ig
ni
fic
an
t c
ha
ng
e 
in
 2
01
1–
12
 c
om
pa
re
d 
w
ith
 2
00
2–
03
; —
 in
di
ca
te
s 
th
er
e 
w
as
 n
o 
si
gn
ifi
ca
nt
 c
ha
ng
e 
in
 2
01
1–
12
 c
om
pa
re
d 
w
ith
 2
00
2–
03
. 
Ŧ
 
R
at
es
 a
re
 r
ep
or
te
d 
to
 o
ne
 d
ec
im
al
 p
la
ce
. T
hi
s 
in
di
ca
te
s 
th
at
 th
e 
ra
te
 is
 le
ss
 th
an
 0
.0
5 
pe
r 
10
0 
en
co
un
te
rs
. 
N
ot
e:
 C
I –
 c
on
fid
en
ce
 in
te
rv
al
; N
/A
 –
 n
ot
 a
pp
lic
ab
le
 (t
ha
t i
s,
 d
ru
g 
w
as
 n
ot
 a
va
ila
bl
e 
at
 th
at
 ti
m
e)
. 
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
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(a
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M
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si
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 d
at
a 
re
m
ov
ed
. 
(b
) 
T
he
 d
ire
ct
io
n 
an
d 
ty
pe
 o
f c
ha
ng
e 
fr
om
 2
00
2–
03
 to
 2
01
1–
12
 is
 in
di
ca
te
d 
fo
r e
ac
h 
re
su
lt:
 
/
 in
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te
s 
a 
st
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al
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t c
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) i
n 
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m
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w
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te
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th
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 n
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ifi
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 c
ha
ng
e 
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 2
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1–
12
 c
om
pa
re
d 
w
ith
 2
00
2–
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. 
Ŧ
 
R
at
es
 a
re
 r
ep
or
te
d 
to
 o
ne
 d
ec
im
al
 p
la
ce
. T
hi
s 
in
di
ca
te
s 
th
at
 th
e 
ra
te
 is
 le
ss
 th
an
 0
.0
5 
pe
r 
10
0 
en
co
un
te
rs
. 
N
ot
e:
 C
I –
 c
on
fid
en
ce
 in
te
rv
al
. 
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(a
) 
T
he
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ire
ct
io
n 
an
d 
ty
pe
 o
f c
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e 
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2–
03
 to
 2
01
1–
12
 is
 in
di
ca
te
d 
fo
r e
ac
h 
re
su
lt:
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/
 in
di
ca
te
s 
a 
st
at
is
tic
al
ly
 s
ig
ni
fic
an
t c
ha
ng
e 
(in
cr
ea
se
 o
r 
de
cr
ea
se
) i
n 
20
11
–1
2 
co
m
pa
re
d 
w
ith
 2
00
2–
03
; 
/
 in
di
ca
te
s 
a 
m
ar
gi
na
lly
 s
ig
ni
fic
an
t c
ha
ng
e 
in
 2
01
1–
12
 c
om
pa
re
d 
w
ith
 2
00
2–
03
; —
 in
di
ca
te
s 
th
er
e 
w
as
 n
o 
si
gn
ifi
ca
nt
 c
ha
ng
e 
in
 2
01
1–
12
 c
om
pa
re
d 
w
ith
 2
00
2–
03
. 
Ŧ
 
R
at
es
 a
re
 r
ep
or
te
d 
to
 o
ne
 d
ec
im
al
 p
la
ce
. T
hi
s 
in
di
ca
te
s 
th
at
 th
e 
ra
te
 is
 le
ss
 th
an
 0
.0
5 
pe
r 
10
0 
pr
ob
le
m
s 
m
an
ag
ed
. 
N
ot
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I –
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 –
 n
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ab
le
 (t
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w
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 n
ot
 a
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ila
bl
e 
at
 th
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 ti
m
e)
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10 Other treatments 
This chapter summarises other non-pharmacological treatments (including clinical and 
procedural treatments) provided at or in conjunction with recorded GP–patient encounters 
in each of the ten years of the BEACH study, 2002–03 to 2011–12. Clinical and procedural 
treatments are defined in Appendix 4, Tables A4.4 and A4.5. The survey form allowed GPs 
to record up to two other treatments for each problem managed at the encounter, and (since 
2005–06) indicate if each of these has been done by a practice nurse. 
In 2004, four Medicare item numbers were introduced into the MBS that allowed GPs to 
claim for specified tasks done by a practice nurse under the direction of the GP.24 In 2005–06 
the BEACH recording form was amended to capture this information. GPs were allowed to 
record multiple (up to three) Medicare item numbers where appropriate, rather than be 
limited to one item number as had been the case in the past. In the ‘other treatments’ section 
for each problem managed, GPs were asked to tick the ‘practice nurse’ box if the treatment 
recorded was provided by the practice nurse rather than by the GP.  
In Sections 10.1 and 10.2 all ‘other treatments’ are reported, irrespective of whether they were 
done by the GP or by the practice nurse at the encounter. That is, the non-pharmacological 
management provided at general practice patient encounters is described, rather than 
management provided specifically by the GP. However in the analysis of procedural 
treatments (Section 10.2), injections given in provision of vaccines have been removed, as this 
action is already counted and reported in medications.  
In Section 10.3, treatments provided by the PN/AHW (including the injections given for 
vaccination) are reported separately, to provide a picture of the work they undertake in 
association with GP–patient encounters. Routine clinical measurements or observations, such 
as measurements of blood pressure and physical examinations, were not included between 
2002–03 and 2004–05. With the inclusion of practice nurse activities in BEACH since 2005–06, 
clinical observations have been recorded, but only when done by the practice nurse. 
In Section 10.4 changes over time in the share between the GP and the practice 
nurses/Aboriginal health workers, of clinical treatments and procedural work done in 
association with the encounter, are investigated. The procedures analysed in Section 10.4 also 
include the injections given for immunisations. 
Other treatments data for the ten years 2002–03 to 2011–12, are reported in two ways: as rates 
per 100 problems managed (e.g. Table 10.1a) and as rates per 100 encounters (e.g. Table 
10.1b). In the text describing changes over time, the rates per 100 problems are reported as 
the primary measure, because there was a significant increase in the number of problems 
managed per encounter over the study period.  
The direction and type of change from 2002–03 to 2011–12 is indicated for each result in the 
far right column of the tables: The direction and type of change from 2002–03 to 2011–12 is 
indicated for each result in the far right column of the tables: / indicates a statistically 
significant change (increase or decrease) comparing 2011–12 with 2002–03; / indicates a 
marginally significant change comparing 2011–12 with 2002–03; — indicates there was no 
significant change across the decade; and § indicates no change a noteworthy change 
comparing 2011–12 with 2002–03 but a noteworthy change within the decade. 
Significant changes in the rate per 100 encounters are extrapolated to estimate the national 
increase or decrease in the other treatments provided between 2002–03 and 2011–12. 
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Examples of extrapolated change are given. The method used to extrapolate to national 
change estimates is described in Section 2.9.  
More detailed analyses of other treatments recorded in BEACH in 2011–12 can be found in 
Chapter 10 of General practice activity in Australia 2011–12.1 
10.1 Clinical treatments by GP, practice nurse, or 
Aboriginal health worker 
There was no difference in the rate of clinical treatments provided in 2002–03 (25.7 per 100 
problems managed) and 2011–12 (24.0 per 100 problems) (Table 10.1a). There was also no 
significant difference in the rate per 100 encounters in 2002–03 and 2011–12 (Table 10.1b). 
There were more encounters claimed through Medicare in 2011–12 than in 2002–03 due to 
the increased attendance rate over the study period and this affects the number of clinical 
treatments provided nationally (see Table 2.1). We estimate that 9.3 million more clinical 
treatments were given by GPs nationally in 2011–12 than ten years earlier. 
While there was no difference in the total clinical treatment rates of 2002–03 and 2011–12 
there were major changes within the decade. The number of clinical treatments provided at 
GP–patient encounters remained steady from 2002–03 to 2004–05. In November 2004, 
practice nurse Medicare item numbers were introduced and changes were made to the 
BEACH recording form to include practice nurse activity associated with the encounter in 
the 2005–06 BEACH year. In 2005–06 there was a sudden and significant decrease in the rate 
at which many clinical treatments were provided by the GP or the practice nurse at GP–
patient encounters. From 2006–07 onwards, rates slowly increased to reach 24.0 per 100 
problems in 2011–12, returning to the level provided ten years earlier.  
This change was reflected in some specific types of clinical treatments. 
• Although there was no difference between 2002–03 and 2011–12, in 2005–06 there were 
significant decreases in the rates of: advice/education not elsewhere classified; 
advice/education about treatment; advice/education about medication; 
reassurance/support; and counselling/advice about smoking (Table 10.1a). These rates 
then slowly returned to a level not significantly different to the rate of a decade earlier. 
• The rate at which counselling/advice about nutrition/weight and counselling/advice 
about exercise was provided also significantly decreased in 2005–06 then remained 
steady at a significantly lower rate in 2011–12 than ten years earlier (Table 10.1a). From 
Table 10.1b we estimate there were 140,000 fewer occasions of counselling/advice about 
nutrition and weight, and 86,000 fewer occasions of counselling/advice about exercise 
given in 2011–12 than in 2002–03. These decreases may be an issue considering the rise in 
the prevalence of overweight and obesity among Australian general practice patients 
(see Section 13.1). 
• The rate of provision of other administrative procedure/document (excluding sickness 
certificate) significantly fell from 1.2 per 100 problems in 2003–04 to 0.9 in 2004–05. From 
2005–06 onwards, rates slowly rose to 1.4 per 100 problems in 2011–12, a significantly 
higher level than that provided in 2002–03.  
• The rate of provision of sickness certificates significantly rose from 0.7 per 100 problems 
in 2003–04 to 1.2 per 100 in 2004–05. From 2004–05 onwards, rates were steady until a 
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significant decrease in 2009–10 back to the level provided in 2002–03. In 2011–12, 
sickness certificates were provided at a rate that was marginally higher than in 2002–03. 
• There was no significant difference in the proportion of problems for which one or more 
clinical treatments were provided in 2002–03 (32.8 per 100 problems) and in 2011–12 
(32.9 per 100) (Table 10.2).  
• In 2011–12, depression was the problem that accounted for the most clinical treatments 
which were provided at a rate of 1.8 per 100 encounters. This means that for every 1,000 
GP–patient encounters in 2011–12, clinical treatment(s) was provided in the management 
of depression on 18 occasions (Table 10.2).  
• There was a significant increase in the rate at which clinical treatments were provided in 
the management of diabetes over the decade with the rate per 100 encounters rising from 
0.8 in 2002–03 to 1.1 in 2011–12. We estimate this increase equates to 570,000 more 
occasions where clinical treatments were provided in the management of diabetes 
nationally in 2011–12 than a decade earlier. (Table 10.2) 
• The provision of clinical treatment(s) in the management of tobacco abuse more than 
doubled from 0.2 per 100 encounters in 2002–03 to 0.5 per 100 in 2011–12. We estimate 
this increase equates to 420,000 more occasions where clinical treatments were provided 
for tobacco abuse nationally in 2011–12 than a decade earlier (Table 10.2). The significant 
increase occurred over the most recent four years and may be associated with the 
acceptance of nicotine patches on the PBS, the availability of prescribed medications to 
assist in smoking cessation, and anti-smoking campaigns promoting discussion with GPs 
as a strategy towards quitting.  
10.2 Procedures by GP, practice nurse, or Aboriginal 
health worker 
The rate at which procedures were recorded per 100 encounters increased significantly from 
14.6.per 100 encounters in 2002–03 to 16.9 per 100 in 2011–12. The extrapolated effect of this 
change is that nationally in 2011–12 there were an estimated 6.6 million more procedures 
undertaken than a decade earlier.  
However, this was largely due to increasing number of problems managed at encounter and 
increased attendance rates. There was no significant change in the rate at which procedures 
were performed per 100 problems managed between 2002–03 (10.1 per 100 problems) and 
2011–12 (11.0 per 100 problems) (Table 10.3a). However, there were significant changes in the 
rates of specific types of procedures within this period.  
• The most frequently recorded group of procedures were excision/removal 
tissue/biopsy/destruction/debridement/cauterisation. These were provided at a similar 
rate throughout the decade, reaching 2.8 per 100 encounters in 2011–12 (Table 10.3b). 
These were followed by dressing/pressure/compression/tamponade, local 
injection/infiltration (excluding all local injection/infiltrations performed for 
immunisations) and physical medicine/rehabilitation (Table 10.3b).  
• There was a marginal increase in the frequency of dressings/pressure/compression/ 
tamponade from 1.3 per 100 problems in 2002–03 to 1.7 per 100 in 2011–12 (Table 10.3b). 
When considered as a rate per 100 encounters, the increase from 2.0 per 100 encounters 
in 2002–03 to 2.5 per 100 in 2011–12 was statistically significant and extrapolates to 
nearly 1.1 million more dressings/pressure/compression/tamponade procedures 
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undertaken at GP–patient encounters nationally in 2011–12 than ten years earlier (Table 
10.3b).  
• The provision of local injections/infiltration (excluding local injection performed for 
immunisations) significantly increased over the decade (Table 10.3a). When 
extrapolated, the increase equates to provision of 1.2 million more local injections/ 
infiltrations nationally in 2011–12 than in 2002–03 (Table 10.3b).  
• In contrast, Table 10.3a shows a significant decrease in the rate of physical 
medicine/rehabilitation (1.5 per 100 problems in 2002–03 to 0.9 per 100 in 2011–12), Pap 
smear (0.7 per 100 problems in 2002–03 to 0.6 per 100 in 2011–12) and other therapeutic 
procedures/surgery NEC (0.8 per 100 problems in 2002–03 to 0.5 per 100 in 2011–12).  
There was an overall increase in the proportion of problems managed with procedural 
treatments from 13.6% in 2002–03 to 15.8% in 2011–12 (Table 10.4).  
• Laceration was the most common problem to be managed with a procedure, increasing 
from 0.6 procedures per 100 encounters managed in 2002–03 to 0.8 per 100 in 2011–12 
(Table 10.4). Extrapolation of this result suggested about 400,000 more procedures 
performed for laceration at GP–patient encounters nationally in 2011–12 than a decade 
earlier. 
• In Chapter 7, we reported a significant increase in the management rate of atrial 
fibrillation over the decade, with an estimated 1.1 million more atrial fibrillation contacts 
in 2011–12 than in 2002–03. There was a rise in the rate of management of atrial 
fibrillation with a procedure from 0.0 per 100 encounters to 0.4 per 100 over the same 
period, equating to 490,000 more procedures for atrial fibrillation being performed in 
2011–12 than in 2002–03.  
• The rise in atrial fibrillation contacts coincided with a statistically significant increase in 
the prescribing rate of warfarin sodium over the past decade (Table 9.3a). INR testing is 
used to monitor patients on warfarin therapy. Collection of information on INR testing 
performed at the encounter began in BEACH in 2006–07. The provision of INR testing at 
the encounter has significant increased from one INR test per 1,000 encounters in  
2006–07 to seven per 1,000 encounters in 2011–12 (Table 10.3a).  
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0.
8 
(0
.7
–1
.0
) 
 
0.
8 
(0
.7
–0
.9
) 
 
0.
9 
(0
.8
–1
.0
) 

 
In
ci
si
on
/d
ra
in
ag
e/
flu
sh
in
g/
 
as
pi
ra
tio
n/
re
m
ov
al
 b
od
y 
flu
id
* 
0.
8 
(0
.7
–0
.8
) 
 
0.
8 
(0
.7
–0
.9
) 
 
0.
7 
(0
.7
–0
.8
) 
 
0.
9 
(0
.8
–1
.0
) 
 
0.
9 
(0
.8
–0
.9
) 
 
0.
8 
(0
.7
–0
.9
) 
 
0.
8 
(0
.8
–0
.9
) 
 
0.
9 
(0
.8
–1
.0
) 
 
0.
8 
(0
.7
–0
.9
) 
 
0.
7 
(0
.7
–0
.8
) 
—
 
R
ep
ai
r/f
ix
at
io
n 
– 
su
tu
re
/ 
ca
st
/p
ro
st
he
tic
 d
ev
ic
e 
(a
pp
ly
/re
m
ov
e)
* 
0.
6 
(0
.6
–0
.7
) 
 
0.
6 
(0
.5
–0
.6
) 
 
0.
6 
(0
.6
–0
.7
) 
 
0.
7 
(0
.6
–0
.7
) 
 
0.
7 
(0
.6
–0
.7
) 
 
0.
6 
(0
.5
–0
.7
) 
 
0.
5 
(0
.5
–0
.6
) 
 
0.
6 
(0
.5
–0
.6
) 
 
0.
6 
(0
.5
–0
.6
) 
 
0.
6 
(0
.5
–0
.6
) 

 
P
ap
 s
m
ea
r*
 
0.
7 
(0
.7
–0
.8
) 
 
0.
7 
(0
.6
–0
.9
) 
 
0.
7 
(0
.6
–0
.8
) 
 
0.
7 
(0
.6
–0
.7
) 
 
0.
6 
(0
.5
–0
.7
) 
 
0.
7 
(0
.6
–0
.8
) 
 
0.
8 
(0
.7
–0
.9
) 
 
0.
7 
(0
.6
–0
.8
) 
 
0.
6 
(0
.5
–0
.7
) 
 
0.
6 
(0
.5
–0
.6
) 

 
O
th
er
 th
er
ap
eu
tic
 
pr
oc
ed
ur
es
/m
in
or
 s
ur
ge
ry
* 
0.
8 
(0
.7
–0
.9
) 
 
0.
8 
(0
.6
–0
.9
) 
 
0.
8 
(0
.6
–1
.1
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
6 
(0
.5
–0
.7
) 
 
0.
6 
(0
.2
–1
.0
) 
 
0.
5 
(0
.3
–0
.6
) 
 
0.
5 
(0
.4
–0
.6
) 

 
IN
R
 te
st
* 
N
/A
 
 
 
N
/A
 
 
 
N
/A
 
 
 
N
/A
 
 
 
0.
1 
(0
.0
–0
.1
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
3 
(0
.3
–0
.4
) 
 
0.
4 
(0
.3
–0
.4
) 
 
0.
4 
(0
.4
–0
.5
) 
 
0.
4 
(0
.4
–0
.5
) 

 
E
le
ct
ric
al
 tr
ac
in
gs
* 
0.
2 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
3 
(0
.3
–0
.4
) 
 
0.
4 
(0
.3
–0
.4
) 
 
0.
3 
(0
.3
–0
.4
) 
 
0.
4 
(0
.3
–0
.4
) 
 
0.
4 
(0
.3
–0
.4
) 
 
0.
4 
(0
.4
–0
.5
) 

 
C
he
ck
-u
p 
–P
N
/A
H
W
* 
N
/A
 
 
 
N
/A
 
 
 
N
/A
 
 
 
N
/A
 
 
 
0.
1 
(0
.1
–0
.2
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
3 
(0
.2
–0
.4
) 
 
0.
4 
(0
.2
–0
.7
) 
 
0.
4 
(0
.3
–0
.5
) 
 
0.
4 
(0
.3
–0
.5
) 

 
P
hy
si
ca
l f
un
ct
io
n 
te
st
* 
0.
4 
(0
.3
–0
.5
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
4 
(0
.3
–0
.5
) 
 
0.
3 
(0
.3
–0
.4
) 
 
0.
3 
(0
.3
–0
.4
) 
 
0.
3 
(0
.3
–0
.4
) 
 
0.
3 
(0
.2
–0
.4
) 
 
0.
4 
(0
.3
–0
.4
) 
—
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 Ta
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e 
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a 
(c
on
tin
ue
d)
: T
he
 m
os
t f
re
qu
en
t p
ro
ce
du
ra
l t
re
at
m
en
ts
 (r
at
e 
pe
r 1
00
 p
ro
bl
em
s)
, 2
00
2–
03
 to
 2
01
1–
12
 
 
R
at
e 
pe
r 1
00
 p
ro
bl
em
s 
(9
5%
 C
I) 
 
 
20
02
–0
3 
 
20
03
–0
4 
 
20
04
–0
5 
 
20
05
–0
6 
 
20
06
–0
7 
 
20
07
–0
8 
 
20
08
–0
9 
 
20
09
–1
0 
 
20
10
–1
1 
 
20
11
–1
2 

(a
)  
 
 
Tr
ea
tm
en
t 
(n
 =
 1
46
,3
36
) 
 (
n 
= 
14
4,
67
4)
  
(n
 =
 1
37
,3
30
) 
 (
n 
= 
14
9,
08
8)
  
(n
 =
 1
36
,3
33
) 
 (
n 
= 
14
5,
07
8)
  
(n
 =
 1
49
,4
62
) 
 (
n 
= 
15
5,
37
3)
  
(n
 =
 1
46
,1
41
) 
 (
n 
= 
15
2,
28
6)
 
O
th
er
 p
re
ve
nt
iv
e 
pr
oc
ed
ur
es
/ 
hi
gh
-r
is
k 
m
ed
ic
at
io
n*
 
0.
1 
(0
.1
–0
.2
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
2 
(0
.1
–0
.2
) 
 
0.
2 
(0
.2
–0
.2
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
4 
(0
.3
–0
.5
) 
 
0.
4 
(0
.3
–0
.4
) 
 
0.
4 
(0
.3
–0
.4
) 
 
0.
3 
(0
.3
–0
.4
) 

 
U
rin
e 
te
st
* 
0.
2 
(0
.1
–0
.2
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.2
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
2 
(0
.1
–0
.2
) 
 
0.
2 
(0
.1
–0
.2
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.3
) 

 
O
th
er
 d
ia
gn
os
tic
 p
ro
ce
du
re
s*
 
0.
1 
(0
.1
–0
.1
) 
 
0.
1 
(0
.1
–0
.2
) 
 
0.
1 
(0
.1
–0
.1
) 
 
0.
1 
(0
.1
–0
.2
) 
 
0.
1 
(0
.1
–0
.2
) 
 
0.
1 
(0
.1
–0
.2
) 
 
0.
2 
(0
.1
–0
.2
) 
 
0.
2 
(0
.1
–0
.2
) 
 
0.
2 
(0
.1
–0
.2
) 
 
0.
2 
(0
.2
–0
.3
) 

 
To
ta
l p
ro
ce
du
ra
l t
re
at
m
en
ts
 
10
.1
 
(9
.6
–1
0.
6)
 
 
10
.1
 
(9
.6
–1
0.
6)
 
 
10
.6
 
(1
0.
0–
11
.3
) 
 
9.
9 
(9
.4
–1
0.
3)
 
 
10
.2
 
(9
.7
–1
0.
7)
 
 
11
.0
 
(1
0.
5–
11
.6
) 
 
10
.8
 
(1
0.
4–
11
.3
) 
 
11
.4
 
(1
0.
8–
12
.1
) 
 
11
.1
 
(1
0.
6–
11
.6
) 
 
11
.0
 
(1
0.
5–
11
.5
) 
—
 
(a
) 
T
he
 d
ire
ct
io
n 
an
d 
ty
pe
 o
f c
ha
ng
e 
fr
om
 2
00
2–
03
 to
 2
01
1–
12
 is
 in
di
ca
te
d 
fo
r e
ac
h 
re
su
lt:
 
/
 in
di
ca
te
s 
a 
st
at
is
tic
al
ly
 s
ig
ni
fic
an
t c
ha
ng
e 
(in
cr
ea
se
 o
r 
de
cr
ea
se
) i
n 
20
11
–1
2 
co
m
pa
re
d 
w
ith
 2
00
2–
03
; 
/
 in
di
ca
te
s 
a 
m
ar
gi
na
lly
 s
ig
ni
fic
an
t c
ha
ng
e 
in
 2
01
1–
12
 c
om
pa
re
d 
w
ith
 2
00
2–
03
; —
 in
di
ca
te
s 
th
er
e 
w
as
 n
o 
si
gn
ifi
ca
nt
 c
ha
ng
e 
in
 2
01
1–
12
 c
om
pa
re
d 
w
ith
 2
00
2–
03
. 
(b
) 
E
xc
lu
de
s 
al
l l
oc
al
 in
je
ct
io
n/
in
fil
tr
at
io
ns
 p
er
fo
rm
ed
 fo
r i
m
m
un
is
at
io
ns
. 
* 
In
cl
ud
es
 m
ul
tip
le
 IC
P
C
-2
 o
r 
IC
P
C
-2
 P
LU
S
 c
od
es
 (
se
e 
A
pp
en
di
x 
4,
 T
ab
le
s 
A
4.
5 
an
d 
A
4.
6,
 <
hd
l.h
an
dl
e.
ne
t/2
12
3/
86
76
>)
. 
N
ot
e:
 C
I –
 c
on
fid
en
ce
 in
te
rv
al
; N
E
C
 –
 n
ot
 e
ls
ew
he
re
 c
la
ss
ifi
ed
; N
/A
 –
 n
ot
 a
pp
lic
ab
le
; P
N
 –
 p
ra
ct
ic
e 
nu
rs
e;
 A
H
W
 –
 A
bo
rig
in
al
 h
ea
lth
 w
or
ke
r.
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b:
 T
he
 m
os
t f
re
qu
en
t p
ro
ce
du
ra
l t
re
at
m
en
ts
 (r
at
e 
pe
r 1
00
 e
nc
ou
nt
er
s)
, 2
00
2–
03
 to
 2
01
1–
12
 
 
R
at
e 
pe
r 1
00
 e
nc
ou
nt
er
s 
(9
5%
 C
I) 
 
 
20
02
–0
3 
 
20
03
–0
4 
 
20
04
–0
5 
 
20
05
–0
6 
 
20
06
–0
7 
 
20
07
–0
8 
 
20
08
–0
9 
 
20
09
–1
0 
 
20
10
–1
1 
 
20
11
–1
2 

(a
)  
 
 
Tr
ea
tm
en
t 
(n
 =
 1
00
,9
87
) 
 
(n
 =
 9
8,
87
7)
 
 
(n
 =
 9
4,
38
6)
 
 (
n 
= 
10
1,
99
3)
  
(n
 =
 9
1,
80
5)
 
 (
n 
= 
95
,8
98
) 
 (
n 
= 
96
,6
88
) 
 (n
 =
 1
01
,3
49
) 
 (
n 
= 
95
,8
39
) 
 (
n 
= 
99
,0
30
) 
E
xc
is
io
n/
re
m
ov
al
 ti
ss
ue
/ 
bi
op
sy
/d
es
tru
ct
io
n/
 
de
br
id
em
en
t/c
au
te
ris
at
io
n*
 
2.
8 
(2
.6
–3
.1
) 
 
3.
1 
(2
.7
–3
.6
) 
 
3.
3 
(3
.0
–3
.6
) 
 
3.
0 
(2
.7
–3
.2
) 
 
3.
3 
(3
.0
–3
.7
) 
 
3.
4 
(3
.1
–3
.8
) 
 
3.
2 
(2
.9
–3
.5
) 
 
3.
0 
(2
.7
–3
.2
) 
 
2.
9 
(2
.6
–3
.1
) 
 
2.
8 
(2
.6
–3
.0
) 
—
 
D
re
ss
in
g/
pr
es
su
re
/ 
co
m
pr
es
si
on
/ta
m
po
na
de
* 
2.
0 
(1
.8
–2
.1
) 
 
1.
8 
(1
.7
–2
.0
) 
 
2.
0 
(1
.8
–2
.1
) 
 
2.
1 
(1
.9
–2
.3
) 
 
2.
3 
(2
.1
–2
.4
) 
 
2.
2 
(2
.1
–2
.4
) 
 
2.
3 
(2
.1
–2
.4
) 
 
2.
4 
(2
.2
–2
.6
) 
 
2.
5 
(2
.4
–2
.7
) 
 
2.
5 
(2
.3
–2
.7
) 

 
Lo
ca
l i
nj
ec
tio
n/
 
in
fil
tra
tio
n*
(b
)  
1.
5 
(1
.3
–1
.7
) 
 
1.
6 
(1
.4
–1
.8
) 
 
2.
0 
(1
.7
–2
.2
) 
 
2.
0 
(1
.8
–2
.2
) 
 
1.
9 
(1
.7
–2
.1
) 
 
2.
3 
(2
.1
–2
.5
) 
 
2.
3 
(2
.1
–2
.4
) 
 
2.
5 
(2
.3
–2
.7
) 
 
2.
4 
(2
.2
–2
.7
) 
 
2.
2 
(2
.0
–2
.4
) 

 
P
hy
si
ca
l m
ed
ic
in
e/
 
re
ha
bi
lit
at
io
n 
– 
al
l* 
2.
1 
(1
.8
–2
.4
) 
 
1.
7 
(1
.5
–1
.9
) 
 
2.
0 
(1
.7
–2
.3
) 
 
1.
4 
(1
.1
–1
.6
) 
 
1.
1 
(0
.9
–1
.3
) 
 
1.
3 
(1
.1
–1
.5
) 
 
1.
2 
(1
.1
–1
.3
) 
 
1.
2 
(1
.0
–1
.5
) 
 
1.
2 
(1
.1
–1
.4
) 
 
1.
4 
(1
.2
–1
.6
) 

 
In
ci
si
on
/d
ra
in
ag
e/
flu
sh
in
g/
 
as
pi
ra
tio
n/
re
m
ov
al
 b
od
y 
flu
id
* 
1.
1 
(1
.0
–1
.2
) 
 
1.
2 
(1
.1
–1
.3
) 
 
1.
0 
(1
.0
–1
.1
) 
 
1.
3 
(1
.2
–1
.4
) 
 
1.
3 
(1
.1
–1
.4
) 
 
1.
2 
(1
.1
–1
.3
) 
 
1.
3 
(1
.2
–1
.4
) 
 
1.
4 
(1
.2
–1
.5
) 
 
1.
2 
(1
.1
–1
.3
) 
 
1.
2 
(1
.0
–1
.3
) 
—
 
R
ep
ai
r/f
ix
at
io
n 
– 
su
tu
re
/ 
ca
st
/p
ro
st
he
tic
 d
ev
ic
e 
(a
pp
ly
/re
m
ov
e)
* 
0.
9 
(0
.8
–1
.0
) 
 
0.
8 
(0
.7
–0
.9
) 
 
0.
9 
(0
.8
–1
.0
) 
 
1.
0 
(0
.9
–1
.1
) 
 
1.
0 
(0
.9
–1
.1
) 
 
0.
9 
(0
.8
–1
.0
) 
 
0.
8 
(0
.7
–0
.9
) 
 
0.
9 
(0
.8
–1
.0
) 
 
0.
8 
(0
.8
–0
.9
) 
 
0.
9 
(0
.8
–1
.0
) 
—
 
P
ap
 s
m
ea
r*
 
1.
1 
(0
.9
–1
.2
) 
 
1.
1 
(0
.9
–1
.3
) 
 
1.
0 
(0
.8
–1
.1
) 
 
1.
0 
(0
.8
–1
.1
) 
 
0.
9 
(0
.8
–1
.0
) 
 
1.
1 
(0
.9
–1
.2
) 
 
1.
2 
(1
.0
–1
.3
) 
 
1.
0 
(0
.9
–1
.2
) 
 
1.
0 
(0
.8
–1
.1
) 
 
0.
9 
(0
.8
–1
.0
) 
—
 
O
th
er
 th
er
ap
eu
tic
 
pr
oc
ed
ur
es
/m
in
or
 s
ur
ge
ry
* 
1.
2 
(1
.0
–1
.4
) 
 
1.
1 
(0
.9
–1
.3
) 
 
1.
2 
(0
.9
–1
.5
) 
 
0.
8 
(0
.7
–0
.9
) 
 
0.
7 
(0
.6
–0
.9
) 
 
0.
8 
(0
.6
–0
.9
) 
 
0.
9 
(0
.7
–1
.1
) 
 
1.
0 
(0
.4
–1
.6
) 
 
0.
7 
(0
.5
–0
.9
) 
 
0.
8 
(0
.6
–1
.0
) 

 
IN
R
 te
st
* 
N
/A
 
 
 
N
/A
 
 
 
N
/A
 
 
 
N
/A
 
 
 
0.
1 
(0
.1
–0
.2
) 
 
0.
4 
(0
.3
–0
.5
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
6 
(0
.4
–0
.7
) 
 
0.
7 
(0
.6
–0
.8
) 
 
0.
7 
(0
.6
–0
.8
) 

 
E
le
ct
ric
al
 tr
ac
in
gs
* 
 
0.
3 
(0
.3
–0
.4
) 
 
0.
3 
(0
.3
–0
.4
) 
 
0.
3 
(0
.3
–0
.4
) 
 
0.
4 
(0
.3
–0
.5
) 
 
0.
5 
(0
.4
–0
.5
) 
 
0.
6 
(0
.5
–0
.6
) 
 
0.
5 
(0
.4
–0
.5
) 
 
0.
6 
(0
.5
–0
.7
) 
 
0.
6 
(0
.5
–0
.6
) 
 
0.
7 
(0
.6
–0
.7
) 

 
C
he
ck
-u
p 
–P
N
/A
H
W
* 
N
/A
 
 
 
N
/A
 
 
 
N
/A
 
 
 
N
/A
 
 
 
0.
2 
(0
.1
–0
.3
) 
 
0.
4 
(0
.3
–0
.4
) 
 
0.
4 
(0
.2
–0
.5
) 
 
0.
7 
(0
.3
–1
.0
) 
 
0.
6 
(0
.4
–0
.8
) 
 
0.
6 
(0
.4
–0
.7
) 

 
P
hy
si
ca
l f
un
ct
io
n 
te
st
* 
0.
5 
(0
.4
–0
.7
) 
 
0.
4 
(0
.3
–0
.5
) 
 
0.
4 
(0
.3
–0
.5
) 
 
0.
4 
(0
.3
–0
.5
) 
 
0.
6 
(0
.4
–0
.7
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
6 
(0
.4
–0
.7
) 
—
 
O
th
er
 p
re
ve
nt
iv
e 
pr
oc
ed
ur
es
/ 
hi
gh
-r
is
k 
m
ed
ic
at
io
n*
 
0.
2 
(0
.1
–0
.2
) 
 
0.
3 
(0
.2
–0
.4
) 
 
0.
3 
(0
.3
–0
.4
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
4 
(0
.3
–0
.5
) 
 
0.
6 
(0
.5
–0
.7
) 
 
0.
5 
(0
.5
–0
.6
) 
 
0.
6 
(0
.5
–0
.7
) 
 
0.
5 
(0
.4
–0
.6
) 

 
(c
on
tin
ue
d)
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(c
on
tin
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d)
: T
he
 m
os
t f
re
qu
en
t p
ro
ce
du
ra
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 c
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10.3 Practice nurse/Aboriginal health worker activity  
This section investigates changes in the activities of practice nurses (PNs) and Aboriginal 
health workers (AHWs) in association with the GP–patient encounters for the years 2005–06 
to 2010–11. 
In 2004, four Medicare item numbers were introduced into the Medical Benefits Schedule 
(MBS) that allowed GPs to claim for specified tasks done by a practice nurse under the 
direction of the GP.24 The BEACH recording form for the 2005–06 BEACH year was amended 
to capture this information. In the ‘other treatments’ section for each problem managed, GPs 
were asked to tick the ‘practice nurse’ box if the treatment recorded was provided by the 
practice nurse rather than by the GP. If the box was not ticked it was assumed the GP gave 
the treatment. 
Over the years, new practice nurse and item numbers were added to the MBS and some 
items were broadened to include work done by Aboriginal health workers. In past years we 
have reported the results referring to practice nurses alone. However in 2011–12, a few GPs 
indicated (of their own accord) that the recorded action was done by an AHW rather than by 
a PN. We have included this information in this section, which now refers to work 
undertaken in conjunction with the GP–patient encounters by practice nurses (PNs) and 
Aboriginal health workers (AHWs), although the vast majority will have been done by PNs. 
There is a limitation to this approach. Few GPs specifically indicated that the work was done 
by an AHW. Others may have thought that because the question referred specifically to 
practice nurses, they were not required to record work done by an AHW. These results 
therefore have the potential to be an underestimate of the work undertaken at GP–patient 
encounters by PNs and AHWs. 
In January 2012, the Australian Government significantly altered the payment structure for 
practice nurse and AHW activities in general practice such that the range of claimable MBS 
item numbers was diminished and the Practice Nurse Incentive Program (PNIP) introduced. 
The PNIP “provides incentive payments to practices … by consolidating funding 
arrangements under the Practice Incentive Program (PIP) Practice Nurse Incentive”. Six of 
the Medicare Benefits Schedule (MBS) practice nurse items covering MBS immunisation, 
cervical smears and treatments of a person’s wound were removed, and the funds redirected 
into a single payment to eligible general practices.58 
This means that Medicare claims for PN/AHW items recorded in BEACH from January 2012 
onwards were limited to a far smaller range of claimable items.59 This means that the 2011–12 
data presented in this report includes a period of nine months (April–December 2011) of the 
old payment system and three months of the new payment system. Likewise, the 
distribution of PN/AHW claims in BEACH and in the MBS claims data reflect this mix. 
The change in payment systems as of 1 January 2012 must be remembered in the following 
section, which investigates changes in: 
• the distribution of the PN and AHW Medicare items recorded as claimable at encounters 
• treatments provided by PNs or AHWs in association with the GP-recorded encounters 
• problems for which the PN or AHW provided the treatment in association with the  
GP-recorded encounters. 
When viewing these results, it must be remembered that these data will not include activities 
undertaken by the PN/AHW during the GP’s BEACH recording period that were outside 
(not associated with) the recorded encounter. Such activities could include Medicare-
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claimable activities (e.g. immunisations/vaccinations), or other services not currently 
claimable from Medicare (e.g. dietary advice to an individual or in a group situation), 
provided at the time separate from the encounter recorded by the GP. 
Note also that in this section clinical procedures include the action of injections given for 
immunisations, which was not the case in earlier sections of this chapter. 
Overview of practice nurse/Aboriginal health worker activity 
Encounters involving a PN/AHW as a proportion of all encounters almost doubled from 
4.2% in 2005–06 to peak at 9.0% in 2009–10 then significantly decreased to 7.4% in 2011–12. 
The proportion of problems managed with PN/AHW at GP encounters also increased 
significantly from 2.8% in 2005–06 to peak to 6.1% in 2009–10 with no significant decrease by 
2011–12 (5.0%).  
In 2005–06, GPs recorded one or more PN/AHW MBS item numbers at 39.2% of encounters 
with recorded PN/AHW activity. By 2009–10 this proportion had risen to 45.5% then 
decreased to 40.2% in 2010–11. In 2011–12, which includes three months of data recorded 
after the change in funding structure, the proportion had decreased to 27.4% (Table 10.5). 
Distribution of PN/AHW item numbers claimed at encounters 
The number of practice nurse items claimed per 100 GP–patient encounters significantly 
increased from 1.7 items per 100 encounters in 2005–06 to peak at 4.2 per 100 in 2009–10 then 
significantly decreased to 3.2 per 100 in 2010–11, and further to 2.0 per 100 in 2012–12 
(Table 10.6). Extrapolation of these results suggests that the BEACH sample represented 
about 1.7 million claimed practice nurse items in 2005–06, and about 4.9 million in 2009–10, 
but receded somewhat to an estimated 3.8 million in 2010–11. 
In 2011–12 which included the change in payment policy for PN/AHW services, there were 
an estimated 2.5 million claims nationally. This recent decrease was also reflected in 
Medicare claims data showing there were 3.2 million such claims in 2005–06 climbing to 
about 7.6 million in 2009–10, and receding to about 6.1 million in the 2010–11 financial year60 
and 4.7 million in the 2011–12 BEACH data period which include three months of post MBS 
changes in the payment system for most of the work of PNs. 
Extrapolation of encounters for which a practice nurse item number was recorded as 
claimable in BEACH to all encounters across the country in each year suggest that the  
2005–06 BEACH sample represented about 53% of the practice nurse activity claimed from 
Medicare during that period, the 2009–10 sample 65.0%, the 2010–11 sample 62% and the 
2011–12 sample about 53%, the same as in 2005–06.The balance of the claims to Medicare for 
practice nurse items would be for services provided by the nurse, independent of the  
GP–patient encounter. This year’s increase in ‘outside the consultation’ work is hardly 
surprising as the removal of most of the PN item numbers from Medicare must give GPs 
more freedom to have the PNs working in greatest area of need in the practice, which may 
not be in the areas that were being funded though Medicare. 
There were two significant differences between 2005–06 and 2011–12 in the distribution of 
practice nurse item numbers claimed for work associated with the BEACH encounters:  
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• in 2011–12 PN/AHW services to a person with a chronic disease (first introduced in 
2007–08), made up a significantly greater proportion of recorded items (3.6%) than in 
2007–08, though there was no change in the proportion between 2010–11 and 2011–12. 
• The proportion of claims accounted for by immunisations was significantly lower in 
2011–12 (55.1%) than in 2005–06 (69.5%) (when there were far fewer such item numbers 
available in the MBS). However this is likely due to the change in funding arrangements 
introduced in January 2012 which removed the PN item number from the MBS. 
Further, the proportion of claims accounted for by wound treatments, had remained steady 
at about one-third of all BEACH recorded PN/AHW item claims, but decreased significantly 
in 2009–10, to 21.3%. In 2010–11 this reverted somewhat to reach 28.1%, close to the 2005–06 
level of 30.0%. Recording of other practice nurse items numbers was rare (Table 10.6). 
Treatments provided by practice nurses and Aboriginal health 
workers  
The rate at which procedures (including tests) were undertaken by PNs/AHWs in 
association with the recorded GP–patient encounters more than doubled from 4.0 per 100 
encounters in 2005–06 to 9.2 per 100 in 2009–10, though it decreased in 2011–12 to 7.2 per 100 
encounters. PNs/AHWs also took over an increasing proportion of the procedural work 
associated with the GP–patient encounters, increasing from 22.7% in 2005–06 to 38.0% in 
2010–11, with no statistical change in 2011–12. 
While their provision of clinical treatments (such as advice and health education) remained 
infrequent at GP–patient encounters, there was a significant increase over the study period, 
from 0.2 clinical treatments per 100 encounters in 2005–06 to 0.9 per 100 in 2011–12. Further, 
nurses did a significantly greater proportion of the clinical treatments recorded at 
encounters, rising from 0.7% in 2005–06 to 2.4% in 2010–11. Overall in 2011–12PNs/AHWs 
provided 14.1% of all ‘other treatments’ recorded at the encounters, a significantly greater 
proportion than in 2005–06 (9.0%) (Table 10.7). 
Individual treatments 
In most cases, through all years, where the PN/AHW provided a treatment associated with a 
GP–patient encounter only one action was recorded. However, there was a statistically 
significant increase in the number of treatments provided from 107.4 per 100 PN/AHP 
involved encounters in 2005–06 to 112.8 per 100 in 2010–11 and this remained steady in  
2011–12 (111.5 per 100) (Table 10.8). 
Paralleling the recent decrease in the number of Medicare claims for immunisations by a PN 
or AHW described above, last year local injections/infiltrations had reverted to the 2005–06 
level of about 41 per 100 practice nurse involved encounters. In 2011–12 the rate decreased 
far more to 35.5 per 100. The lower 2011–12 rate may be linked to the removal of the 
Medicare item number for immunisations in January 2012, but may also reflect a move over 
the last several years for immunisations to be provided more often by PNs/AHWs 
independent of the GP–patient consultations.  
Check-ups by PNs/AHWs continued to increase, conducted at a rate of 8.0 per 100  
 GP–patient encounters in which the PN/AHW actions were recorded, double the rate at 
which they were conducted in their first year of MBS funding. International normalised ratio 
(INR) blood testing frequency more than tripled, from 1.8 per 100 practice nurse encounters 
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in 2006–07 to 6.8 in 2010–11 and remained steady at 6.9 in 2011–12. Glucose testing doubled 
from 0.7 per 100 PN/AHW involved encounters in 2005–06 to 1.2 per 100 in 2011–12, and 
may relate to the increase in claims for services provided to a patient with chronic disease. 
In clinical treatments, PN/AHW carried out administrative procedures (excluding sickness 
certificates) at an ever increasing rate, rising from 0.7 per 100 PN/AHW involved encounter 
in 2005–06, to 3.6 per 100 in 2011–12. Increases also occurred in their provision of advice/ 
education about medication and in consultations with primary care providers (Table 10.8). 
Problems managed with practice nurse or Aboriginal health worker 
involvement at GP–patient encounters 
Changes in the problems for which PNs/AHWs were involved in management are shown in 
Table 10.9 and largely reflect the changes in the activities undertaken. There were significant 
increases in the rate at which they were involved in management of check-ups, diabetes, 
atrial fibrillation/flutter and urinary tract infections. Some of these increases may well have 
been stimulated by the introduction of MBS item 10997 for services provided to a person 
with a chronic disease in 2007–08.  
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.8
) 
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.1
 
(2
4.
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.7
) 
 
33
.3
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9.
1–
37
.5
) 
§ 
10
99
7(
e)
 
S
er
vi
ce
 to
 a
 p
er
so
n 
w
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 c
hr
on
ic
 
di
se
as
e 
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 a
 P
N
 o
r r
eg
is
te
re
d 
A
H
W
  
N
/A
 
 
N
/A
 
 
0.
7 
(0
.2
–1
.2
) 
 
1.
9 
(0
.9
–2
.9
) 
 
3.
0 
(1
.7
–4
.2
) 
 
3.
6 
(2
.5
–4
.6
) 
 
3.
6 
(2
.5
–4
.6
) 

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ta
l p
ra
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e 
nu
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e 
ite
m
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um
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rs
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 p
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l 
en
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un
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rs
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.4
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.0
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.7
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.9
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.4
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–2
.9
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.7
–4
.7
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2 
(2
.8
–3
.6
) 
 
2.
0 
(1
.8
–2
.3
) 
§ 
(a
) 
T
he
 d
ire
ct
io
n 
an
d 
ty
pe
 o
f c
ha
ng
e 
fr
om
 2
00
2–
03
 to
 2
01
1–
12
 is
 in
di
ca
te
d 
fo
r e
ac
h 
re
su
lt:
 
/
 in
di
ca
te
s 
a 
st
at
is
tic
al
ly
 s
ig
ni
fic
an
t c
ha
ng
e 
(in
cr
ea
se
 o
r 
de
cr
ea
se
) i
n 
20
11
–1
2 
co
m
pa
re
d 
w
ith
 2
00
2–
03
; —
 in
di
ca
te
s 
th
er
e 
w
as
 n
o 
si
gn
ifi
ca
nt
 c
ha
ng
e 
in
 2
01
1–
12
 c
om
pa
re
d 
w
ith
 2
00
2–
03
; a
nd
 §
 in
di
ca
te
s 
a 
no
te
w
or
th
y 
ch
an
ge
 d
ur
in
g 
th
e 
de
ca
de
. 
N
ot
e:
 P
N
/A
H
W
 –
 p
ra
ct
ic
e 
nu
rs
e 
or
 A
bo
rig
in
al
 h
ea
lth
 w
or
ke
r; 
N
/A
 –
 N
ot
 a
pp
lic
ab
le
; t
he
re
 w
er
e 
no
 o
cc
ur
re
nc
es
 o
f o
th
er
 a
va
ila
bl
e 
ite
m
 n
um
be
rs
 in
 a
ny
 y
ea
rs
 r
ep
or
te
d 
in
 th
is
 ta
bl
e.
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
(a
)  

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 =
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4.
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.5
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.5
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.6
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.8
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.7
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6.
4 
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.2
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8.
7 
(7
.9
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.6
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8.
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N
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H
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P
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ce
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at
m
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(b
)  
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.7
 
(2
0.
2–
25
.2
) 
 
28
.1
 
(2
5.
5–
30
.8
) 
 
29
.7
 
(2
7.
5–
32
.0
) 
 
30
.4
 
(2
8.
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32
.9
) 
 
39
.6
 
(3
6.
5–
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.6
) 
 
38
.0
 
(3
5.
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.5
) 
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.4
 
(3
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9–
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.8
) 

 
C
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(0
.5
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(0
.9
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.2
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(1
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.6
) 
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(1
.1
–1
.6
) 
 
2.
0 
(1
.4
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.5
) 
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(1
.6
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2.
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(1
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
 
Al
l o
th
er
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9.
0 
(7
.9
–1
0.
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.8
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0.
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) 
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.9
 
(1
0.
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.0
) 
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.5
 
(1
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3–
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.7
) 
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.0
 
(1
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4–
18
.7
) 
 
15
.4
 
(1
4.
0–
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.9
) 
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.1
 
(1
2.
9–
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.4
) 

 
(a
) 
T
he
 d
ire
ct
io
n 
an
d 
ty
pe
 o
f c
ha
ng
e 
fr
om
 2
00
2–
03
 to
 2
01
1–
12
 is
 in
di
ca
te
d 
fo
r e
ac
h 
re
su
lt:
 
/
 in
di
ca
te
s 
a 
st
at
is
tic
al
ly
 s
ig
ni
fic
an
t c
ha
ng
e 
(in
cr
ea
se
 o
r 
de
cr
ea
se
) i
n 
20
11
–1
2 
co
m
pa
re
d 
w
ith
 2
00
2–
03
. 
(b
) 
P
N
/A
H
W
 –
 p
ra
ct
ic
e 
nu
rs
e 
or
 A
bo
rig
in
al
 h
ea
lth
 w
or
ke
r;
 p
ro
ce
du
ra
l t
re
at
m
en
ts
 h
er
e 
in
cl
ud
e 
al
l i
nj
ec
tio
ns
 fo
r i
m
m
un
is
at
io
ns
/v
ac
ci
na
tio
ns
. T
he
se
 a
re
 n
ot
 in
cl
ud
ed
 in
 th
e 
su
m
m
ar
y 
of
 th
e 
co
nt
en
t o
f e
nc
ou
nt
er
 in
 T
ab
le
 5
.1
, 
su
m
m
ar
y 
of
 m
an
ag
em
en
t i
n 
T
ab
le
 8
.1
 o
r i
n 
th
e 
an
al
ys
es
 o
f o
th
er
 tr
ea
tm
en
ts
 in
 C
ha
pt
er
 1
0,
 b
ec
au
se
 th
e 
im
m
un
is
at
io
n/
va
cc
in
at
io
n 
is
 a
lre
ad
y 
co
un
te
d 
as
 a
 p
re
sc
rip
tio
n 
or
 G
P
-s
up
pl
ie
d 
m
ed
ic
at
io
n.
 
N
ot
e:
 C
I –
 c
on
fid
en
ce
 in
te
rv
al
; P
N
/A
H
W
 –
 p
ra
ct
ic
e 
nu
rs
e 
or
 A
bo
rig
in
al
 h
ea
lth
 w
or
ke
r. 
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 =
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.6
–1
05
.4
) 
 
99
.3
 
(9
6.
5–
10
2.
0)
 
—
 
 
Lo
ca
l i
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) 
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) 
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D
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g/
pr
es
su
re
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pr
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m
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* 
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) 
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
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
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ra
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.0
–8
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–6
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) 
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E
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ac
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* 
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.1
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) 
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.7
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) 
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.6
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) 
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3 
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.7
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) 
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(4
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R
ep
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r/f
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su
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ro
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m
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E
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/b
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n/
de
br
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t/c
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l f
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.0
) 
 
1.
4 
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0.
7 
 
(0
.3
–1
.1
) 
 
1.
0 
 
(0
.4
–1
.5
) 
 
1.
0 
 
(0
.7
–1
.3
) 
 
1.
0 
(0
.6
–1
.3
) 
 
0.
6 
(0
.4
–0
.8
) 
 
1.
5 
(0
.7
–2
.3
) 
 
1.
2 
 
(1
.5
–2
.8
) 

 
 
O
th
er
 d
ia
gn
os
tic
 p
ro
ce
du
re
s*
 
0 
 
0.
1 
(0
.0
–0
.2
) 
 
0.
1 
(0
.0
–0
.2
) 
 
0.
5 
(0
.2
–0
.8
) 
 
0.
7 
(0
.4
–1
.0
) 
 
1.
3 
(0
.2
–2
.3
) 
 
0.
8 
(0
.4
–1
.2
) 

 
(c
on
tin
ue
d)
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10.4 Distribution of clinical treatments between GPs 
and PNs/AHWs at GP–patient encounters 
The introduction of MBS item numbers for some PN and AHW activities in 2004 clearly 
influenced some of the GP activity at GP–patient encounters. 
Clinical treatments 
In 2005–06 the number of clinical treatments (counselling, advice and education etc) recorded 
at BEACH encounters (counts both the GP provided clinical activities and those provided by 
a PN/AHW in association with the encounter) decreased significantly (from 39.2 to 29.2 per 
100 GP–patient encounters). The clinical treatment rate stayed at this level in 2006–07 and 
then suddenly increased significantly in 2007–09 to 34.5 per 100 encounters, a level retained 
for the next three years. 
The PN/AHW contribution to clinical treatments associated with GP–patient encounters was 
very small throughout the ten years, accounting for less than 1% of all clinical treatments 
recorded in all years (Table 10.10). 
Table 10.10: GPs and PNs/AHWs clinical treatments at GP-patient encounters 
 Rate per 100 encounters (95% CI) 
 2002–03 2003–04 2004–05 2005–06 2006–07 2007–08 2008–09 2009–10 2010–11 2011–12 
Total  37.2 36.6 39.2 29.2 29.5 34.5 34.0 35.0 35.5 37.0 
GP 37.2 36.6 39.2 29.0 29.0 34.1 33.5 34.3 34.8 36.1 
PN/AHW 0.0 0.0 0.0 0.2 0.5 0.5 0.5 0.7 0.7 0.9 
Note: There was no facility to record practice nurse or Aboriginal health worker activities at the encounter prior to 2005–06. PN—practice nurse; 
AHW – Aboriginal health worker. 
When the drop occurred in 2005–06 we assumed that the PNs/AHWs were taking over the 
responsibility for some of these clinical treatments in patient contacts that were independent 
of the GP–patient encounter. However, if that was the case we would have expected that this 
role would grow—that we would see a further decrease in clinical treatments recorded at the 
encounters in the following years. In reality the rate at which clinical treatments were 
recorded at GP–patient encounters hit bottom in 2005–06 and in 2006–07, then gradually 
crept up to reach the same level as that recorded in 2004–05. Table 10.1(a) demonstrates that 
this pattern was particularly apparent in advice/education (including that about treatment, 
about medication) and the provision of reassurance and support. In contrast significant 
decreases in recorded rates of advice/education about exercise and about nutrition/weight 
failed to return to their earlier levels.  
We hypothesised in 2005–06 that when the PN/AHW Medicare items were introduced, the 
GPs felt that some of the advice and education would be picked up outside the consultation, 
by a PN/AHW. Perhaps over time, they realised that this was not always the case, so 
returned to their earlier behaviour in providing such advice themselves. Of concern 
however, is the lack of such reversion in rates of provision of advice about exercise and 
about nutrition/weight. Hopefully these two areas are being covered by PNs and AHWs 
independently of the GP-patient encounters, but we have no data about their non  
GP–patient encounter activities to determine if this is true. 
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Procedural treatments 
After the introduction of PN/AHW item number in 2004–05 there was a significant decrease 
in the rate at which GPs undertook procedures (including injections for immunisations) at 
GP–patient encounters, from 17.6 (95% CI: 16.6–18.6) per 100 encounters, to 13.9 (95% CI: 
13.2–14.6) per 100. This rate then stayed relatively steady through to 2011–12.  
However, in combination with the PN/AHWs procedural work at GP–patient encounters, 
the overall procedural rate increased, the PN/AHWs having taken some of the clinical load 
from the GP. 
In 2005–06 the PNs/AHWs undertook about one in five of the procedures associated with 
the encounter and the GP procedural load decreased accordingly. By 2010–11 the PNs/AHW 
were doing almost two in five of the procedures conducted in association with the 
encounters.  
The removal of many of the PN Medicare item numbers in January 2012 with the move to 
practice based funding contribution of practice nurse salaries, may well lead to greater 
independence of the procedural work of PNs, so that more of their work is not associated 
with the patients’ GP visits. The lack of quality data available about the growing non GP–
patient encounter activity of PNs/AHWs is limiting our understanding of the total services 
provided to patients by general practices, and this limitation will grow with increasing 
independence of PN/AHW clinical activity. 
 
 
0
5
10
15
20
25
Total procedures 16.0 16.3 17.6 17.7 18.5 20.5 21.1 23.4 21.1 20.4
GP 16.0 16.3 17.6 13.9 13.3 14.4 14.7 14.1 13.1 13.2
PN/AHW  0.0 0.0 0.0 3.8 5.2 6.1 6.4 9.2 8.0 7.2
2002–03 2003–04 2004–05 2005–06 2006–07 2007–08 2008–09 2009–10 2010–11 2011–12
 
Note: GP—general practitioner undertook the procedures; PN/AHW— a practice nurse or Aboriginal Health Worker undertook the procedure. 
Figure 10.1: GP and PN/AHW share of procedural work undertaken at GP encounters,  
2002–03 to 2011–12 
Rate per 100 encounters 
BEACH data year 
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11 Referrals and admissions 
A referral is defined as the process by which the responsibility for part or all of the care of a 
patient is temporarily transferred to another health care provider. GPs were instructed only 
to record new referrals arising at the encounter (that is, not to record continuations). For each 
encounter, GPs could record up to two referrals, and each referral was linked by the GP to 
the problem(s) for which the patient was referred. Referrals included those to medical 
specialists, allied health services, hospitals for admission, emergency departments, and those 
to other services (including those to outpatient clinics and to other GPs). 
Referral data for the ten years, 2002–03 to 2011–12, are reported in two ways: as rates per 100 
problems managed (Table 11.1a) and as rates per 100 encounters (Table 11.1b). In the text 
describing changes over time, the rates per 100 problems are reported as the primary 
measure, because there was a significant increase in the number of problems managed per 
encounter over the study period reported here.  
The direction and type of change from 2002–03 to 2011–12 is indicated for each result in the 
far right column of the tables: / indicates a statistically significant change (increase or 
decrease) in 2011–12 compared with 2002–03; / indicates a marginally significant change 
in 2011–12 compared with 2002–03; — indicates there was no significant change in 2011–12 
compared with 2002–03; and § indicates a noteworthy change during the decade. Significant 
changes in the rate per 100 encounters can be extrapolated to estimate the national increase 
or decrease in the measured event between 2002–03 and 2011–12. Examples of extrapolated 
change are given. The method used to extrapolate to national change estimates is described 
in Section 2.9. 
The number of GP–patient encounters claimed through the MBS nationally increased by 25.6 
million (26.4%) between 2002–03 (96.9 million encounters) and 2011–12 (122.5 million 
encounters). As a result, a decreased rate of a particular ‘measured event’ per 100 encounters 
may occasionally yield a national increased absolute number of those events. 
More specific analyses of referrals recorded by participating GPs in the 2011–12 BEACH year 
can be found in the companion report General practice activity in Australia 2011–12.1 
11.1 Results 
The likelihood that a problem being managed at encounter would be referred increased 
significantly over the study period, 7.7% of problems being referred in 2002–03, rising to 
9.3% in 2011–12. There was a significant increase in the overall rate of referrals, from 7.7 per 
100 problems managed in 2002–03 to 9.4 per 100 in 2011–12 (Table 11.1a). This increase was 
largely due to an increasing referral rate to allied health professionals, rather than an 
increase in those to medical specialists, which remained stable. However, there was a small 
but significant increase in the referral rate to cardiologists.  
The rate of referral to allied health services per 100 problems managed almost doubled from 
1.7 in 2002–03 to 3.0 per 100 in 2011–12. There were significant increases in the rates of 
referral to psychologists, podiatrists/chiropodists, dietitians/nutritionists, and dentists, and 
a marginal increase in the rate of referral to physiotherapists per 100 problems managed. 
There was a significant increase in referrals to emergency departments and a marginal 
decrease in the rate of referral/admission to hospitals over the decade (Table 11.1a). 
121
  
 
Table 11.1b also shows that over time there was an increasing likelihood that GP–patient 
encounters would involve one or more referrals (10.6% involving a referral in 2002–03 and 
13.3% in 2011–12). Overall, referrals increased significantly, from 11.2 referrals per 100 
encounters in 2002–03 to 14.5 per 100 in 2011–12.  
Extrapolation of this change suggests there were about 6.9 million more GP referrals 
nationally in 2011–12 than in 2002–03. These included about 3.2 million more referrals to 
medical specialists and about 3.3 million more to allied health services. Of those to allied 
health services, an additional 910,000 were to psychologists, probably largely as a result of 
government’s introduction of the Better Outcomes61 and later the Better Access62 mental 
health programs. There were also about 520,00 more referrals to physiotherapists, which may 
also be due to government policy, with its introduction of MBS item numbers for limited 
physiotherapy services for selected patients referred by a GP.55  
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0.
1 
(0
.1
–0
.1
) 
 
0.
1 
(0
.1
–0
.1
) 
 
0.
1 
(0
.1
–0
.2
) 
 
0.
1 
(0
.1
–0
.1
) 
 
0.
1 
(0
.1
–0
.1
) 
 
0.
1 
(0
.1
–0
.2
) 
—
 
 
R
he
um
at
ol
og
is
t 
0.
1 
(0
.1
–0
.1
) 
 
0.
1 
(0
.1
–0
.1
) 
 
0.
1 
(0
.1
–0
.1
) 
 
0.
1 
(0
.1
–0
.1
) 
 
0.
1 
(0
.1
–0
.1
) 
 
0.
1 
(0
.1
–0
.1
) 
 
0.
1 
(0
.1
–0
.1
) 
 
0.
1 
(0
.1
–0
.1
) 
 
0.
1 
(0
.1
–0
.1
) 
 
0.
1 
(0
.1
–0
.1
) 
—
 
A
lli
ed
 h
ea
lth
 s
er
vi
ce
s*
 
1.
7 
(1
.6
–1
.9
) 
 
1.
8 
(1
.7
–1
.9
) 
 
1.
9 
(1
.7
–2
.0
) 
 
2.
0 
(1
.8
–2
.1
) 
 
2.
1 
(1
.9
–2
.2
) 
 
2.
3 
(2
.1
–2
.4
) 
 
2.
5 
(2
.3
–2
.7
) 
 
2.
6 
(2
.4
–2
.7
) 
 
2.
8 
(2
.6
–2
.9
) 
 
3.
0 
(2
.8
–3
.2
) 

 
 
P
hy
si
ot
he
ra
py
 
0.
7 
(0
.7
–0
.8
) 
 
0.
7 
(0
.6
–0
.8
) 
 
0.
7 
(0
.6
–0
.8
) 
 
0.
8 
(0
.7
–0
.9
) 
 
0.
7 
(0
.7
–0
.8
) 
 
0.
8 
(0
.7
–0
.9
) 
 
0.
8 
(0
.7
–0
.8
) 
 
0.
7 
(0
.7
–0
.8
) 
 
0.
7 
(0
.7
–0
.8
) 
 
0.
9 
(0
.8
–0
.9
) 

 
 
P
sy
ch
ol
og
is
t 
0.
1 
(0
.1
–0
.1
) 
 
0.
1 
(0
.1
–0
.2
) 
 
0.
2 
(0
.1
–0
.2
) 
 
0.
2 
(0
.2
–0
.2
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
4 
(0
.4
–0
.5
) 
 
0.
5 
(0
.5
–0
.6
) 
 
0.
5 
(0
.5
–0
.6
) 
 
0.
6 
(0
.5
–0
.6
) 
 
0.
6 
(0
.5
–0
.6
) 

 
 
P
od
ia
tri
st
/c
hi
ro
po
di
st
 
0.
1 
(0
.1
–0
.2
) 
 
0.
1 
(0
.1
–0
.1
) 
 
0.
2 
(0
.1
–0
.2
) 
 
0.
2 
(0
.1
–0
.2
) 
 
0.
2 
(0
.2
–0
.2
) 
 
0.
2 
(0
.2
–0
.2
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
3 
(0
.3
–0
.3
) 

 
 
D
ie
tit
ia
n/
nu
tri
tio
ni
st
 
0.
1 
(0
.1
–0
.1
) 
 
0.
1 
(0
.1
–0
.2
) 
 
0.
1 
(0
.1
–0
.2
) 
 
0.
2 
(0
.1
–0
.2
) 
 
0.
2 
(0
.1
–0
.2
) 
 
0.
1 
(0
.1
–0
.2
) 
 
0.
2 
(0
.1
–0
.2
) 
 
0.
2 
(0
.1
–0
.2
) 
 
0.
2 
(0
.1
–0
.2
) 
 
0.
2 
(0
.2
–0
.3
) 

 
 
D
en
tis
t 
0.
1 
(0
.1
–0
.1
) 
 
0.
1 
(0
.1
–0
.1
) 
 
0.
1 
(0
.1
–0
.1
) 
 
0.
1 
(0
.1
–0
.1
) 
 
0.
1 
(0
.1
–0
.1
) 
 
0.
1 
(0
.1
–0
.1
) 
 
0.
1 
(0
.1
–0
.2
) 
 
0.
2 
(0
.2
–0
.2
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.3
) 

 
H
os
pi
ta
l* 
0.
4 
(0
.3
–0
.4
) 
 
0.
4 
(0
.3
–0
.4
) 
 
0.
3 
(0
.3
–0
.4
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.2
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.3
) 

 
E
m
er
ge
nc
y 
de
pa
rtm
en
t*
 
0.
1 
(0
.1
–0
.1
) 
 
0.
1 
(0
.1
–0
.1
) 
 
0.
1 
(0
.1
–0
.1
) 
 
0.
1 
(0
.1
–0
.2
) 
 
0.
1 
(0
.1
–0
.1
) 
 
0.
1 
(0
.1
–0
.2
) 
 
0.
1 
(0
.1
–0
.2
) 
 
0.
1 
(0
.1
–0
.2
) 
 
0.
2 
(0
.2
–0
.2
) 
 
0.
2 
(0
.2
–0
.2
) 

 
O
th
er
 re
fe
rr
al
s*
 
0.
2 
(0
.2
–0
.2
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
3 
(0
.3
–0
.4
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
4 
(0
.3
–0
.4
) 
 
0.
3 
(0
.3
–0
.4
) 
 
0.
2 
(0
.2
–0
.2
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
4 
(0
.3
–0
.5
) 
 
0.
4 
(0
.3
–0
.5
) 

 
To
ta
l r
ef
er
ra
ls
 
7.
7 
(7
.4
–8
.0
) 
 
7.
9 
(7
.6
–8
.3
) 
 
7.
9 
(7
.6
–8
.2
) 
 
8.
2 
(7
.9
–8
.5
) 
 
8.
2 
(7
.9
–8
.5
) 
 
8.
3 
(8
.0
–8
.6
) 
 
8.
9 
(8
.6
–9
.2
) 
 
8.
7 
(8
.4
–9
.0
) 
 
9.
3 
(8
.9
–9
.6
) 
 
9.
4 
(9
.1
–9
.8
) 

 
(a
) 
T
he
 d
ire
ct
io
n 
an
d 
ty
pe
 o
f c
ha
ng
e 
fr
om
 2
00
2–
03
 to
 2
01
1–
12
 is
 in
di
ca
te
d 
fo
r e
ac
h 
re
su
lt:
 
/
 in
di
ca
te
s 
a 
st
at
is
tic
al
ly
 s
ig
ni
fic
an
t c
ha
ng
e 
(in
cr
ea
se
 o
r 
de
cr
ea
se
) i
n 
20
11
–1
2 
co
m
pa
re
d 
w
ith
 2
00
2–
03
; 
/
 in
di
ca
te
s 
a 
m
ar
gi
na
lly
 s
ig
ni
fic
an
t c
ha
ng
e 
in
 2
01
1–
12
 c
om
pa
re
d 
w
ith
 2
00
2–
03
; —
 in
di
ca
te
s 
th
er
e 
w
as
 n
o 
si
gn
ifi
ca
nt
 c
ha
ng
e 
in
 2
01
1–
12
 c
om
pa
re
d 
w
ith
 2
00
2–
03
. 
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e 
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b:
 T
he
 m
os
t f
re
qu
en
t r
ef
er
ra
ls
 (r
at
e 
pe
r 1
00
 e
nc
ou
nt
er
s)
, 2
00
2–
03
 to
 2
01
1–
12
 
 
R
at
e 
pe
r 1
00
 e
nc
ou
nt
er
s 
(9
5%
 C
I) 
 
 
20
02
–0
3 
 
20
03
–0
4 
 
20
04
–0
5 
 
20
05
–0
6 
 
20
06
–0
7 
 
20
07
–0
8 
 
20
08
–0
9 
 
20
09
–1
0 
 
20
10
–1
1 
 
20
11
–1
2 

(a
) 
 
 
R
ef
er
ra
l 
(n
 =
 1
00
,9
87
) 
 
(n
 =
 9
8,
87
7)
 
 
(n
 =
 9
4,
38
6)
 
 (
n 
= 
10
1,
99
3)
  
(n
 =
 9
1,
80
5)
 
 (
n 
= 
95
,8
98
) 
 (
n 
= 
96
,6
88
) 
 (n
 =
 1
01
,3
49
) 
 (
n 
= 
95
,8
39
) 
 (
n 
= 
99
,0
30
) 
A
t l
ea
st
 o
ne
 re
fe
rr
al
 
10
.6
 
(1
0.
2–
11
.0
) 
 
11
.0
 
(1
0.
5–
11
.5
) 
 
10
.9
 
(1
0.
5–
11
.3
) 
 
11
.3
 
(1
0.
9–
11
.8
) 
 
11
.5
  
(1
1.
0–
11
.9
) 
 
11
.8
 
(1
1.
3–
12
.2
) 
 
12
.8
 
(1
2.
3–
13
.2
) 
 
12
.4
 
(1
1.
9–
12
.9
) 
 
13
.0
 
(1
2.
5–
13
.5
) 
 
13
.3
 
(1
2.
8–
13
.8
) 

 
M
ed
ic
al
 s
pe
ci
al
is
t*
 
7.
6 
(7
.3
–8
.0
) 
 
7.
9 
(7
.5
–8
.2
) 
 
7.
7 
(7
.4
–8
.1
) 
 
8.
2 
(7
.8
–8
.5
) 
 
8.
1 
(7
.7
–8
.4
) 
 
8.
0 
(7
.6
–8
.3
) 
 
9.
0 
(8
.7
–9
.3
) 
 
8.
4 
(8
.1
–8
.8
) 
 
8.
6 
(8
.2
–9
.0
) 
 
8.
6 
(8
.2
–8
.9
) 

 
 
S
ur
ge
on
 
0.
7 
(0
.7
–0
.8
) 
 
0.
8 
(0
.8
–0
.9
) 
 
0.
8 
(0
.7
–0
.9
) 
 
0.
8 
(0
.7
–0
.8
) 
 
0.
8 
(0
.8
–0
.9
) 
 
0.
8 
(0
.8
–0
.9
) 
 
0.
9 
(0
.8
–1
.0
) 
 
0.
8 
(0
.7
–0
.9
) 
 
0.
8 
(0
.8
–0
.9
) 
 
0.
8 
(0
.8
–0
.9
) 

 
 
O
rth
op
ae
di
c 
su
rg
eo
n 
0.
8 
(0
.7
–0
.8
) 
 
0.
7 
(0
.6
–0
.8
) 
 
0.
7 
(0
.6
–0
.8
) 
 
0.
7 
(0
.6
–0
.8
) 
 
0.
7 
(0
.7
–0
.8
) 
 
0.
7 
(0
.6
–0
.7
) 
 
0.
8 
(0
.7
–0
.9
) 
 
0.
8 
(0
.7
–0
.8
) 
 
0.
7 
(0
.6
–0
.8
) 
 
0.
8 
(0
.7
–0
.8
) 
—
 
 
C
ar
di
ol
og
is
t  
0.
4 
(0
.4
–0
.5
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
5 
(0
.5
–0
.6
) 
 
0.
6 
(0
.5
–0
.7
) 
 
0.
6 
(0
.5
–0
.7
) 
 
0.
5 
(0
.5
–0
.6
) 
 
0.
6 
(0
.5
–0
.7
) 
 
0.
5 
(0
.5
–0
.6
) 
 
0.
6 
(0
.6
–0
.7
) 
 
0.
7 
(0
.6
–0
.8
) 

 
 
D
er
m
at
ol
og
is
t  
0.
6 
(0
.5
–0
.6
) 
 
0.
6 
(0
.6
–0
.7
) 
 
0.
7 
(0
.6
–0
.8
) 
 
0.
7 
(0
.6
–0
.8
) 
 
0.
6 
(0
.5
–0
.7
) 
 
0.
7 
(0
.6
–0
.7
) 
 
0.
7 
(0
.7
–0
.8
) 
 
0.
6 
(0
.6
–0
.7
) 
 
0.
7 
(0
.6
–0
.8
) 
 
0.
7 
(0
.6
–0
.7
) 

 
 
O
ph
th
al
m
ol
og
is
t 
0.
7 
(0
.7
–0
.8
) 
 
0.
8 
(0
.7
–0
.9
) 
 
0.
8 
(0
.7
–0
.9
) 
 
0.
8 
(0
.7
–0
.9
) 
 
0.
8 
(0
.7
–0
.9
) 
 
0.
7 
(0
.6
–0
.7
) 
 
0.
8 
(0
.7
–0
.9
) 
 
0.
7 
(0
.6
–0
.8
) 
 
0.
6 
(0
.6
–0
.7
) 
 
0.
6 
(0
.6
–0
.7
) 

 
 
G
as
tro
en
te
ro
lo
gi
st
 
0.
4 
(0
.4
–0
.5
) 
 
0.
4 
(0
.4
–0
.5
) 
 
0.
4 
(0
.3
–0
.4
) 
 
0.
5 
(0
.5
–0
.6
) 
 
0.
4 
(0
.4
–0
.5
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
5 
(0
.5
–0
.6
) 
 
0.
6 
(0
.5
–0
.6
) 
 
0.
5 
(0
.5
–0
.6
) 
 
0.
5 
(0
.5
–0
.6
) 

 
 
E
ar
, n
os
e 
an
d 
th
ro
at
 
0.
5 
(0
.5
–0
.6
) 
 
0.
5 
(0
.5
–0
.6
) 
 
0.
5 
(0
.5
–0
.6
) 
 
0.
5 
(0
.4
–0
.5
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
5 
(0
.5
–0
.6
) 
 
0.
6 
(0
.5
–0
.6
) 
 
0.
5 
(0
.5
–0
.6
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
5 
(0
.4
–0
.5
) 
—
 
 
G
yn
ae
co
lo
gi
st
 
0.
6 
(0
.6
–0
.7
) 
 
0.
6 
(0
.5
–0
.6
) 
 
0.
5 
(0
.5
–0
.6
) 
 
0.
5 
(0
.5
–0
.6
) 
 
0.
5 
(0
.5
–0
.6
) 
 
0.
4 
(0
.4
–0
.5
) 
 
0.
5 
(0
.5
–0
.6
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
5 
(0
.4
–0
.5
) 

 
 
U
ro
lo
gi
st
 
0.
3 
(0
.3
–0
.3
) 
 
0.
3 
(0
.3
–0
.4
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
3 
(0
.3
–0
.4
) 
 
0.
3 
(0
.3
–0
.4
) 
 
0.
3 
(0
.3
–0
.3
) 
 
0.
4 
(0
.3
–0
.4
) 
 
0.
3 
(0
.3
–0
.4
) 
 
0.
3 
(0
.3
–0
.4
) 
 
0.
3 
(0
.3
–0
.4
) 
—
 
 
N
eu
ro
lo
gi
st
 
0.
3 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.3
) 
—
 
 
P
sy
ch
ia
tri
st
 
0.
3 
(0
.2
–0
.3
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.2
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.3
) 
—
 
 
P
ae
di
at
ric
ia
n 
 
0.
2 
(0
.2
–0
.2
) 
 
0.
2 
(0
.2
–0
.2
) 
 
0.
2 
(0
.2
–0
.2
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.2
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.2
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.3
) 
—
 
(c
on
tin
ue
d)
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e 
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.1
b 
(c
on
tin
ue
d)
: T
he
 m
os
t f
re
qu
en
t r
ef
er
ra
ls
 (r
at
e 
pe
r 1
00
 e
nc
ou
nt
er
s)
, 2
00
2–
03
 to
 2
01
1–
12
 
 
R
at
e 
pe
r 1
00
 e
nc
ou
nt
er
s 
(9
5%
 C
I) 
 
 
20
02
–0
3 
 
20
03
–0
4 
 
20
04
–0
5 
 
20
05
–0
6 
 
20
06
–0
7 
 
20
07
–0
8 
 
20
08
–0
9 
 
20
09
–1
0 
 
20
10
–1
1 
 
20
11
–1
2 

(a
) 
 
 
R
ef
er
ra
l 
(n
 =
 1
00
,9
87
) 
 
(n
 =
 9
8,
87
7)
 
 
(n
 =
 9
4,
38
6)
 
 (
n 
= 
10
1,
99
3)
  
(n
 =
 9
1,
80
5)
 
 (
n 
= 
95
,8
98
) 
 (
n 
= 
96
,6
88
) 
 (n
 =
 1
01
,3
49
) 
 (
n 
= 
95
,8
39
) 
 (
n 
= 
99
,0
30
) 
A
lli
ed
 h
ea
lth
 s
er
vi
ce
s*
 
2.
5 
(2
.3
–2
.7
) 
 
2.
6 
(2
.4
–2
.8
) 
 
2.
7 
(2
.5
–2
.9
) 
 
2.
9 
(2
.7
–3
.1
) 
 
3.
1 
(2
.9
–3
.3
) 
 
3.
4 
(3
.2
–3
.7
) 
 
3.
9 
(3
.6
–4
.1
) 
 
3.
9 
(3
.7
–4
.2
) 
 
4.
2 
(3
.9
–4
.5
) 
 
4.
7 
(4
.4
–5
.0
) 

 
 
P
hy
si
ot
he
ra
py
 
1.
1 
(0
.9
–1
.2
) 
 
1.
0 
(0
.9
–1
.1
) 
 
1.
0 
(0
.9
–1
.1
) 
 
1.
1 
(1
.0
–1
.3
) 
 
1.
1 
(1
.0
–1
.2
) 
 
1.
2 
(1
.1
–1
.3
) 
 
1.
2 
(1
.1
–1
.3
) 
 
1.
1 
(1
.0
–1
.3
) 
 
1.
1 
(1
.0
–1
.2
) 
 
1.
3 
(1
.2
–1
.4
) 

 
 
P
sy
ch
ol
og
is
t 
0.
2 
(0
.1
–0
.2
) 
 
0.
2 
(0
.1
–0
.2
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
4 
(0
.4
–0
.5
) 
 
0.
7 
(0
.6
–0
.7
) 
 
0.
8 
(0
.7
–0
.9
) 
 
0.
8 
(0
.7
–0
.9
) 
 
0.
9 
(0
.8
–1
.0
) 
 
0.
9 
(0
.8
–1
.0
) 

 
 
P
od
ia
tri
st
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12 Investigations 
Investigations ordered by GPs for each of the ten years 2002–03 to 2011–12, are reported in 
two ways: as rates per 100 problems managed (for example, Table 12.1a) and as rates per 
100 encounters (for example, Table 12.1b). In the text describing changes over time, the rates 
per 100 problems are reported as the primary measure, because there was a significant 
increase in the number of problems managed per encounter.  
The direction and type of change from 2002–03 to 2011–12 is indicated for each result in the 
far right column of the tables: / indicates a statistically significant change (increase or 
decrease) in 2011–12 compared with 2002–03; / indicates a marginally significant change 
in 2011–12 compared with 2002–03; — indicates there was no significant change in 2011–12 
compared with 2002–03; and § indicates a noteworthy change during the decade. 
Significant linear changes in the rate per 100 encounters can be extrapolated to estimate the 
national increase or decrease in the other investigations provided between 2002–03 and 
2011–12. Examples of extrapolated change are given. The method used to extrapolate to 
national change estimates is described in Section 2.9. 
The GPs participating in BEACH were asked to record (in free text) any pathology, imaging 
or other tests ordered or done at the encounter, and to nominate the patient problem(s) 
associated with each test order. This allows the linkage of a test order to a single problem or 
multiple problems. Up to five orders for pathology and two for imaging and other tests 
could be recorded at each encounter. A single test may have been ordered for the 
management of multiple problems, and multiple tests may have been used in the 
management of a single problem. 
A pathology test order may be for a single test (for example, Pap smear, HbA1c) or for a 
battery of tests (for example, lipids, full blood count). Where a battery of tests was ordered, 
the battery name was recorded rather than each individual test. GPs also recorded the body 
site for any imaging ordered (for example, x-ray chest, computerised tomography head). 
More detailed analyses of investigations ordered by GPs in 2011–12 can be found in  
Chapter 12 of General practice activity in Australia 2011–12.1 
Comprehensive investigation of GPs’ pathology and imaging ordering was published in 
several reports. Interested readers may wish to consult: 
• a comprehensive report on pathology ordering by GPs in Australia in 1998, written by 
the then General Practice Statistics and Classification Unit using BEACH data, was 
published on the internet by the then Department of Health and Aged Care.63 
• a report on imaging orders by GPs in Australia in 1999–2000 using BEACH data, 
published as an AIHW–University of Sydney book in the GP series in 2001.64 
• a report on changes in pathology ordering by GPs from 1998 to 2001 using BEACH data, 
published as an AIHW–University of Sydney book in the GP series in 2003.65 
• a review of GP pathology ordering in the National Health Priority Areas and other 
selected problems between 2000 and 2008, reported in the AIHW–University of Sydney 
publication General practice in Australia, health priorities and policies 1998 to 2008.66 
• a report Evidence-practice gap in GP pathology test ordering: a comparison of BEACH pathology 
data and recommended testing, prepared for the Australian Government Quality Use of 
Pathology Program in June 2009.67 
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12.1 Number of problems or encounters where 
pathology or imaging was ordered 
Table 12.1a shows there was a significant increase in the proportion of problems for which 
pathology or imaging was ordered. 
• The likelihood of ordering at least one pathology test increased from 11.4% of all 
problems managed in 2002–03 to 13.6% in 2011–12. 
• The proportion of problems generating imaging orders increased marginally from 5.3% 
in 2002–03 to 5.8% in 2011–12. 
Between 2002–03 and 2011–12, the number of problems managed per 100 encounters rose 
from 144.9 to 153.8 (Table 5.1). Both the rise in problems generating test orders and the rise in 
the number of problems managed per encounter contributed to an overall increase in the 
proportion of encounters involving a pathology or imaging test (Table 12.1b).  
• The likelihood of ordering at least one pathology test increased from 14.7% of encounters 
in 2002–03 to 18.1% in 2011–12, which is almost 8 million additional encounters at which 
pathology was ordered in 2011–12 than ten years earlier. 
• The proportion of encounters generating imaging orders increased from 7.5% in 2002–03 
to 8.6% in 2011–12, resulting in an estimated 3.3 million more encounters nationally at 
which imaging was ordered in 2011–12 than in 2002–03. 
Both the likelihood of ordering pathology and the total number of pathology tests ordered 
per 100 problems or per 100 encounters significantly increased over the ten years to 2011–12. 
However virtually all of the rises occurred between 2002–03 and 2007–08 and orders have 
remained stable since that time (Figure 12.1). The growth in the number of tests/batteries 
ordered was larger than the growth in likelihood of ordering because, once a decision to 
order was made, the number of tests ordered significantly increased from an average of 2.0 
tests/batteries per tested problem in 2002–0351 to 2.4 per tested problem in 2011–12.1 
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12.2 Pathology test orders by MBS groups 
Tables 12.2a and 12.2b show the changes in the total number of pathology test orders, and in 
the distribution of these by MBS pathology groups.68  
The number of pathology tests ordered increased from 22.7 tests/batteries of tests per 
100 problems managed in 2002–03 to 30.6 per 100 problems in 2011–12 (Table 12.2a). 
The largest increase was in orders for chemical pathology, which increased from 12.2 per 
100 problems in 2002–03 to 18.0 per 100 in 2011–12. Haematology increased at a slower rate, 
from 4.3 per 100 problems in 2002–03 to 5.5 in 2011–12. Microbiology test orders increased 
marginally from 3.5 per 100 problems in 2002–03 to 4.0 in 2011–12. There was a far smaller 
increase in order rates for immunology, a marginal increase in orders for tissue pathology 
and simple tests, and no increases in the other test groups. 
The number of pathology tests ordered per 100 encounters increased from 
32.9 tests/batteries of tests per 100 encounters in 2002–03 to 47.0 in 2011–12 (Table 12.2b), 
which, when combined with the increase in attendance rate, extrapolates to approximately 
25.7 million more test orders in 2011–12 than in 2002–03 nationally. 
The largest increase was in orders for chemical pathology, which increased from 17.7 per 
100 encounters in 2002–03 to 27.6 in 2011–12. This extrapolates to an estimated 16.7 million 
additional chemistry test orders in 2011–12 than ten years earlier. Haematology increased at 
a slower rate, rising from 6.3 tests per 100 encounters in 2002–03 to 8.5 in 2011–12, a national 
increase of approximately 4.3 million tests. Microbiology test orders increased from 5.1 per 
100 encounters in 2002–03 to 6.2 in 2011–12, extrapolating to an increase of about 2.7 million 
additional test orders in 2011–12. There were far smaller increases in order rates for 
immunology and tissue pathology, a marginal increase in simple tests, and no increases in 
the other test groups. 
12.3 Imaging test orders by MBS group 
Tables 12.3a and 12.3b show the changes in imaging orders by MBS imaging group from 
2002–03 to 2011–12. 
Total imaging test orders increased significantly from 5.9 per 100 problems managed in 
2002–03 to 6.6 per 100 in 2011–12 (Table 12.3a). Ultrasound imaging increased from 1.8 tests 
per 100 problems in 2002–03 to 2.6 per 100 in 2011–12. Computerised tomography increased 
from 0.5 to 0.8 per 100 problems. Magnetic resonance imaging increased from less than 0.05 
per 100 problems in 2002–03 to 0.1 in 2011–12. Diagnostic radiology decreased from 3.5 per 
100 problems in 2002–03 to 3.0 in 2011–12. Nuclear medicine order rates did not change 
during this period. 
Total imaging test orders per 100 encounters also increased significantly from 8.6 in 2002–03 
to 10.1 in 2011–12, suggesting a national increase of 4 million encounters generating an order 
for imaging (Table 12.3b). Ultrasound imaging increased from 2.6 tests per 100 encounters in 
2002–03 to 4.0 per 100 in 2011–12, a national increase of about 2.4 million encounters with 
ultrasound orders. Computerised tomography increased from 0.8 per 100 encounters in 
2002–03 to 1.2 in 2011–12, equating to an additional 690,000 encounters. Magnetic resonance 
imaging orders increased from less than 0.05 per 100 encounters in 2002–03 to 0.2 in 2011–12. 
The diagnostic radiology order rate did not change during this period and nuclear medicine 
orders decreased marginally. 
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86
) 
C
he
m
is
try
* 
12
.2
 
(1
1.
6–
12
.8
) 
 
13
.0
 
(1
2.
4–
13
.7
) 
 
14
.0
 
(1
3.
4–
14
.6
) 
 
14
.9
 
(1
4.
1–
15
.6
) 
 
16
.5
 
(1
5.
8–
17
.2
) 
 
16
.5
 
(1
5.
7–
17
.2
) 
 
17
.4
 
(1
6.
7–
18
.1
) 
 
16
.9
 
(1
6.
1–
17
.6
) 
 
17
.2
 
(1
6.
5–
17
.9
) 
 
18
.0
 
(1
7.
1–
18
.8
) 

 
H
ae
m
at
ol
og
y*
 
4.
3 
(4
.1
–4
.6
) 
 
4.
6 
(4
.4
–4
.9
) 
 
4.
8 
(4
.5
–5
.0
) 
 
5.
0 
(4
.7
–5
.3
) 
 
5.
3 
(5
.0
–5
.6
) 
 
5.
2 
(5
.0
–5
.5
) 
 
5.
3 
(5
.0
–5
.5
) 
 
5.
4 
(5
.1
–5
.7
) 
 
5.
3 
(5
.0
–5
.5
) 
 
5.
5 
(5
.2
–5
.8
) 

 
M
ic
ro
bi
ol
og
y*
 
3.
5 
(3
.3
–3
.8
) 
 
3.
6 
(3
.4
–3
.9
) 
 
3.
6 
(3
.3
–3
.8
) 
 
3.
8 
(3
.6
–4
.1
) 
 
3.
9 
(3
.7
–4
.2
) 
 
3.
7 
(3
.5
–4
.0
) 
 
3.
7 
(3
.5
–3
.9
) 
 
4.
1 
(3
.9
–4
.3
) 
 
4.
3 
(3
.9
–4
.6
) 
 
4.
0 
(3
.8
–4
.3
) 

 
C
yt
op
at
ho
lo
gy
* 
1.
2 
(1
.0
–1
.3
) 
 
1.
2 
(1
.1
–1
.3
) 
 
1.
1 
(1
.0
–1
.3
) 
 
1.
2 
(1
.1
–1
.3
) 
 
1.
1 
(1
.0
–1
.3
) 
 
1.
2 
(1
.1
–1
.4
) 
 
1.
3 
(1
.1
–1
.4
) 
 
1.
1 
(1
.0
–1
.2
) 
 
1.
1 
(1
.0
–1
.2
) 
 
1.
1 
(1
.0
–1
.2
) 
—
 
O
th
er
 N
E
C
* 
0.
5 
(0
.4
–0
.6
) 
 
0.
6 
(0
.5
–0
.6
) 
 
0.
6 
(0
.5
–0
.7
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
5 
(0
.4
–0
.7
) 
 
0.
7 
(0
.5
–0
.8
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
6 
(0
.5
–0
.7
) 
 
0.
6 
(0
.5
–0
.7
) 
—
 
Im
m
un
ol
og
y*
 
0.
3 
(0
.3
–0
.4
) 
 
0.
3 
(0
.3
–0
.4
) 
 
0.
4 
(0
.3
–0
.4
) 
 
0.
4 
(0
.4
–0
.5
) 
 
0.
4 
(0
.4
–0
.5
) 
 
0.
5 
(0
.4
–0
.5
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
6 
(0
.5
–0
.7
) 
 
0.
5 
(0
.5
–0
.6
) 
 
0.
5 
(0
.5
–0
.6
) 

 
Ti
ss
ue
 p
at
ho
lo
gy
* 
0.
4 
(0
.3
–0
.4
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
4 
(0
.3
–0
.5
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
4 
(0
.3
–0
.5
) 
 
0.
5 
(0
.4
–0
.6
) 

 
S
im
pl
e 
te
st
s*
 
0.
1 
(0
.1
–0
.1
) 
 
0.
1 
(0
.1
–0
.1
) 
 
0.
1 
(0
.1
–0
.1
) 
 
0.
1 
(0
.1
–0
.1
) 
 
0.
1 
(0
.1
–0
.1
) 
 
0.
1 
(0
.1
–0
.1
) 
 
0.
1 
(0
.1
–0
.2
) 
 
0.
1 
(0
.1
–0
.1
) 
 
0.
1 
(0
.1
–0
.2
) 
 
0.
2 
(0
.1
–0
.2
) 

 
In
fe
rti
lit
y/
pr
eg
na
nc
y*
 
0.
2 
(0
.1
–0
.2
) 
 
0.
1 
(0
.1
–0
.2
) 
 
0.
2 
(0
.1
–0
.2
) 
 
0.
2 
(0
.1
–0
.2
) 
 
0.
1 
(0
.1
–0
.2
) 
 
0.
1 
(0
.1
–0
.1
) 
 
0.
1 
(0
.1
–0
.2
) 
 
0.
2 
(0
.1
–0
.2
) 
 
0.
2 
(0
.1
–0
.2
) 
 
0.
2 
(0
.1
–0
.2
) 
—
 
To
ta
l p
at
ho
lo
gy
 te
st
s 
22
.7
 
(2
1.
8–
23
.6
) 
 
24
.1
 
(2
3.
1–
25
.0
) 
 
25
.2
 
(2
4.
3–
26
.2
) 
 
26
.4
 
(2
5.
3–
27
.5
) 
 
28
.6
 
(2
7.
5–
29
.6
) 
 
28
.5
 
(2
7.
4–
29
.6
) 
 
29
.5
 
(2
8.
4–
30
.5
) 
 
29
.3
 
(2
8.
2–
30
.4
) 
 
29
.6
 
(2
8.
6–
30
.7
) 
 
30
.6
 
(2
9.
3–
31
.8
) 

 
(a
) 
T
he
 d
ire
ct
io
n 
an
d 
ty
pe
 o
f c
ha
ng
e 
fr
om
 2
00
2–
03
 to
 2
01
1–
12
 is
 in
di
ca
te
d 
fo
r e
ac
h 
re
su
lt:
 
/
 in
di
ca
te
s 
a 
st
at
is
tic
al
ly
 s
ig
ni
fic
an
t c
ha
ng
e 
(in
cr
ea
se
 o
r 
de
cr
ea
se
) i
n 
20
11
–1
2 
co
m
pa
re
d 
w
ith
 2
00
2–
03
; 
/
 in
di
ca
te
s 
a 
m
ar
gi
na
lly
 s
ig
ni
fic
an
t c
ha
ng
e 
in
 2
01
1–
12
 c
om
pa
re
d 
w
ith
 2
00
2–
03
; —
 in
di
ca
te
s 
th
er
e 
w
as
 n
o 
si
gn
ifi
ca
nt
 c
ha
ng
e 
in
 2
01
1–
12
 c
om
pa
re
d 
w
ith
 2
00
2–
03
. 
* 
In
cl
ud
es
 m
ul
tip
le
 IC
P
C
-2
 a
nd
 IC
P
C
-2
 P
LU
S
 c
od
es
 (s
ee
 A
pp
en
di
x 
4,
 T
ab
le
 A
4.
8,
 <
hd
l.h
an
dl
e.
ne
t/2
12
3/
86
76
>)
. 
N
ot
e:
 C
I –
 c
on
fid
en
ce
 in
te
rv
al
; N
E
C
 –
 n
ot
 e
ls
ew
he
re
 c
la
ss
ifi
ed
. 
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e 
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b:
 P
at
ho
lo
gy
 o
rd
er
s 
by
 M
BS
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at
ho
lo
gy
 g
ro
up
s 
(r
at
e 
pe
r 1
00
 e
nc
ou
nt
er
s)
, 2
00
2–
03
 to
 2
01
1–
12
  
 
R
at
e 
pe
r 1
00
 e
nc
ou
nt
er
s 
(9
5%
 C
I) 
 
 
20
02
–0
3 
 
20
03
–0
4 
 
20
04
–0
5 
 
20
05
–0
6 
 
20
06
–0
7 
 
20
07
–0
8 
 
20
08
–0
9 
 
20
09
–1
0 
 
20
10
–1
1 
 
20
11
–1
2 

(a
)  
 
 
Pa
th
ol
og
y 
te
st
 o
rd
er
ed
 
(n
 =
 1
00
,9
87
) 
 
(n
 =
 9
8,
87
7)
 
 
(n
 =
 9
4,
38
6)
 
 (
n 
= 
10
1,
99
3)
  
(n
 =
 9
1,
80
4)
 
 
(n
 =
 9
5,
89
8)
 
 
(n
 =
 9
6,
68
8)
 
 (
n 
= 
10
1,
34
9)
  
(n
 =
 9
5,
83
9)
 
 
(n
 =
 9
9,
03
0)
 
C
he
m
is
try
* 
17
.7
 
(1
6.
8–
18
.6
) 
 
19
.1
 
(1
8.
1–
20
.1
) 
 
20
.4
 
(1
9.
4–
21
.4
) 
 
21
.7
 
(2
0.
5–
22
.9
) 
 
24
.5
 
(2
3.
3–
25
.7
) 
 
24
.9
 
(2
3.
6–
26
.2
) 
 
27
.0
 
(2
5.
7–
28
.2
) 
 
25
.9
 
(2
4.
6–
27
.2
) 
 
26
.2
 
(2
5.
0–
27
.4
) 
 
27
.6
 
(2
6.
1–
29
.1
) 

 
H
ae
m
at
ol
og
y*
 
6.
3 
(5
.9
–6
.6
) 
 
6.
8 
(6
.4
–7
.2
) 
 
7.
0 
(6
.6
–7
.3
) 
 
7.
3 
(6
.9
–7
.7
) 
 
7.
9 
(7
.5
–8
.3
) 
 
7.
9 
(7
.5
–8
.3
) 
 
8.
2 
(7
.8
–8
.6
) 
 
8.
3 
(7
.8
–8
.7
) 
 
8.
1 
(7
.6
–8
.5
) 
 
8.
5 
(8
.0
–8
.9
) 

 
M
ic
ro
bi
ol
og
y*
 
5.
1 
(4
.8
–5
.5
) 
 
5.
3 
(4
.9
–5
.6
) 
 
5.
2 
(4
.8
–5
.6
) 
 
5.
6 
(5
.2
–5
.9
) 
 
5.
8 
(5
.4
–6
.2
) 
 
5.
7 
(5
.3
–6
.0
) 
 
5.
7 
(5
.3
–6
.1
) 
 
6.
3 
(5
.9
–6
.6
) 
 
6.
5 
(6
.0
–7
.0
) 
 
6.
2 
(5
.9
–6
.6
) 

 
C
yt
ol
op
at
ho
lo
gy
* 
1.
7 
(1
.5
–1
.8
) 
 
1.
8 
(1
.5
–2
.0
) 
 
1.
6 
(1
.5
–1
.8
) 
 
1.
7 
(1
.6
–1
.9
) 
 
1.
7 
(1
.5
–1
.9
) 
 
1.
9 
(1
.7
–2
.1
) 
 
2.
0 
(1
.7
–2
.2
) 
 
1.
7 
(1
.5
–1
.9
) 
 
1.
7 
(1
.5
–1
.8
) 
 
1.
7 
(1
.5
–1
.9
) 
—
 
O
th
er
 N
E
C
* 
0.
8 
(0
.6
–0
.9
) 
 
0.
8 
(0
.7
–0
.9
) 
 
0.
8 
(0
.7
–1
.0
) 
 
0.
7 
(0
.6
–0
.8
) 
 
0.
8 
(0
.7
–1
.0
) 
 
1.
0 
(0
.8
–1
.2
) 
 
0.
8 
(0
.7
–1
.0
) 
 
0.
7 
(0
.6
–0
.9
) 
 
0.
9 
(0
.7
–1
.0
) 
 
0.
9 
(0
.7
–1
.1
) 
—
 
Im
m
un
ol
og
y*
 
0.
5 
(0
.4
–0
.5
) 
 
0.
5 
(0
.4
–0
.6
) 
 
0.
6 
(0
.5
–0
.6
) 
 
0.
6 
(0
.5
–0
.7
) 
 
0.
7 
(0
.6
–0
.7
) 
 
0.
7 
(0
.6
–0
.8
) 
 
0.
8 
(0
.7
–0
.9
) 
 
0.
9 
(0
.8
–1
.0
) 
 
0.
8 
(0
.7
–0
.9
) 
 
0.
8 
(0
.7
–0
.9
) 

 
Ti
ss
ue
 p
at
ho
lo
gy
* 
0.
5 
(0
.4
–0
.6
) 
 
0.
7 
(0
.5
–0
.8
) 
 
0.
8 
(0
.6
–0
.9
) 
 
0.
6 
(0
.5
–0
.7
) 
 
0.
7 
(0
.6
–0
.8
) 
 
0.
8 
(0
.6
–0
.9
) 
 
0.
7 
(0
.6
–0
.9
) 
 
0.
8 
(0
.7
–0
.9
) 
 
0.
6 
(0
.5
–0
.7
) 
 
0.
8 
(0
.7
–0
.9
) 

 
S
im
pl
e 
te
st
s*
 
0.
1 
(0
.1
–0
.2
) 
 
0.
1 
(0
.1
–0
.2
) 
 
0.
1 
(0
.1
–0
.1
) 
 
0.
1 
(0
.1
–0
.2
) 
 
0.
2 
(0
.1
–0
.2
) 
 
0.
2 
(0
.1
–0
.2
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.2
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
3 
(0
.2
–0
.3
) 

 
In
fe
rti
lit
y/
pr
eg
na
nc
y*
 
0.
2 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
2 
(0
.1
–0
.2
) 
 
0.
2 
(0
.2
–0
.3
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
3 
(0
.2
–0
.3
) 
 
0.
2 
(0
.2
–0
.3
) 
—
 
To
ta
l p
at
ho
lo
gy
 te
st
s 
32
.9
 
(3
1.
4–
34
.4
) 
 
35
.2
 
(3
3.
7–
36
.8
) 
 
36
.7
 
(3
5.
2–
38
.2
) 
 
38
.6
 
(3
6.
9–
40
.3
) 
 
42
.4
 
(4
0.
7–
44
.2
) 
 
43
.1
 
(4
1.
3–
45
.0
) 
 
45
.6
 
(4
3.
8–
47
.4
) 
 
45
.0
 
(4
3.
1–
46
.9
) 
 
45
.2
 
(4
3.
4–
47
.0
) 
 
47
.0
 
(4
4.
9–
49
.1
) 

 
(a
) 
T
he
 d
ire
ct
io
n 
an
d 
ty
pe
 o
f c
ha
ng
e 
fr
om
 2
00
2–
03
 to
 2
01
1–
12
 is
 in
di
ca
te
d 
fo
r e
ac
h 
re
su
lt:
 
/
 in
di
ca
te
s 
a 
st
at
is
tic
al
ly
 s
ig
ni
fic
an
t c
ha
ng
e 
(in
cr
ea
se
 o
r 
de
cr
ea
se
) i
n 
20
11
–1
2 
co
m
pa
re
d 
w
ith
 2
00
2–
03
; 
/
 in
di
ca
te
s 
a 
m
ar
gi
na
lly
 s
ig
ni
fic
an
t c
ha
ng
e 
in
 2
01
1–
12
 c
om
pa
re
d 
w
ith
 2
00
2–
03
; —
 in
di
ca
te
s 
th
er
e 
w
as
 n
o 
si
gn
ifi
ca
nt
 c
ha
ng
e 
in
 2
01
1–
12
 c
om
pa
re
d 
w
ith
 2
00
2–
03
. 
* 
In
cl
ud
es
 m
ul
tip
le
 IC
P
C
-2
 a
nd
 IC
P
C
-2
 P
LU
S
 c
od
es
 (s
ee
 A
pp
en
di
x 
4,
 T
ab
le
 A
4.
8,
 <
hd
l.h
an
dl
e.
ne
t/2
12
3/
86
76
>)
. 
N
ot
e:
 C
I –
 c
on
fid
en
ce
 in
te
rv
al
; N
E
C
 –
 n
ot
 e
ls
ew
he
re
 c
la
ss
ifi
ed
. 
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e 
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.3
a:
 Im
ag
in
g 
or
de
rs
 b
y 
M
BS
 im
ag
in
g 
gr
ou
ps
 (r
at
e 
pe
r 1
00
 p
ro
bl
em
s)
, 2
00
2–
03
 to
 2
01
1–
12
 
 
R
at
e 
pe
r 1
00
 p
ro
bl
em
s 
(9
5%
 C
I) 
 
 
20
02
–0
3 
 
20
03
–0
4 
 
20
04
–0
5 
 
20
05
–0
6 
 
20
06
–0
7 
 
20
07
–0
8 
 
20
08
–0
9 
 
20
09
–1
0 
 
20
10
–1
1 
 
20
11
–1
2 
 
(a
)  
 
 
Im
ag
in
g 
te
st
 o
rd
er
ed
 
(n
 =
 1
46
,3
36
) 
 (
n 
= 
14
4,
67
4)
  
(n
 =
 1
37
,3
30
) 
 (
n 
= 
14
9,
08
8)
  
(n
 =
 1
36
,3
33
) 
 (
n 
= 
14
5,
07
8)
  
(n
 =
 1
49
,4
62
) 
 (n
 =
 1
55
,3
73
) 
 (n
 =
 1
46
,1
41
) 
 (n
 =
 1
52
,2
86
) 
D
ia
gn
os
tic
 ra
di
ol
og
y*
 
3.
5 
(3
.3
–3
.7
) 
 
3.
1 
(3
.0
–3
.3
) 
 
3.
1 
(2
.9
–3
.2
) 
 
3.
3 
(3
.1
–3
.4
) 
 
3.
1 
(2
.9
–3
.2
) 
 
3.
2 
(3
.0
–3
.3
) 
 
3.
1 
(2
.9
–3
.2
) 
 
3.
0 
(2
.8
–3
.1
) 
 
3.
0 
(2
.9
–3
.2
) 
 
3.
0 
(2
.8
–3
.2
) 

 
U
ltr
as
ou
nd
* 
1.
8 
(1
.7
–1
.9
) 
 
1.
8 
(1
.7
–1
.9
) 
 
1.
8 
(1
.7
–1
.9
) 
 
2.
0 
(1
.9
–2
.1
) 
 
2.
1 
(2
.0
–2
.2
) 
 
2.
2 
(2
.1
–2
.3
) 
 
2.
3 
(2
.2
–2
.4
) 
 
2.
4 
(2
.3
–2
.5
) 
 
2.
5 
(2
.4
–2
.6
) 
 
2.
6 
(2
.5
–2
.7
) 

 
C
om
pu
te
ris
ed
 
to
m
og
ra
ph
y*
 
0.
5 
(0
.5
–0
.6
) 
 
0.
6 
(0
.5
–0
.6
) 
 
0.
7 
(0
.6
–0
.8
) 
 
0.
7 
(0
.6
–0
.8
) 
 
0.
7 
(0
.7
–0
.8
) 
 
0.
8 
(0
.7
–0
.9
) 
 
0.
8 
(0
.8
–0
.9
) 
 
0.
8 
(0
.7
–0
.9
) 
 
0.
7 
(0
.7
–0
.8
) 
 
0.
8 
(0
.7
–0
.8
) 

 
M
ag
ne
tic
 re
so
na
nc
e 
im
ag
in
g*
 
0.
0Ŧ
 
(0
.0
–0
.0
) 
 
0.
0Ŧ
 
(0
.0
–0
.0
) 
 
0.
0Ŧ
 
(0
.0
–0
.0
) 
 
0.
0Ŧ
 
(0
.0
–0
.0
) 
 
0.
0Ŧ
 
(0
.0
–0
.0
) 
 
0.
0Ŧ
 
(0
.0
–0
.1
) 
 
0.
0Ŧ
 
(0
.0
–0
.1
) 
 
0.
1 
(0
.1
–0
.1
) 
 
0.
1 
(0
.1
–0
.1
) 
 
0.
1 
(0
.1
–0
.2
) 

 
N
uc
le
ar
 m
ed
ic
in
e*
 
0.
1 
(0
.1
–0
.1
) 
 
0.
1 
(0
.1
–0
.1
) 
 
0.
1 
(0
.1
–0
.1
) 
 
0.
1 
(0
.1
–0
.1
) 
 
0.
1 
(0
.0
–0
.1
) 
 
0.
1 
(0
.1
–0
.1
) 
 
0.
1 
(0
.1
–0
.1
) 
 
0.
1 
(0
.1
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13 Patient risk factors 
General practice is a useful intervention point for health promotion because the majority of 
the population visit a GP at least once per year – in 2011–12, 83% of Australians visited a GP 
at least once (personal communication DoHA, April 2012). Through ongoing professional 
education, GPs have substantial knowledge of population health and screening programs. 
They are in an ideal position to advise patients about the benefits of health screening, and to 
individually counsel patients about their lifestyle choices. 
Since the beginning of the BEACH program (1998), a section on the bottom of each encounter 
form has been used to investigate aspects of patient health or healthcare delivery not covered 
by general practice encounter-based information. These additional substudies are referred to 
as Supplementary Analysis of Nominated Data (SAND). The SAND methods are described 
in Chapter 2, Section 2.6. 
In brief, measured patient risk factors include self-reported height and weight (to calculate 
BMI), alcohol consumption and smoking status. Each GP completes risk factor questions for 
patients at a subsample of 40 encounters. An example of the encounter form with the patient 
risk factor SAND questions is included in Appendix 1. The method used to investigate each 
risk factor is summarised in the appropriate section of this chapter. Further detail is provided 
in Chapter 13 of the companion report General practice activity in Australia 2011–12.1 
This chapter includes data about the risk behaviours of general practice patients from each of 
the most recent ten years of the BEACH study from 2002–03 to 2011–12. The direction and 
type of change from 2002–03 to 2011–12 is indicated for each result in the far right column of 
the tables: / indicates a statistically significant change (increase or decrease) in 2011–12 
compared with 2002–03; / indicates a marginally significant change in 2011–12 
compared with 2002–03; — indicates there was no significant change in 2011–12 compared 
with 2002–03; and § indicates a noteworthy change during the decade. 
13.1 Body mass index 
Patient BMI was investigated for a subsample of 40 patients per GP. Each GP was instructed 
to ask the patient (or their carer in the case of children): 
• What is your height in centimetres (without shoes)? 
• What is your weight in kilograms (unclothed)? 
Metric conversion tables (feet and inches; stones and pounds) were provided to the GP. 
The BMI for an individual was calculated by dividing weight (kilograms) by height (metres) 
squared. The WHO recommendations69 for BMI groups were used, which specify that an 
adult (18 years and over) with a BMI: 
• less than 18.5 is underweight 
• greater than or equal to 18.5 and less than 25 is normal 
• greater than or equal to 25 and less than 30 is overweight 
• of 30 or more is obese. 
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The BEACH data on BMI are presented separately for adults (aged 18 years and over) and 
children (aged 2–17 years). The standard BMI cut-offs described above were applied for the 
adult sample, and the method described by Cole et al. (2000 & 2007) was used for children 
(aged 2–17 years).70,71  
Adults 
Overall prevalence of overweight and obesity in adults attending general practice increased 
significantly from 54.7% in 2002–03 (95% CI: 53.8–55.6) to 61.6% in 2011–12  
(95% CI: 60.7–62.4) (results not tabulated). 
• there was a significant increase in the prevalence of obesity in adults attending general 
practice, from 20.9% in 2002–03 to 26.6% in 2011–12 (Table 13.1). The significant increase 
in adult obesity was apparent among both male and female patients (Tables 13.2 and 
13.3).  
• the prevalence of normal weight and underweight in adults decreased significantly from 
42.4% and 2.9% respectively in 2002–03 to 36.2% and 2.3% in 2011–12 (Table 13.1). This 
significant decrease in normal weight was apparent among both male and female 
patients, however the decrease in underweight was only apparent among female 
patients (Tables 13.2 and 13.3). 
In summary, for both male female patients between 2002–03 and 2011–12, there was a 
significant increase in obesity and a significant decrease in normal and underweight. 
Effectively a significant proportion of patients moved from the normal weight range into 
being overweight, and a similar proportion of those who were overweight moved into the 
obese weight range. This upward movement from normal weight, to overweight, and 
overweight to obesity has huge public health impacts if it continues. 
Children 
The prevalence of overweight and obesity in children aged 2–17 years attending general 
practice remained static from 2002–03 to 2011–12, with about 11–12% of children being obese 
and about 18% overweight (Table 13.1). This stability was apparent among both young male 
and female patients. 
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13.2 Smoking 
GPs were instructed to ask adult patients (18 years and over): 
• What best describes your smoking status?  Smoke daily 
 Smoke occasionally 
 Previous smoker 
 Never smoked 
Results 
There was a significant decrease in the prevalence of current daily and occasional smoking in 
adults aged 18 years and over attending general practice, from 17.2% and 4.1% respectively 
in 2002–03 to 14.7% and 2.5% in 2011–12 (Table 13.1). These decreases were apparent among 
both male and female patients (Tables 13.2 and 13.3). 
Rates of daily smoking were significantly higher among male patients than female patients 
in all years, decreasing to 18.0% of males and 12.6% of females in 2011–12. 
13.3 Alcohol consumption 
To measure alcohol consumption, BEACH uses AUDIT-C72 which is the first three items 
from the WHO Alcohol Use Disorders Identification Test (AUDIT),73 with scoring for an 
Australian setting.74 The AUDIT-C has demonstrated validity and internal consistency and 
performs as well as the full AUDIT tool.75 The three–AUDIT-C tool is practical and valid in a 
primary care setting to assess ‘at-risk’ alcohol consumption (heavy drinking and/or active 
alcohol dependence).72 The scores for each question range from zero to four. A total (sum of 
all three questions) score of five or more for males or four or more for females suggests that 
the person’s drinking level is placing him or her at-risk.74 
GPs were instructed to ask adult patients (18 years and over): 
• How often do you have a drink containing alcohol? Never 
 Monthly or less 
 Once a week/fortnight 
 2–3 times a week 
 4 times a week or more 
• How many standard drinks do you have on a typical day when you are drinking?  
 _______________ 
• How often do you have six or more standard drinks on one occasion?  
 Never 
 Less than monthly 
 Monthly 
 Weekly 
 Daily or almost daily 
A standard drinks chart was provided to each GP to help the patient identify the number of 
standard drinks consumed. 
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Results 
Prevalence of at-risk levels of alcohol consumption among adults attending general practice 
remained static at about 25–26% of adult patients between 2002–03 and 2011–12 (Table 13.1). 
However the prevalence of at-risk drinking among male patients significantly decreased 
over the decade from 32.8% to 29.3%, while among female patients it remained static at 
about 22%. Similarly prevalence of non-drinkers increased significantly over the decade from 
20.5% to 24.0% among males, while among females it remained static at around 37% 
(Tables 13.2 and 13.3). 
13.4 Risk factor profile of adult patients 
All patient risk factor questions (BMI, smoking and alcohol consumption) were asked of the 
same subsample of adult patients. This allows us to build a risk profile for this sample for the 
three risk elements: overweight of obese weight status, daily smoking and at-risk drinking. 
Each adult can have between zero and three of these risk factors. 
Results 
There was a significant decrease in the proportion of adults with none of these risk factors 
from 28.6% in 2002–03 to 25.4% in 2011–12. In parallel, the proportion of adults with one risk 
factor increased significantly from 48.1% to 52.1% (Table 13.1). This pattern was apparent 
among both male and female patients (Tables 13.2 and 13.3). There was no change in the 
proportion with two or three risk factors among either male or female patients. 
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31
,1
90
 
 
33
,2
57
 
. .
 
 
A
t-r
is
k 
al
co
ho
l l
ev
el
 
26
.2
 
(2
5.
3–
27
.1
) 
 
26
.7
 
(2
5.
8–
27
.6
) 
 
26
.4
 
(2
5.
5–
27
.3
) 
 
25
.9
 
(2
5.
0–
26
.8
) 
 
27
.0
 
(2
6.
1–
28
.0
) 
 
26
.2
 
(2
5.
3–
27
.1
) 
 
25
.2
 
(2
4.
3–
26
.0
) 
 
26
.5
 
(2
5.
7–
27
.4
) 
 
24
.8
 
(2
3.
9–
25
.7
) 
 
24
.5
 
(2
3.
7–
25
.4
) 

 
 
R
es
po
ns
ib
le
 d
rin
ke
r 
44
.2
 
(4
3.
4–
45
.1
) 
 
44
.9
 
(4
4.
1–
45
.8
) 
 
44
.9
 
(4
4.
0–
45
.7
) 
 
44
.8
 
(4
4.
0–
45
.7
) 
 
44
.6
 
(4
3.
7–
45
.5
) 
 
44
.6
 
(4
3.
7–
45
.5
) 
 
45
.2
 
(4
4.
3–
46
.1
) 
 
44
.4
 
(4
3.
5–
45
.3
) 
 
44
.0
 
(4
3.
0–
44
.9
) 
 
43
.7
 
(4
2.
9–
44
.6
) 
—
 
 
N
on
-d
rin
ke
r 
29
.5
 
(2
8.
5–
30
.6
) 
 
28
.4
 
(2
7.
3–
29
.4
) 
 
28
.7
 
(2
7.
7–
29
.8
) 
 
29
.3
 
(2
8.
2–
30
.4
) 
 
28
.3
 
(2
7.
3–
29
.4
) 
 
29
.3
 
(2
8.
2–
30
.3
) 
 
29
.6
 
(2
8.
6–
30
.7
) 
 
29
.1
 
(2
8.
0–
30
.1
) 
 
31
.3
 
(3
0.
2–
32
.4
) 
 
31
.7
 
(3
0.
6–
32
.8
) 

 
 (c
on
tin
ue
d)
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.1
 (c
on
tin
ue
d)
: P
at
ie
nt
 ri
sk
 fa
ct
or
s,
 2
00
2–
03
 to
 2
01
1–
12
 
R
is
k 
fa
ct
or
 
Pe
r c
en
t (
95
%
 C
I) 

(a
)  
 
 
20
02
–0
3 
 
20
03
–0
4 
 
20
04
–0
5 
 
20
05
–0
6 
 
20
06
–0
7 
 
20
07
–0
8 
 
20
08
–0
9 
 
20
09
–1
0 
 
20
10
–1
1 
 
20
11
–1
2 
 A
du
lts
 (a
ge
d 
18
 y
ea
rs
 a
nd
 o
ve
r)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 N
um
be
r o
f r
is
k 
fa
ct
or
s(
c)
 (n
) 
31
,1
52
 
 
30
,7
13
 
 
29
,4
18
 
 
32
,0
76
 
 
29
,3
86
 
 
30
,0
02
 
 
32
,4
32
 
 
30
,7
95
 
 
30
,1
77
 
 
31
,4
01
 
. .
 
Ze
ro
 
28
.6
 
(2
7.
7–
29
.5
) 
 
27
.2
 
(2
6.
4–
28
.1
) 
 
27
.0
 
(2
6.
1–
27
.8
) 
 
27
.5
 
(2
6.
7–
28
.3
) 
 
26
.0
 
(2
5.
2–
26
.8
) 
 
26
.1
 
(2
5.
3–
26
.9
) 
 
25
.0
 
(2
4.
2–
25
.7
) 
 
25
.8
 
(2
5.
0–
26
.5
) 
 
25
.0
 
(2
4.
3–
25
.7
) 
 
25
.4
 
(2
4.
6–
26
.2
) 

 
O
ne
 
48
.1
 
(4
7.
5–
48
.8
) 
 
49
.0
 
(4
8.
4–
49
.7
) 
 
48
.8
 
(4
8.
1–
49
.6
) 
 
49
.2
 
(4
8.
5–
49
.9
) 
 
49
.8
 
(4
9.
1–
50
.6
) 
 
50
.1
 
(4
9.
4–
50
.8
) 
 
51
.8
 
(5
1.
1–
52
.5
) 
 
50
.3
 
(4
9.
6–
51
.0
) 
 
52
.2
 
(5
1.
5–
52
.9
) 
 
52
.1
 
(5
1.
4–
52
.8
) 

 
Tw
o 
19
.6
 
(1
9.
0–
20
.2
) 
 
19
.8
 
(1
9.
2–
20
.4
) 
 
20
.3
 
(1
9.
6–
20
.9
) 
 
19
.4
 
(1
8.
8–
20
.0
) 
 
20
.4
 
(1
9.
8–
21
.1
) 
 
19
.8
 
(1
9.
1–
20
.4
) 
 
19
.5
 
(1
8.
9–
20
.0
) 
 
20
.1
 
(1
9.
5–
20
.7
) 
 
19
.1
 
(1
8.
5–
19
.8
) 
 
18
.9
 
(1
8.
3–
19
.5
) 
—
 
Th
re
e 
3.
6 
(3
.4
–3
.9
) 
 
4.
0 
(3
.7
–4
.3
) 
 
4.
0 
(3
.7
–4
.2
) 
 
3.
9 
(3
.6
–4
.1
) 
 
3.
7 
(3
.5
–4
.0
) 
 
4.
1 
(3
.8
–4
.4
) 
 
3.
8 
(3
.5
–4
.1
) 
 
3.
8 
(3
.6
–4
.1
) 
 
3.
7 
(3
.4
–4
.0
) 
 
3.
6 
(3
.3
–3
.9
) 
—
 
 C
hi
ld
re
n 
(a
ge
d 
2–
17
 y
ea
rs
)(d
) (n
) 
3,
38
0 
 
3,
18
9 
 
3,
01
8 
 
3,
33
8 
 
3,
08
7 
 
3,
04
6 
 
2,
97
0 
 
3,
18
3 
 
3,
00
8 
 
3,
09
3 
. .
 
O
be
se
 
11
.9
 
(1
0.
5–
13
.2
) 
 
11
.8
 
(1
0.
5–
13
.2
) 
 
10
.8
 
(9
.5
–1
2.
2)
 
 
10
.9
 
(9
.7
–1
2.
1)
 
 
10
.6
 
(9
.3
–1
1.
9)
 
 
11
.2
 
(1
0.
0–
12
.5
) 
 
10
.5
 
(9
.3
–1
1.
7)
 
 
9.
6 
(8
.4
–1
0.
8)
 
 
10
.6
 
(9
.3
–1
2.
0)
 
 
11
.1
 
(9
.8
–1
2.
5)
 
—
 
O
ve
rw
ei
gh
t 
18
.3
 
(1
6.
9–
19
.6
) 
 
19
.2
 
(1
7.
7–
20
.7
) 
 
17
.7
 
(1
6.
3–
19
.1
) 
 
17
.9
 
(1
6.
5–
19
.2
) 
 
18
.6
 
(1
7.
2–
20
.0
) 
 
17
.1
 
(1
5.
7–
18
.5
) 
 
16
.7
 
(1
5.
3–
18
.2
) 
 
18
.0
 
(1
6.
7–
19
.4
) 
 
17
.7
 
(1
6.
2–
19
.1
) 
 
17
.6
 
(1
6.
2–
19
.0
) 
—
 
N
or
m
al
 
60
.9
 
(5
9.
1–
62
.7
) 
 
57
.9
 
(5
6.
0–
59
.7
) 
 
60
.6
 
(5
8.
7–
62
.5
) 
 
60
.7
 
(5
8.
9–
62
.5
) 
 
61
.2
 
(5
9.
3–
63
.0
) 
 
61
.7
 
(5
9.
7–
63
.6
) 
 
62
.9
 
(6
1.
0–
64
.8
) 
 
62
.3
 
(6
0.
4–
64
.1
) 
 
61
.8
 
(5
9.
9–
63
.8
) 
 
60
.3
 
(5
8.
4–
62
.3
) 
—
 
U
nd
er
w
ei
gh
t 
8.
9 
(7
.9
–1
0.
0)
 
 
11
.1
 
(9
.9
–1
2.
4)
 
 
10
.9
 
(9
.7
–1
2.
1)
 
 
10
.5
 
(9
.3
–1
1.
7)
 
 
9.
7 
(8
.6
–1
0.
8)
 
 
10
.1
 
(8
.9
–1
1.
2)
 
 
9.
9 
(8
.8
–1
1.
1)
 
 
10
.1
 
(9
.0
–1
1.
3)
 
 
9.
9 
(8
.7
–1
1.
0)
 
 
11
.0
 
(9
.7
–1
2.
2)
 
—
 
(a
) 
T
he
 d
ire
ct
io
n 
an
d 
ty
pe
 o
f c
ha
ng
e 
fr
om
 2
00
2–
03
 to
 2
01
1–
12
 is
 in
di
ca
te
d 
fo
r e
ac
h 
re
su
lt:
 
/
 in
di
ca
te
s 
a 
st
at
is
tic
al
ly
 s
ig
ni
fic
an
t c
ha
ng
e 
(in
cr
ea
se
 o
r 
de
cr
ea
se
) i
n 
20
11
–1
2 
co
m
pa
re
d 
w
ith
 2
00
2–
03
; 
/
 in
di
ca
te
s 
a 
m
ar
gi
na
lly
 s
ig
ni
fic
an
t c
ha
ng
e 
in
 2
01
1–
12
 c
om
pa
re
d 
w
ith
 2
00
2–
03
; —
 in
di
ca
te
s 
th
er
e 
w
as
 n
o 
si
gn
ifi
ca
nt
 c
ha
ng
e 
in
 2
01
1–
12
 c
om
pa
re
d 
w
ith
 2
00
2–
03
. 
(b
) 
A
du
lt 
pa
tie
nt
s 
ag
ed
 1
8 
ye
ar
s 
an
d 
ov
er
 w
ith
 a
 re
co
rd
ed
 h
ei
gh
t o
ut
si
de
 th
e 
A
us
tr
al
ia
n 
B
ur
ea
u 
of
 S
ta
tis
tic
s 
he
ig
ht
 r
an
ge
 b
as
ed
 o
n 
ag
e 
an
d 
se
x 
w
er
e 
ex
cl
ud
ed
. 
(c
) 
B
ei
ng
 o
ve
rw
ei
gh
t o
r o
be
se
, a
 d
ai
ly
 s
m
ok
er
 o
r 
an
 a
t-r
is
k 
dr
in
ke
r a
re
 th
e 
ris
k 
fa
ct
or
s 
an
 a
du
lt 
m
ay
 h
av
e.
 A
 ri
sk
  
(d
) 
C
hi
ld
re
n 
(a
ge
d 
2–
17
 y
ea
rs
) 
w
ith
 h
ei
gh
t o
ut
si
de
 th
e 
A
us
tr
al
ia
n 
B
ur
ea
u 
of
 S
ta
tis
tic
s 
or
 C
en
tr
es
 fo
r 
D
is
ea
se
 C
on
tro
l, 
he
ig
ht
 r
an
ge
 b
as
ed
 o
n 
ag
e 
an
d 
se
x 
w
er
e 
ex
cl
ud
ed
. C
hi
ld
 B
M
I w
as
 re
-c
al
cu
la
te
d 
fo
r 2
00
2–
03
 to
 
20
05
–0
6,
 a
nd
 w
ill
 d
iff
er
 fr
om
 d
at
a 
pr
ev
io
us
ly
 p
ub
lis
he
d 
to
 in
co
rp
or
at
e 
th
is
 e
xc
lu
si
on
 a
nd
 to
 a
pp
ly
 a
 m
or
e 
pr
ec
is
e 
m
et
ho
d 
fo
r 
ca
lc
ul
at
in
g 
ch
ild
 B
M
I. 
N
ot
e:
 C
I –
 c
on
fid
en
ce
 in
te
rv
al
. 
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: P
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ie
nt
 ri
sk
 fa
ct
or
s 
am
on
g 
ad
ul
t m
al
es
, 2
00
2–
03
 to
 2
01
1–
12
 
 
Pe
r c
en
t (
95
%
 C
I) 

(a
)  
 
 
R
is
k 
fa
ct
or
 
20
02
–0
3 
 
20
03
–0
4 
 
20
04
–0
5 
 
20
05
–0
6 
 
20
06
–0
7 
 
20
07
–0
8 
 
20
08
–0
9 
 
20
09
–1
0 
 
20
10
–1
1 
 
20
11
–1
2 
 B
od
y 
m
as
s 
in
de
x 
cl
as
s(
b)
 (n
) 
12
,4
50
 
 
12
,4
34
 
 
12
,2
88
 
 
12
,8
82
 
 
12
,7
15
 
 
12
,1
26
 
 
13
,5
95
 
 
11
,9
45
 
 
12
,3
22
 
 
12
,5
31
 
. .
 
 
O
be
se
 
19
.9
 
(1
9.
1–
20
.8
) 
 
20
.7
 
(1
9.
8–
21
.5
) 
 
21
.3
 
(2
0.
4–
22
.3
) 
 
21
.6
 
(2
0.
7–
22
.5
) 
 
22
.4
 
(2
1.
6–
23
.3
) 
 
23
.1
 
(2
2.
1–
24
.1
) 
 
25
.0
 
(2
4.
1–
26
.0
) 
 
25
.5
 
(2
4.
6–
26
.5
) 
 
26
.1
 
(2
5.
2–
27
.1
) 
 
26
.4
 
(2
5.
4–
27
.4
) 

 
 
O
ve
rw
ei
gh
t 
41
.5
 
(4
0.
5–
42
.4
) 
 
42
.3
 
(4
1.
3–
43
.2
) 
 
42
.0
 
(4
1.
0–
43
.0
) 
 
42
.6
 
(4
1.
6–
43
.6
) 
 
42
.3
 
(4
1.
4–
43
.3
) 
 
43
.0
 
(4
2.
0–
44
.0
) 
 
43
.6
 
(4
2.
7–
44
.6
) 
 
42
.1
 
(4
1.
1–
43
.0
) 
 
42
.2
 
(4
1.
2–
43
.2
) 
 
42
.5
 
(4
1.
5–
43
.5
) 
—
 
 
N
or
m
al
 
37
.2
 
(3
6.
2–
38
.3
) 
 
35
.6
 
(3
4.
5–
36
.7
) 
 
35
.3
 
(3
4.
2–
36
.5
) 
 
34
.3
 
(3
3.
3–
35
.4
) 
 
34
.0
 
(3
2.
9–
35
.1
) 
 
32
.7
 
(3
1.
6–
33
.8
) 
 
30
.3
 
(2
9.
3–
31
.4
) 
 
31
.6
 
(3
0.
2–
32
.3
) 
 
30
.6
 
(2
9.
5–
31
.6
) 
 
29
.9
 
(2
8.
8–
30
.9
) 

 
 
U
nd
er
w
ei
gh
t 
1.
4 
(1
.1
–1
.6
) 
 
1.
5 
(1
.3
–1
.7
) 
 
1.
4 
(1
.1
–1
.6
) 
 
1.
5 
(1
.3
–1
.7
) 
 
1.
2 
(1
.0
–1
.4
) 
 
1.
2 
(1
.0
–1
.4
) 
 
1.
0 
(0
.8
–1
.2
) 
 
1.
2 
(1
.0
–1
.4
) 
 
1.
1 
(0
.9
–1
.3
) 
 
1.
3 
(1
.1
–1
.5
) 
—
 
 S
m
ok
in
g 
st
at
us
 (n
) 
12
,5
21
 
 
12
,6
92
 
 
12
,6
13
 
 
13
,0
16
 
 
12
,2
57
 
 
12
,3
35
 
 
13
,8
41
 
 
12
,2
60
 
 
12
,6
00
 
 
12
,7
77
 
. .
 
 
D
ai
ly
 
20
.4
 
(1
9.
4–
21
.4
) 
 
21
.0
 
(2
0.
0–
22
.0
) 
 
21
.2
 
(2
0.
2–
22
.3
) 
 
20
.7
 
(1
9.
7–
21
.8
) 
 
19
.4
 
(1
8.
3–
20
.5
) 
 
19
.8
 
(1
8.
8–
20
.8
) 
 
18
.1
 
(1
7.
2–
19
.0
) 
 
18
.1
 
(1
7.
1–
19
.1
) 
 
17
.8
 
(1
6.
9–
18
.7
) 
 
18
.0
 
(1
7.
1–
19
.0
) 

 
 
O
cc
as
io
na
l 
4.
5 
(4
.0
–5
.0
) 
 
4.
5 
(4
.0
–4
.9
) 
 
4.
3 
(3
.9
–4
.7
) 
 
4.
1 
(3
.7
–4
.6
) 
 
3.
8 
(3
.4
–4
.2
) 
 
3.
3 
(2
.9
–3
.7
) 
 
3.
0 
(2
.6
–3
.4
) 
 
3.
1 
(2
.8
–3
.5
) 
 
3.
1 
(2
.7
–3
.5
) 
 
2.
9 
(2
.6
–3
.3
) 

 
 
P
re
vi
ou
s 
36
.4
 
(3
5.
2–
37
.6
) 
 
37
.3
 
(3
6.
2–
38
.5
) 
 
36
.5
 
(3
5.
3–
37
.6
) 
 
35
.7
 
(3
4.
5–
36
.9
) 
 
37
.1
 
(3
5.
8–
38
.4
) 
 
36
.5
 
(3
5.
3–
37
.7
) 
 
37
.9
 
(3
6.
8–
39
.1
) 
 
36
.9
 
(3
5.
8–
38
.1
) 
 
36
.8
 
(3
5.
6–
38
.0
) 
 
36
.3
 
(3
5.
1–
37
.4
) 
—
 
 
N
ev
er
 
38
.7
 
(3
7.
5–
40
.0
) 
 
37
.2
 
(3
6.
0–
38
.4
) 
 
38
.0
 
(3
6.
8–
39
.2
) 
 
39
.5
 
(3
8.
2–
40
.7
) 
 
39
.7
 
(3
8.
5–
41
.0
) 
 
40
.4
 
(3
9.
2–
41
.6
) 
 
41
.0
 
(3
9.
8–
42
.2
) 
 
41
.8
 
(4
0.
6–
43
.0
) 
 
42
.3
 
(4
1.
1–
43
.5
) 
 
42
.8
 
(4
1.
6–
44
.0
) 

 
 A
lc
oh
ol
 c
on
su
m
pt
io
n 
(n
) 
12
,3
91
 
 
12
,3
34
 
 
12
,2
94
 
 
12
,7
92
 
 
12
,0
05
 
 
12
,0
71
 
 
13
,5
83
 
 
11
,9
74
 
 
12
,3
21
 
 
12
,5
72
 
. .
 
 
A
t-r
is
k 
al
co
ho
l l
ev
el
 
32
.8
 
(3
1.
6–
34
.1
) 
 
33
.1
 
(3
1.
9–
34
.3
) 
 
32
.6
 
(3
1.
3–
33
.8
) 
 
31
.6
 
(3
0.
3–
32
.8
) 
 
32
.5
 
(3
1.
2–
33
.8
) 
 
31
.7
 
(3
0.
5–
32
.9
) 
 
30
.1
 
(2
8.
9–
31
.2
) 
 
31
.6
 
(3
0.
4–
32
.8
) 
 
30
.0
 
(2
8.
8–
31
.2
) 
 
29
.3
 
(2
8.
1–
30
.5
) 

 
 
R
es
po
ns
ib
le
 d
rin
ke
r 
46
.6
 
(4
5.
5–
47
.8
) 
 
47
.3
 
(4
6.
1–
48
.5
) 
 
47
.7
 
(4
6.
4–
48
.9
) 
 
47
.9
 
(4
6.
7–
49
.1
) 
 
48
.0
 
(4
6.
7–
49
.2
) 
 
47
.6
 
(4
6.
4–
48
.8
) 
 
48
.9
 
(4
7.
8–
50
.1
) 
 
47
.6
 
(4
6.
4–
48
.8
) 
 
47
.7
 
(4
6.
5–
48
.9
) 
 
46
.7
 
(4
5.
5–
48
.0
) 
—
 
 
N
on
-d
rin
ke
r 
20
.5
 
(1
9.
5–
21
.5
) 
 
19
.6
 
(1
8.
5–
20
.7
) 
 
19
.8
 
(1
8.
7–
20
.9
) 
 
20
.5
 
(1
9.
4–
21
.6
) 
 
19
.5
 
(1
8.
5–
20
.6
) 
 
20
.7
 
(1
9.
6–
21
.8
) 
 
21
.0
 
(2
0.
0–
22
.0
) 
 
20
.8
 
(1
9.
7–
21
.9
) 
 
22
.3
 
(2
1.
2–
23
.5
) 
 
24
.0
 
(2
2.
8–
25
.2
) 

 
(c
on
tin
ue
d)
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00
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03
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 2
01
1–
12
 
R
is
k 
fa
ct
or
 
Pe
r c
en
t (
95
%
 C
I) 

(a
)  
 
 
20
02
–0
3 
 
20
03
–0
4 
 
20
04
–0
5 
 
20
05
–0
6 
 
20
06
–0
7 
 
20
07
–0
8 
 
20
08
–0
9 
 
20
09
–1
0 
 
20
10
–1
1 
 
20
11
–1
2 
 A
du
lt 
m
al
es
 (a
ge
d 
18
 y
ea
rs
 a
nd
 o
ve
r)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 N
um
be
r o
f r
is
k 
fa
ct
or
s(
c)
 (n
) 
12
,0
58
 
 
11
,9
99
 
 
11
,9
00
 
 
12
,5
72
 
 
11
,6
62
 
 
11
,7
84
 
 
13
,2
28
 
 
11
,6
13
 
 
11
,9
55
 
 
12
,2
52
 
. .
 
Ze
ro
 
22
.3
 
(2
1.
3–
23
.3
) 
 
21
.1
 
(2
0.
2–
22
.1
) 
 
20
.7
 
(1
9.
8–
21
.6
) 
 
21
.1
 
(2
0.
1–
22
.0
) 
 
20
.3
 
(1
9.
4–
21
.2
) 
 
20
.2
 
(1
9.
2–
21
.1
) 
 
19
.0
 
(1
8.
1–
19
.8
) 
 
19
.6
 
(1
8.
7–
20
.5
) 
 
19
.2
 
(1
8.
3–
20
.0
) 
 
18
.9
 
(1
8.
0–
19
8.
) 

 
O
ne
 
46
.2
 
(4
5.
2–
47
.2
) 
 
46
.9
 
(4
5.
9–
47
.9
) 
 
47
.0
 
(4
6.
0–
48
.1
) 
 
47
.3
 
(4
6.
3–
48
.3
) 
 
48
.0
 
(4
7.
0–
49
.1
) 
 
48
.0
 
(4
7.
0–
49
.0
) 
 
50
.5
 
(4
9.
6–
51
.5
) 
 
49
.0
 
(4
8.
0–
50
.0
) 
 
50
.9
 
(4
9.
8–
51
.9
) 
 
51
.5
 
(5
0.
4–
52
.5
) 

 
Tw
o 
25
.9
 
(2
4.
9–
26
.9
) 
 
25
.9
 
(2
4.
9–
26
.8
) 
 
26
.7
 
(2
5.
7–
27
.6
) 
 
25
.7
 
(2
4.
8–
26
.7
) 
 
26
.2
 
(2
5.
2–
27
.2
) 
 
25
.9
 
(2
4.
9–
26
.9
) 
 
25
.0
 
(2
4.
1–
25
.9
) 
 
25
.8
 
(2
4.
9–
26
.8
) 
 
24
.7
 
(2
3.
7–
25
.6
) 
 
24
.3
 
(2
3.
3–
25
.2
) 
—
 
Th
re
e 
5.
6 
(5
.1
–6
.0
) 
 
6.
1 
(5
.6
–6
.6
) 
 
5.
6 
(5
.1
–6
.1
) 
 
5.
9 
(5
.5
–6
.4
) 
 
5.
5 
(5
.0
–6
.0
) 
 
5.
9 
(5
.4
–6
.4
) 
 
5.
5 
(5
.0
–5
.9
) 
 
5.
6 
(5
.1
–6
.1
) 
 
5.
3 
(4
.9
–5
.8
) 
 
5.
4 
(4
.9
–5
.8
) 
—
 
 M
al
e 
ch
ild
re
n 
 
 (a
ge
d 
2–
17
 y
ea
rs
)(d
)  (
n)
 
1,
62
0 
 
1,
48
5 
 
1,
45
1 
 
1,
64
0 
 
1,
50
9 
 
1,
48
4 
 
1,
41
5 
 
1,
49
9 
 
1,
45
0 
 
1,
48
7 
. .
 
O
be
se
 
12
.5
 
(1
0.
7–
14
.4
) 
 
13
.7
 
(1
1.
8–
15
.6
) 
 
10
.8
 
(9
.1
–1
2.
6)
 
 
11
.6
 
(9
.9
–1
3.
3)
 
 
11
.6
 
(9
.8
–1
3.
4)
 
 
11
.9
 
(1
0.
1–
13
.7
) 
 
10
.3
 
(8
.6
–1
1.
9)
 
 
10
.5
 
(8
.9
–1
2.
2)
 
 
11
.2
 
(9
.4
–1
2.
9)
 
 
11
.8
 
(1
0.
0–
13
.7
) 
—
 
O
ve
rw
ei
gh
t 
18
.9
 
(1
6.
9–
20
.9
) 
 
20
.3
 
(1
8.
2–
22
.4
) 
 
17
.4
 
(1
5.
3–
19
.4
) 
 
17
.1
 
(1
5.
3–
19
.0
) 
 
19
.7
 
(1
7.
7–
21
.7
) 
 
17
.3
 
(1
5.
4–
19
.3
) 
 
18
.2
 
(1
6.
1–
20
.4
) 
 
17
.4
 
(1
5.
3–
19
.5
) 
 
17
.4
 
(1
5.
4–
19
.5
) 
 
17
.8
 
(1
5.
7–
19
.8
) 
—
 
N
or
m
al
 
60
.3
 
(5
7.
7–
62
.9
) 
 
56
.0
 
(5
3.
4–
58
.6
) 
 
60
.4
 
(5
7.
7–
63
.1
) 
 
60
.3
 
(5
7.
8–
62
.8
) 
 
58
.8
 
(5
6.
2–
61
.4
) 
 
61
.1
 
(5
8.
5–
63
.5
) 
 
62
.0
 
(5
9.
3–
64
.7
) 
 
62
.2
 
(5
9.
6–
64
.9
) 
 
62
.4
 
(5
9.
7–
65
.2
) 
 
60
.1
 
(5
7.
4–
62
.9
) 
—
 
U
nd
er
w
ei
gh
t 
8.
3 
(6
.8
–9
.7
) 
 
9.
9 
(8
.3
–1
1.
5)
 
 
11
.4
 
(9
.7
–1
3.
2)
 
 
11
.0
 
(9
.3
–1
2.
6)
 
 
9.
9 
(8
.4
–1
1.
5)
 
 
9.
6 
(8
.0
–1
1.
3)
 
 
9.
5 
(8
.0
–1
1.
1)
 
 
9.
8 
(8
.2
–1
1.
4)
 
 
9.
0 
(7
.4
–1
0.
6)
 
 
10
.3
 
(8
.6
–1
2.
0)
 
—
 
(a
) 
T
he
 d
ire
ct
io
n 
an
d 
ty
pe
 o
f c
ha
ng
e 
fr
om
 2
00
2–
03
 to
 2
01
1–
12
 is
 in
di
ca
te
d 
fo
r e
ac
h 
re
su
lt:
 
/
 in
di
ca
te
s 
a 
st
at
is
tic
al
ly
 s
ig
ni
fic
an
t c
ha
ng
e 
(in
cr
ea
se
 o
r 
de
cr
ea
se
) i
n 
20
11
–1
2 
co
m
pa
re
d 
w
ith
 2
00
2–
03
; i
nd
ic
at
es
  
th
er
e 
w
as
 n
o 
si
gn
ifi
ca
nt
 c
ha
ng
e 
in
 2
01
1–
12
 c
om
pa
re
d 
w
ith
 2
00
2–
03
. 
(b
) 
A
du
lt 
pa
tie
nt
s 
ag
ed
 1
8 
ye
ar
s 
an
d 
ov
er
 w
ith
 a
 re
co
rd
ed
 h
ei
gh
t o
ut
si
de
 th
e 
A
us
tr
al
ia
n 
B
ur
ea
u 
of
 S
ta
tis
tic
s 
he
ig
ht
 r
an
ge
 b
as
ed
 o
n 
ag
e 
an
d 
se
x 
w
er
e 
ex
cl
ud
ed
. 
(c
) 
T
he
 ri
sk
 fa
ct
or
s 
fo
r 
an
 a
du
lt 
in
cl
ud
ed
 b
ei
ng
: o
ve
rw
ei
gh
t o
r 
ob
es
e,
 a
 d
ai
ly
 s
m
ok
er
 o
r 
an
 a
t-
ris
k 
dr
in
ke
r. 
 
(d
) 
C
hi
ld
re
n 
(a
ge
d 
2–
17
 y
ea
rs
) 
w
ith
 h
ei
gh
t o
ut
si
de
 th
e 
A
us
tr
al
ia
n 
B
ur
ea
u 
of
 S
ta
tis
tic
s 
or
 C
en
tr
es
 fo
r 
D
is
ea
se
 C
on
tro
l, 
he
ig
ht
 r
an
ge
 b
as
ed
 o
n 
ag
e 
an
d 
se
x 
w
er
e 
ex
cl
ud
ed
. C
hi
ld
 B
M
I w
as
 re
-c
al
cu
la
te
d 
fo
r 2
00
2–
03
 to
 
20
05
–0
6,
 a
nd
 w
ill
 d
iff
er
 fr
om
 d
at
a 
pr
ev
io
us
ly
 p
ub
lis
he
d 
to
 in
co
rp
or
at
e 
th
is
 e
xc
lu
si
on
 a
nd
 to
 a
pp
ly
 a
 m
or
e 
pr
ec
is
e 
m
et
ho
d 
fo
r 
ca
lc
ul
at
in
g 
ch
ild
 B
M
I. 
N
ot
e:
 C
I –
 c
on
fid
en
ce
 in
te
rv
al
. 
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ie
nt
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ad
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00
2–
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 2
01
1–
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Pe
r c
en
t (
95
%
 C
I) 

(a
)  
 
 
R
is
k 
fa
ct
or
 
20
02
–0
3 
 
20
03
–0
4 
 
20
04
–0
5 
 
20
05
–0
6 
 
20
06
–0
7 
 
20
07
–0
8 
 
20
08
–0
9 
 
20
09
–1
0 
 
20
10
–1
1 
 
20
11
–1
2 
 B
od
y 
m
as
s 
in
de
x 
cl
as
s(
b)
 (n
) 
19
,6
70
 
 
19
,2
14
 
 
17
,9
76
 
 
19
,9
76
 
 
19
,4
10
 
 
18
,7
03
 
 
19
,6
71
 
 
19
,7
35
 
 
18
,7
41
 
 
19
,6
05
 
. .
 
 
O
be
se
 
21
.5
 
(2
0.
7–
22
.3
) 
 
23
.0
 
(2
2.
1–
23
.8
) 
 
23
.2
 
(2
2.
4–
24
.1
) 
 
22
.6
 
(2
1.
7–
23
.4
) 
 
24
.2
 
(2
3.
3–
25
.1
) 
 
24
.3
 
(2
3.
5–
25
.2
) 
 
25
.6
 
(2
4.
8–
26
.4
) 
 
26
.2
 
(2
5.
3–
27
.0
) 
 
27
.2
 
(2
6.
3–
28
.1
) 
 
26
.7
 
(2
5.
8–
27
.5
) 

 
 
O
ve
rw
ei
gh
t 
29
.0
 
(2
8.
2–
29
.8
) 
 
29
.4
 
(2
8.
6–
30
.1
) 
 
29
.3
 
(2
8.
6–
30
.1
) 
 
29
.3
 
(2
8.
6–
30
.0
) 
 
30
.1
 
(2
9.
4–
30
.9
) 
 
30
.4
 
(2
9.
7–
31
.2
) 
 
30
.9
 
(3
0.
2–
31
.6
) 
 
29
.6
 
(2
8.
9–
30
.3
) 
 
30
.3
 
(2
9.
6–
31
.0
) 
 
30
.2
 
(2
9.
5–
30
.9
) 
—
 
 
N
or
m
al
 
45
.7
 
(4
4.
7–
46
.8
) 
 
44
.1
 
(4
3.
1–
45
.1
) 
 
43
.8
 
(4
2.
7–
44
.8
) 
 
44
.6
 
(4
3.
6–
45
.6
) 
 
42
.2
 
(4
1.
2–
43
.2
) 
 
41
.9
 
(4
0.
9–
43
.0
) 
 
40
.0
 
(3
9.
1–
41
.0
) 
 
41
.1
 
(4
0.
1–
42
.0
) 
 
39
.3
 
(3
8.
3–
40
.3
) 
 
40
.2
 
(3
9.
3–
41
.2
) 

 
 
U
nd
er
w
ei
gh
t 
3.
8 
(3
.5
–4
.2
) 
 
3.
6 
(3
.3
–3
.9
) 
 
3.
6 
(3
.3
–4
.0
) 
 
3.
5 
(3
.2
–3
.8
) 
 
3.
5 
(3
.2
–3
.8
) 
 
3.
3 
(3
.0
–3
.6
) 
 
3.
4 
(3
.2
–3
.7
) 
 
3.
2 
(2
.9
–3
.5
) 
 
3.
2 
(2
.9
–3
.5
) 
 
2.
9 
(2
.6
–3
.1
) 

 
 S
m
ok
in
g 
st
at
us
 (n
) 
19
,8
75
 
 
19
,7
80
 
 
18
,4
68
 
 
20
,2
88
 
 
18
,7
18
 
 
19
,0
81
 
 
20
,0
79
 
 
20
,2
24
 
 
19
,3
01
 
 
20
,0
60
 
. .
 
 
D
ai
ly
 
15
.2
 
(1
4.
4–
15
.9
) 
 
15
.4
 
(1
4.
6–
16
.1
) 
 
15
.7
 
(1
5.
0–
16
.5
) 
 
14
.7
 
(1
4.
0–
15
.4
) 
 
14
.0
 
(1
3.
3–
14
.8
) 
 
14
.4
 
(1
3.
7–
15
.2
) 
 
13
.3
 
(1
2.
6–
14
.0
) 
 
13
.3
 
(1
2.
6–
14
.0
) 
 
12
.9
 
(1
2.
2–
13
.6
) 
 
12
.6
 
(1
1.
8–
13
.3
) 

 
 
O
cc
as
io
na
l 
3.
9 
(3
.5
–4
.3
) 
 
4.
2 
(3
.9
–4
.6
) 
 
3.
3 
(3
.0
–3
.7
) 
 
3.
3 
(3
.0
–3
.6
) 
 
2.
7 
(2
.5
–3
.0
) 
 
2.
6 
(2
.4
–2
.9
) 
 
2.
4 
(2
.2
–2
.7
) 
 
2.
4 
(2
.2
–2
.7
) 
 
2.
4 
(2
.2
–2
.7
) 
 
2.
2 
(2
.0
–2
.4
) 

 
 
P
re
vi
ou
s 
21
.5
 
(2
0.
7–
22
.3
) 
 
22
.0
 
(2
1.
2–
22
.8
) 
 
22
.2
 
(2
1.
3–
23
.0
) 
 
21
.5
 
(2
0.
7–
22
.3
) 
 
23
.3
 
(2
2.
5–
24
.2
) 
 
22
.3
 
(2
1.
4–
23
.1
) 
 
22
.5
 
(2
1.
7–
23
.3
) 
 
22
.8
 
(2
2.
0–
23
.7
) 
 
22
.7
 
(2
1.
8–
23
.5
) 
 
22
.6
 
(2
1.
8–
23
.5
) 
—
 
 
N
ev
er
 
59
.4
 
(5
8.
3–
60
.5
) 
 
58
.4
 
(5
7.
3–
59
.5
) 
 
58
.8
 
(5
7.
7–
59
.9
) 
 
60
.5
 
(5
9.
5–
61
.6
) 
 
59
.9
 
(5
8.
8–
61
.0
) 
 
60
.7
 
(5
9.
6–
61
.7
) 
 
61
.7
 
(6
0.
7–
62
.7
) 
 
61
.5
 
(6
0.
4–
62
.5
) 
 
62
.1
 
(6
1.
0–
63
.1
) 
 
62
.6
 
(6
1.
6–
63
.7
) 

 
 A
lc
oh
ol
 c
on
su
m
pt
io
n 
(n
) 
19
,7
49
 
 
19
,3
87
 
 
18
,1
20
 
 
19
,9
61
 
 
18
,3
42
 
 
18
,7
15
 
 
19
,7
64
 
 
19
,9
79
 
 
18
,8
69
 
 
19
,6
85
 
. .
 
 
A
t-r
is
k 
al
co
ho
l l
ev
el
 
22
.1
 
(2
1.
2–
23
.0
) 
 
22
.6
 
(2
1.
7–
23
.6
) 
 
22
.2
 
(2
1.
3–
23
.2
) 
 
22
.2
 
(2
1.
3–
23
.2
) 
 
23
.5
 
(2
2.
5–
24
.5
) 
 
22
.6
 
(2
1.
6–
23
.6
) 
 
21
.8
 
(2
0.
8–
22
.7
) 
 
23
.4
 
(2
2.
5–
24
.4
) 
 
21
.4
 
(2
0.
5–
22
.3
) 
 
21
.5
 
(2
0.
6–
22
.5
) 
—
 
 
R
es
po
ns
ib
le
 d
rin
ke
r 
42
.7
 
(4
1.
7–
43
.8
) 
 
43
.5
 
(4
2.
4–
44
.5
) 
 
43
.0
 
(4
1.
9–
44
.0
) 
 
42
.8
 
(4
1.
8–
43
.9
) 
 
42
.4
 
(4
1.
3–
43
.5
) 
 
42
.6
 
(4
1.
6–
43
.7
) 
 
42
.6
 
(4
1.
6–
43
.7
) 
 
42
.5
 
(4
1.
5–
43
.6
) 
 
41
.5
 
(4
0.
4–
42
.6
) 
 
41
.8
 
(4
0.
8–
42
.8
) 
—
 
 
N
on
-d
rin
ke
r 
35
.2
 
(3
3.
9–
36
.5
) 
 
33
.9
 
(3
2.
7–
35
.2
) 
 
34
.8
 
(3
3.
4–
36
.2
) 
 
35
.0
 
(3
3.
6–
36
.3
) 
 
34
.1
 
(3
2.
8–
35
.4
) 
 
34
.8
 
(3
3.
5–
36
.1
) 
 
35
.6
 
(3
4.
3–
36
.9
) 
 
34
.0
 
(3
2.
8–
35
.3
) 
 
37
.1
 
(3
5.
7–
38
.5
) 
 
36
.7
 
(3
5.
3–
38
.0
) 
—
 
(c
on
tin
ue
d)
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00
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1–
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R
is
k 
fa
ct
or
 
Pe
r c
en
t (
95
%
 C
I) 
 
(a
)  
 
 
20
02
–0
3 
 
20
03
–0
4 
 
20
04
–0
5 
 
20
05
–0
6 
 
20
06
–0
7 
 
20
07
–0
8 
 
20
08
–0
9 
 
20
09
–1
0 
 
20
10
–1
1 
 
20
11
–1
2 
 A
du
lt 
re
m
al
es
 (a
ge
d 
18
 y
ea
rs
 a
nd
 o
ve
r)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
. .
 
 N
um
be
r o
f r
is
k 
fa
ct
or
s(
c)
 (n
) 
19
,0
94
 
 
18
,7
14
 
 
17
,5
18
 
 
19
,5
04
 
 
17
,7
24
 
 
18
,2
18
 
 
19
,2
04
 
 
19
,1
82
 
 
18
,2
22
 
 
19
,1
49
 
 
Ze
ro
 
32
.6
 
(3
1.
5–
33
.6
) 
 
31
.2
 
(3
0.
2–
32
.2
) 
 
31
.2
 
(3
0.
2–
32
.2
) 
 
31
.7
 
(3
0.
7–
32
.7
) 
 
29
.8
 
(2
8.
8–
30
.7
) 
 
29
.9
 
(2
8.
9–
30
.8
) 
 
29
.1
 
(2
8.
1–
30
.0
) 
 
29
.5
 
(2
8.
6–
30
.4
) 
 
28
.8
 
(2
7.
9–
29
.7
) 
 
29
.5
 
(2
8.
6–
30
.5
) 

 
O
ne
 
49
.4
 
(4
8.
5–
50
.3
) 
 
50
.4
 
(4
9.
5–
51
.2
) 
 
50
.1
 
(4
9.
2–
50
.9
) 
 
50
.4
 
(4
9.
5–
51
.2
) 
 
51
.0
 
(5
0.
1–
51
.9
) 
 
51
.4
 
(5
0.
6–
52
.3
) 
 
52
.7
 
(5
1.
8–
53
.5
) 
 
51
.2
 
(5
0.
3–
52
.0
) 
 
53
.1
 
(5
2.
2–
53
.9
) 
 
52
.5
 
(5
1.
7–
53
.4
) 

 
Tw
o 
15
.6
 
(1
5.
0–
16
.3
) 
 
15
.9
 
(1
5.
2–
16
.5
) 
 
15
.9
 
(1
5.
3–
16
.6
) 
 
15
.4
 
(1
4.
7–
16
.0
) 
 
16
.6
 
(1
5.
9–
17
.3
) 
 
15
.8
 
(1
5.
2–
16
.5
) 
 
15
.6
 
(1
5.
0–
16
.3
) 
 
16
.6
 
(1
5.
9–
17
.2
) 
 
15
.5
 
(1
4.
8–
16
.2
) 
 
15
.5
 
(1
4.
8–
16
.1
) 
—
 
Th
re
e 
2.
4 
(2
.1
–2
.7
) 
 
2.
6 
(2
.3
–2
.9
) 
 
2.
8 
(2
.6
–3
.1
) 
 
2.
6 
(2
.3
–2
.8
) 
 
2.
6 
(2
.3
–2
.9
) 
 
2.
9 
(2
.6
–3
.2
) 
 
2.
6 
(2
.4
–2
.9
) 
 
2.
8 
(2
.5
–3
.0
) 
 
2.
6 
(2
.3
–2
.9
) 
 
2.
5 
(2
.2
–2
.8
) 
—
 
 F
em
al
e 
ch
ild
re
n 
 
 (a
ge
d 
2–
17
 y
ea
rs
)(d
)  (
n)
 
1,
76
0 
 
1,
70
4 
 
1,
56
7 
 
1,
69
8 
 
1,
57
8 
 
1,
56
2 
 
1,
55
5 
 
1,
68
4 
 
1,
55
8 
 
1,
60
6 
 
O
be
se
 
11
.3
 
(9
.6
–1
2.
9)
 
 
10
.2
 
(8
.6
–1
1.
8)
 
 
10
.8
 
(9
.1
–1
2.
6)
 
 
10
.3
 
(8
.7
–1
1.
8)
 
 
9.
6 
(8
.1
–1
1.
2)
 
 
10
.6
 
(8
.9
–1
2.
2)
 
 
10
.7
 
(9
.1
–1
2.
3)
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Abbreviations 
ACRRM Australian College of Rural and Remote Medicine 
AHW Aboriginal health worker 
AIHW Australian Institute of Health and Welfare 
ASGC Australian Standard Geographical Classification 
ATC Anatomical Therapeutic Chemical (classification) 
BEACH Bettering the Evaluation and Care of Health 
BMI body mass index 
CAPS Coding Atlas for Pharmaceutical Substances 
CI confidence interval (in this report 95% CI is used) 
CT computerised tomography 
DoHA Australian Government Department of Health and Ageing 
DVA Australian Government Department of Veterans’ Affairs 
FACRRM Fellow of the Australian College of Rural and Remote Medicine 
FMRC Family Medicine Research Centre 
FRACGP Fellow of the Royal Australian College of General Practitioners 
FTE full-time equivalent 
GP general practitioner 
HbA1c haemoglobin, type A1c 
ICPC International Classification of Primary Care 
ICPC-2 International Classification of Primary Care – Version 2 
ICPC-2 PLUS a terminology classified according to ICPC-2 
INR international normalised ratio 
LCL lower confidence limit 
MBS Medicare Benefits Schedule 
OTC over-the-counter (medications advised for over-the-counter purchase) 
PBS Pharmaceutical Benefits Scheme 
PN Practice nurse 
RACGP Royal Australian College of General Practitioners 
RFE reason for encounter 
RRMA Rural, Remote and Metropolitan Area classification 
SAND Supplementary Analysis of Nominated Data 
SAS Statistical Analysis System 
UCL upper confidence limit 
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URTI upper respiratory tract infection  
WHO World Health Organization 
Wonca World Organization of Family Doctors 
Symbols 
. . intentionally left blank 
< less than 
> more than 
n number 
N/A not applicable 
NAv not available 
NEC not elsewhere classified 
NOS not otherwise specified 
 indicates a statistically significant increase in 2011–12 when compared 
with the first year of data reported 
 indicates a statistically significant decrease in 2011–12 when compared 
with the first year of data reported 
 indicates a marginally significant increase in 2011–12 when compared 
with the first year of data reported 
 indicates a marginally significant decrease in 2011–12 when compared 
with the first year of data reported 
§ indicates a noteworthy change during the decade. 
— indicates no significant change in 2011–12 when compared with the first 
year of data reported 
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Glossary 
A1 Medicare items: see MBS/DVA items: A1 Medicare items. 
Aboriginal: The patient identifies himself or herself as an Aboriginal person. 
Activity level: The number of general practice A1 Medicare items claimed during the previous 
3 months by a participating GP. 
Allied health services: Clinical and other specialised health services provided in the 
management of patients by allied and other health professionals including physiotherapists, 
occupational therapists, dietitians, dentists and pharmacists. 
Chapters (ICPC-2): The main divisions within ICPC-2. There are 17 chapters primarily 
representing the body systems. 
Chronic problem: see Diagnosis/problem: Chronic problem. 
Commonwealth concession card: An entitlement card provided by the Australian Government, 
which entitles the holder to reduced-cost medicines under the Pharmaceutical Benefits 
Scheme and some other concessions from state and local government authorities. 
Complaint: A symptom or disorder expressed by the patient when seeking care. 
Component (ICPC-2): In ICPC-2 there are seven components that act as a second axis across all 
chapters. 
Consultation: See Encounter. 
Diagnosis/problem: A statement of the provider’s understanding of a health problem 
presented by a patient, family or community. GPs are instructed to record at the most 
specific level possible from the information available at the time. It may be limited to the 
level of symptoms. 
• New problem: The first presentation of a problem, including the first presentation of a 
recurrence of a previously resolved problem, but excluding the presentation of a 
problem first assessed by another provider. 
• Old problem: A previously assessed problem that requires ongoing care, including 
follow-up for a problem or an initial presentation of a problem previously assessed by 
another provider. 
• Chronic problem: A medical condition characterised by a combination of the following 
characteristics: duration that has lasted or is expected to last six months or more, a 
pattern of recurrence or deterioration, a poor prognosis, and consequences or sequelae 
that impact on an individual’s quality of life. (Source: O’Halloran J, Miller GC, Britt H 
2004. Defining chronic conditions for primary care with ICPC-2. Fam Pract 21(4):381–6).  
• Work-related problem: Irrespective of the source of payment for the encounter, it is likely 
in the GP’s view that the problem has resulted from work-related activity or workplace 
exposure, or that a pre-existing condition has been significantly exacerbated by work 
activity or workplace exposure. 
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Encounter (enc): Any professional interchange between a patient and a GP. 
• Indirect: Encounter where there is no face-to-face meeting between the patient and the GP 
but a service is provided (for example, prescription, referral). 
• Direct: Encounter where there is a face-to-face meeting of the patient and the GP. These 
can be further divided into: 
– MBS/DVA-claimable: Encounters for which GPs have recorded at least one MBS 
item number as claimable, where the conditions of use of the item require that the 
patient be present at the encounter.  
– Workers compensation: Encounters paid by workers compensation insurance. 
– Other paid: Encounters paid from another source (for example, state). 
General practitioner (GP): A medical practitioner who provides primary comprehensive and 
continuing care to patients and their families within the community (Royal Australian 
College of General Practitioners). 
GP consultation service items: see MBS/DVA items: GP consultation service items.  
Marginally significant: See Significant 
MBS/DVA items: MBS item numbers recorded as claimable for activities undertaken by GPs 
and staff under the supervision of GPs. In BEACH a MBS item number may be funded by 
Medicare or by the Department of Veterans’ Affairs (DVA). 
• A1 Medicare items: Medicare item numbers 1, 2, 3, 4, 13, 19, 20, 23, 24, 25, 33, 35, 36, 37, 38, 
40, 43, 44, 47, 48, 50, 51, 601, 602. 
• GP consultation service items: Includes GP services provided under the MBS professional 
services category including MBS items classed as A1, A2, A5, A6, A7, A14, A17, A18, 
A19, A20, A22 and selected items provided by GPs classified in A11, A15 and A27. 
• MBS/DVA item categories: (Note: item numbers recorded in BEACH in earlier years 
which are no longer valid are mapped to the current MBS groups) 
– Surgery consultations: identified by any of the following item numbers: short 3, 52, 
5000, 52003; standard 23, 53, 5020, 5203; long 36, 54, 5040; prolonged 44, 57, 5060, 
5208. 
– Residential aged care facility: identified by any of the following item numbers: 20, 35, 
43, 51, 92, 93, 95, 96, 5010, 5028, 5049, 5067, 5260, 5263, 5265, 5267. 
– Home or institution visits (excluding residential aged care facilities): identified by any of 
the following item numbers:: 4, 19, 24, 33, 37, 40, 47, 50, 58, 59, 60, 65, 87, 89, 90, 91, 
503, 507, 5003, 5023, 5043, 5063, 5220, 5223, 5227, 5228. 
– GP mental health care: identified by any of the following item numbers: 2700, 2701, 
2702, 2704, 2705, 2710, 2712, 2713, 2715, 2717, 2721, 2723, 2725. 
– Chronic disease management items: identified by any of the following item numbers: 
720, 721, 722, 723, 724, 725, 726, 727, 729, 730, 731, 732. 
– Health assessments: identified by any of the following item numbers: 700, 702, 703, 
704, 705, 706, 707, 708, 709, 710, 712, 713, 714, 715, 717, 718, 719. 
– Case conferences: identified by any of the following item numbers: 734, 735, 736, 738, 
739, 740, 742, 743, 744, 750, 762, 765, 773, 775, 778. 
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– Attendances associated with Practice Incentives Program payments: identified by any of 
the following item numbers: 2497, 2501, 2503, 2504, 2506, 2507, 2509, 2517, 2518, 2521, 
2522, 2525, 2526, 2546, 2547, 2552, 2553, 2558, 2559, 2574, 2575, 2577, 2598, 2600, 2603, 
2606, 2610, 2613, 2616, 2620, 2622, 2624, 2631, 2633, 2635, 2664, 2666, 2667, 2668, 2673, 
2675, 2677, 2704, 2705. 
– GP bulk-billed incentive payment: identified by any of the following item numbers: 
10990,10991,10992,74990,74991. 
– Practice nurse/Aboriginal health worker/allied health worker services: identified by any of 
the following item numbers: 711, 10950, 10951, 10960, 10966, 10970, 10986, 10987, 
10989, 10993, 10994, 10995, 10996, 10997, 10998, 10999, 16400, 82210. 
– Acupuncture: identified by any of the following item numbers: 173, 193, 195, 197, 199. 
– Diagnostic procedures and investigations: identified by item numbers: 11000–12533. 
– Therapeutic procedures: identified by item numbers: 13015–25205 (excluding 16400). 
– Surgical operations: identified by item numbers: 30001–53706. 
– Diagnostic imaging services: identified by item numbers: 55028–64991. 
– Pathology services: identified by item numbers: 65060–74999. 
Medication: Medication that is prescribed, provided by the GP at the encounter or advised for 
over-the-counter purchase. 
Medication rates: The rate of use of all medications, including medications that were 
prescribed, supplied by the GP and advised for over-the-counter purchase. 
Medication status: 
• New: The medication prescribed/provided at the encounter/advised is being used for 
the management of the problem for the first time. 
• Continued: The medication prescribed/provided at the encounter/advised is a 
continuation or repeat of previous therapy for this problem. 
• Old: See Continued. 
Morbidity: Any departure, subjective or objective, from a state of physiological wellbeing. 
In this sense, sickness, illness and morbid conditions are synonymous. 
Patient status: The status of the patient to the practice. 
• New patient: The patient has not been seen before in the practice. 
• Patient seen previously: The patient has attended the practice before. 
Prescribed rates: The rate of use of prescribed medications (that is, does not include 
medications that were GP-supplied or advised for over-the-counter purchase). 
Problem managed: See Diagnosis/problem. 
Provider: A person to whom a patient has access when contacting the healthcare system. 
Reasons for encounter (RFEs): The subjective reasons given by the patient for seeing or 
contacting the general practitioner. These can be expressed in terms of symptoms, diagnoses 
or the need for a service. 
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Recognised GP: A medical practitioner who is: 
• vocationally recognised under Section 3F of the Health Insurance Act, or 
• a holder of the Fellowship of the Royal Australian College of General Practitioners who 
participates in, and meets the requirements for, quality assurance and continuing 
medical education as defined in the Royal Australian College of General Practitioners 
(RACGP) Quality Assurance and Continuing Medical Education Program, or 
• undertaking an approved placement in general practice as part of a training program for 
general practice leading to the award of the Fellowship of the Royal Australian College 
of General Practitioners, or undertaking an approved placement in general practice as 
part of some other training program recognised by the RACGP as being of equivalent 
standard. (Source: Commonwealth Department of Health and Aged Care 2001. Medicare 
benefits schedule book. Canberra: DHAC).  
Referral: The process by which the responsibility for part or all of the care of a patient is 
temporarily transferred to another health care provider. Only new referrals to specialists and 
allied health services, and for hospital and residential aged care facility admissions arising at 
a recorded encounter are included. Continuation referrals are not included. Multiple 
referrals can be recorded at any one encounter. 
Repatriation health card: An entitlement card provided by the Department of Veterans’ Affairs 
that entitles the holder to access a range of repatriation health care benefits, including access 
to prescription and other medications under the Pharmaceutical Benefits Scheme. 
Rubric: The title of an individual code in ICPC-2. 
Significant: This term is used to refer to a statistically significant difference between two 
results, and is measured through non-overlapping 95% confidence intervals. The exception is 
Chapter 4 (The Participating GPs), where statistical significance is measured with the chi 
square statistic, (p = 0.01). Marginally significant refers to results for which the confidence 
intervals around two results butt together. 
Torres Strait Islander: The patient identifies himself or herself as a Torres Strait Islander 
person. 
Work-related problem: See Diagnosis/problem. 
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Appendices 
Appendix 1: Example of a 2011–12 recording form 
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Appendix 2: GP characteristics questionnaire, 
2011–12 
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Appendix 3: Patient information card, 2011–12 
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Appendix 4: Code groups from ICPC-2 and 
ICPC-2 PLUS 
Available at: <purl.library.usyd.edu.au/sup/9781743320204>, see ‘Electronic editions and 
downloads’. 
Table A4.1:  Code groups from ICPC-2 and ICPC-2 PLUS – reasons for encounter  
and problems managed 
Table A4.2: Code groups from ICPC-2 and ICPC-2 PLUS – chronic problems 
Table A4.3: Code groups from ICPC-2 and ICPC-2 PLUS – problems managed by  
practice nurses 
Table A4.4: Code groups from ICPC-2 and ICPC-2 PLUS – clinical treatments 
Table A4.5: Code groups from ICPC-2 and ICPC-2 PLUS – procedures 
Table A4.6: Code groups from ICPC-2 and ICPC-2 PLUS – clinical measurements 
Table A4.7: Code groups from ICPC-2 and ICPC-2 PLUS – referrals 
Table A4.8:  Code groups from ICPC-2 and ICPC-2 PLUS – pathology test orders  
(MBS groups) 
Table A4.9:  Code groups from ICPC-2 and ICPC-2 PLUS – imaging test orders  
(MBS groups) 
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This report highlights changes in general practice activity 
in Australia over the most recent decade (April 2002 to 
March 2012) of the BEACH program, a national cross-
sectional study of general practice activity. Over this 
time 9,802 GPs provided details of 980,200 GP–patient 
encounters. The report highlights changes that have 
occurred over the decade in the characteristics of GPs 
and the patients they see, the problems managed, and 
the treatments provided. Changes in prevalence of 
overweight and obesity, smoking status and alcohol use 
are also described for subsamples of more than 30,000 
adult patients each year.
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